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Introduction
Techniques for manipulating neural systems in general and neuroendocrine systems
in particular have matured greatly compared to the era in which nerve cell destruc-
tion and electrical stimulation provided our main tools. In theory, nerve cell groups
connected with hormonal systems should offer strategic advantages to the stem cell
biologist because of the wealth of chemically understood regulatory steps to
exploit. While the current volume cannot provide a comprehensive review of the
quickly evolving applications of stem cell biology, it does provide a first view of
some of the early successes and new possibilities.
For example, the striking successes of Lorenz Studer with dopamine-expressing
neurons may not only prove to be of surpassing importance for Parkinson’s disease
but may also shed light on dopaminergic neuron participation in basic processes of
behavioral reward. Inna Tabansky, in addition, portrays how neuroendocrine neu-
rons derived from stem cells can provide models of disease processes that then
could be attacked under well-defined in vitro conditions. In a different type of
presentation, Alon Chen provides a vision of how stem cell biology could be
applied in a neuroendocrine system crucial for responses to stress: the
corticotropin-releasing hormone system.
The final chapter, from the highly experienced developmental biology lab of
Karine Rizzoti and Robin Lovell-Badge at the Crick Institute, presents an overview
from both outside and inside the central nervous system of the likely contributions
of such work to the new field of regenerative medicine.
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Daniel A. Lee Solomon H. Snyder Department of Neuroscience, Johns Hopkins
University School of Medicine, Baltimore, MD, USA
Division of Biology and Biomedical Engineering, California Institute of Technol-
ogy, Pasadena, CA, USA
xi
Robin Lovell-Badge The Crick Institute, Mill Hill Laboratory, The Ridgeway,
London, United Kingdom
Maryem Manzoor The Rockefeller University, New York, NY, USA
Thomas Pak Solomon H. Snyder Department of Neuroscience, Johns Hopkins
University School of Medicine, Baltimore, MD, USA
D. Pfaff The Rockefeller University, New York, NY, USA
Carlotta Pires University of Copenhagen, Frederiksberg, Denmark
Karine Rizzoti The Crick Institute, Mill Hill Laboratory, The Ridgeway, London,
United Kingdom
Joel N.H. Stern Department of Neurobiology and Behavior, The Rockefeller
University, New York, NY, USA
Department of Autoimmunity, The Feinstein Institute for Medical Research,
Northwell Health System, Manhasset, NY, USA
Departments of Neurology, Molecular Medicine, and Science Education, Hofstra
Northwell School of Medicine, Hempstead, NY, USA
Lorenz Studer Developmental Biology, The Center for Stem Cell Biology,
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Hidetaka Suga Department of Endocrinology and Diabetes, Nagoya University
Hospital, Nagoya, Aich, Japan
Inna Tabansky Department of Neurobiology and Behavior, The Rockefeller
University, New York, NY, USA
Viviane Tabar Department of Neurosurgery, The Center for Stem Cell Biology,
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Hugo Vankelecom Department of Development and Regeneration, Cluster of
Stem Cell Biology and Embryology, Unit of Stem Cell Research, KU Leuven
(University of Leuven), Campus Gasthuisberg O&N4, Leuven, Belgium
Sooyeon Yoo Solomon H. Snyder Department of Neuroscience, Johns Hopkins
University School of Medicine, Baltimore, MD, USA
P.A. Zunszain Department of Psychological Medicine, Section of Stress, Psychi-
atry and Immunology, King’s College London, Institute of Psychiatry, Psychology
and Neuroscience, London, United Kingdom
xii List of Contributors
A Brief Overview of Techniques
for Modulating Neuroendocrine and Other
Neural Systems
Maryem Manzoor and Donald Pfaff
Abstract The history of experimental approaches to the nervous system forms the
backdrop for new opportunities of using stem cell technologies in neuroendocrine
systems. The emphasis of this chapter is on attempts at therapeutic maneuvers.
A Brief View of the Oldest, Most Primitive Approaches
No one uncovers the historical roots, the origins of ancient neuroscience, better than
Stanley Finger of the Washington University School of Medicine. Egyptians whose
names have been lost, writing during the age of the Pyramids, treated “involved
individuals who suffered from head injuries. The descriptions revealed that early
Egyptian physicians were aware that symptoms of central nervous system injuries
could occur far from the locus of the damage.” The Greek physician Alcmaeon
(around the fifth century BCE) did various dissections and “proposed that the brain
was the central organ of sensation and thought.” But things got serious when the
Greek anatomist Galen (AD 130–200) numbered the cranial nerves, distinguished
sensory and motor pathways, distinguished the cerebellum from the cortex, and
described the autonomic ganglia that control our viscera.
The historical origins of the information on sensory pathways begin with studies
of the visual system that “described two distinct types of endings (rods and cones)
in the retina” and later, in fact, the discovery of one of the visual pigments,
rhodopsin. Anatomical studies then proceeded to the visual pathways, both the
direct “reflex action” pathways to the superior colliculus and to the classical
thalamo-cortical system. In turn, one contrasts vision with olfaction, which does
not use the thalamus to signal to the cortex. According to Finger, “until the second
half of the eighteenth century, air was viewed as an element and passive carrier of
foreign particles that could affect the health of an organism.” Putrid smells were
avoided. Soon the adequate stimulus for olfaction as particles in the air was
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recognized. It was known that olfactory receptors were in the nose, but the exact
locations of the receptor-bearing cells were not known until the end of the nine-
teenth century. As with vision, investigations then proceeded to the central olfac-
tory pathways in the brain.
Some of the initial findings reported paralysis on the side of the body that was
opposite to brain damage that was limited to the cerebral cortex. Theorists supposed
that the motor cortex was toward the front of the brain. But, in Finger’s words, the
“unequivocal experimental confirmation of a ‘motor’ cortex’ electrically stimulated
that part of cortex and caused movement.” Confirming their results, subsequent
removal of that part of the cortex of laboratory dogs led to motor deficits. Then,
neurophysiologists would go on to define motor cortex precisely and to describe the
motor tracts that lead from the forebrain toward the spinal cord.
Early ideas about emotion emphasized our visceral nervous systems, including
both the sympathetic nervous system (raising blood pressure, heart rate, etc.) and
the parasympathetic nervous system (usually the opposite effects of the sympa-
thetic). In fact, the great psychologist/philosopher William James, at the end of the
nineteenth century, actually proposed that we feel emotions consequent to changes
in the autonomic nervous systems—feelings secondary to vascular changes. Walter
Bradford Cannon and Philip Bard (at Johns Hopkins University) took a more
straightforward view because they were able to stimulate the hypothalamus and
directly cause emotional changes in experimental animals, changes like the induc-
tion of rage behavior. In subsequent years, the circuitry of the forebrain connected
intimately to the hypothalamus (where we have done most of our work) proved to
be essential for the performance of all emotional and motivated behaviors.
In the nineteenth century, clinicians had to deduce “how the brain works” by
observing how behavioral capacities changed after brain damage. A special case
was the British neurologist John Hughlings Jackson, who inferred which brain
centers were “higher” and which “lower” by carefully noting how certain epileptic
seizures in a given patient changed across time.
The Disciplines
Historically, the temporal order of accomplishment and understanding of brain
function was that structure (morphology) led the way, followed by physiology
(electrical recording), then chemistry (neurotransmitters), and now both genetics
and computational neuroscience (in the most recent 30 or so years).
Morphology
Following Galen, mentioned above, an excellent example of progress comes from
the work of Andreas Vesalius (1543, De Humani Corporis Fabrica). Here is the
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level of detail he achieved: “Professors of dissection usually divide the anterior
brain, which they call the cerebrum, from the posterior brain, which they call the
cerebellum: in turn, the anterior is normally divided into right and left. Not that the
great masters of anatomy think that the brain is entirely divided. . .”
For me, the breakthrough to modern neurobiology occurred when chemical
stains were discovered that would reveal microscopic details of nerve cells. The
Italian scientist Camillo Golgi got a lucky break when nighttime cleaning person-
nel, servicing the hospital kitchen that Golgi had turned into a laboratory, knocked
one of his human brain specimens into a slop bucket. Intrigued by the apparent
staining of cells in that specimen, Golgi found that a key ingredient in turning some
of the neurons dense-black was (and still is) silver nitrate. A brilliant exponent of
Golgi stain-based nerve cell biology was the Spanish neuroanatomist Ramon y
Cajal.
Cajal clearly stated the “neuron doctrine.” The brain is not just a continuous
string of fibers forming anastomoses to make never-ending nets. Instead, as Nobel-
ist Cajal concluded, each nerve cell is an autonomous unit. “The neuron is the
anatomical and physiological unit of the nervous system.” And the rest is history.
How do neurons talk to each other (Kruger and Otis 2007)? The Nobel winning
physiologist Sir Charles Sherrington (1857–1952) “developed the concept of the
synapse” and introduced modern neurophysiology in his 1932 book, “The Integra-
tive Action of the Nervous System.”
For decades the development and use of new neuroanatomical techniques
dominated the scene. For example, a Dutch neuroanatomist, Walle J.H. Nauta,
my teacher, who had survived World War II by eating tulip bulbs, came to the
United States (MIT) and developed techniques for seeing very fine nerve fibers.
This type of technical development led to our current state, when neuroscientists
ambitiously are trying to map all the connections in the human brain.
Physiology
After microscopic techniques for looking at neurons gave our field a running start,
scientists good at electrical recording invented what is called “neurophysiology.”
For example, in Britain, Lord Adrian received the Nobel Prize for showing, in 1938,
how to record from individual nerve fibers. Later, tiny wire probes called micro-
electrodes were developed so that we could put them deep into the brain and record
the electrical activity of individual neurons. Most prominent during the early years
of this technical endeavor were David Hubel and Torsten Wiesel, who used such
electrodes to elucidate the neurophysiology of the visual cortex. And, of course,
recording in a non-invasive manner on the surface of the skin over the skull gives
you “EEG:” electroencephalography of wave-like activity of the cerebral cortex so
useful for clinical diagnosis, as in epilepsy or sleep problems. Sakmann’s and
Neher’s Nobel prize-winning invention led to a modern development of the micro-
electrode: a tiny pipette that suctions onto the surface of an individual neuron,
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breaks through that membrane and records from inside the neuron. This is the
“patch clamp” technique, which unveils the subtlest details of cross-membrane
currents in nerve cells, especially in brain slices or in nerve cell culture.
Chemistry
Later still came the origins of neurochemistry. Of course, the discoveries of how
neurotransmitters such as dopamine and acetylcholine are produced in neurons and
how they are released at synapses and eventually broken down took center stage.
The Nobel prize winner Julius Axelrod, running a large lab at the National Institutes
of Health, became famous not only for his own work but also for mentoring an
entire generation of neurochemical geniuses. One of those geniuses, Solomon
Snyder, not only discovered opiate receptors in the brain but also could claim
such a large number of advances in neurochemistry that the entire department of
neuroscience at Johns Hopkins Medical School now is named after him.
Rita Levi-Montalcini’s discovery of nerve growth factor (NGF) opened a new
arena of neurochemistry in which peptide chemistry was paramount and led to the
elucidation of families of related growth factors.
As DNA’s chemistry and its regulation in gene expression became easier and
easier to study, neuroscientists jumped on the bandwagon. For example, I was able
to prove (reviewed in Pfaff 2002; Lee et al, 2009) that expression of a particular
gene (that which codes for an estrogen receptor) in particular neurons of the brain
(hypothalamic and preoptic neurons) is absolutely essential for specific instinctive
behaviors (mating behavior and maternal behavior). And now the focus has shifted
to the nuclear proteins that coat DNA in the neuron and regulate gene expression.
Genetics, Genomics
To manipulate gene expression in neuroendocrine cells, siRNA (small interfering
RNA) was used to knock out a single gene (estrogen receptor-alpha) in specific
neurons, which abolished all aspects of female reproductive behavior: in temporal
order, lateral preoptic neurons (courtship behavior); ventromedial hypothalamic
neurons (sex behavior; reviewed in Pfaff 2002); and medial preoptic neurons
(maternal behavior; Ribeiro et al. 2012). These studies comprised a behaviorally
relevant extension of nuclear hormone receptor chemistry in neuroendocrinology.
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Cognitive Neuroscience
As recently as 70 years ago, studies that dealt with complex behaviors—psychol-
ogy, personality, and so forth—were dismissed by some as “soft.” The scientific
qualities of accuracy and precision were doubted for those fields. But the field of
cognitive science has come a long way. As things began to improve, some 100 years
ago, scientific approaches to the behaviors of animals were split into two parts. One
approach, called ethology, most popular in Europe, usually treated the natural
behaviors of animals in their natural environments. Ethology was rooted in biology.
The other approach, experimental psychology, was more popular in America.
Derived from physics, experimental psychological studies would feature well-
controlled experiments in the laboratory to answer specific, precisely worded
questions or to test formal hypotheses. Both of these approaches could be applied
to human subjects. Finally, most famously, the Viennese neurologist Sigmund
Freud originated the psychodynamic theory of the human mind and brain,
psychoanalysis.
Cognitive neuroscientists often united these studies of behavior with the various
neuroscientific methodologies and techniques mentioned above. Historically, brain
lesions and their behavioral analyses came earliest. Well known currently, for
example, is the patient HM. The Canadian neurosurgeon William Scoville removed
most of his hippocampus on both sides of his brain to prevent continuing epileptic
seizures. Then the Canadian psychologist Brenda Milner documented his perma-
nent loss of memory for recent events. In other studies, human language was
emphasized, as summarized by Chatterjee and Coslett (2014).
Looking back, the first great victory regarding language was the observation by
the French neurologist Broca that loss of a delimited region on the lower side of the
left frontal lobe impaired the production of speech. On the other hand, damage to a
cortical area farther posterior, near the juncture of the temporal lobe and parietal
lobe, again on the left side, would impair, in Heidi Roth’s words “the acoustic
images of words.” Patients with this type of brain damage, studied by the German
neurologist Carl Wernicke, could not identify or recognize normal speech. As you
can imagine, these studies were based on small numbers of patients. More patients
had to be studied, brain damage had to be better defined and the language analyses
had to be more sophisticated. But Broca and Wernicke had paved the way.
From there neurologists and neuroscientists went on to initiate the study of all
aspects of human behavior. My own lab has zeroed in on the most fundamental
influence within the brain, a concept I call “generalized brain arousal,” which is
essential for initiation of all behaviors. On the other hand, neurologists tend to
concentrate on specific disorders, such as epilepsy, autism, memory, and addiction.
A Brief Overview of Techniques for Modulating Neuroendocrine and Other. . . 5
Computational Approaches
One branch of neuroscience came out of engineering, physics and mathematics.
The theorem of McCulloch and Pitts, published in 1943, coupled with the interests
of Alan Turing sparked the field alive. Then, in 1956, electrical engineers Claude
Shannon (the inventor of information theory), John McCarthy and Marvin Minsky
conceived and led the conference that generated the field of “artificial intelligence,”
the basis of sophisticated robotic behavioral regulation. All these scientists were
applying techniques that had already been proven successful and using them for the
potential understanding and mimicry of the brain’s behavioral regulation.
Neuroscientific work now has reached such a level of precision that our data
often can be treated with computations based on applied mathematics and statistics.
Computational neuroscience can be divided into two parts: analysis and so-called
“modeling,” which means devising computer programs that are supposed to
embody the essential features of some well-chosen groups of neurons in the
brain. Both parts of computational neuroscience contribute to the type of artificial
intelligence that regulates behaviors by robots and computations by neural
networks.
As stated by Eve Marder, a prominent computational neuroscientist at Brandeis
University, “computational models are invaluable and necessary in this task and
yield insights that cannot otherwise be obtained. However, building and
interpreting good computational models is a substantial challenge, especially so
in the era of large datasets.” Fitting detailed models to experimental data is difficult
and often requires onerous assumptions, whereas more loosely constrained concep-
tual models that explore broad hypotheses and principles can yield more useful
insights.
George Reeke, at Rockefeller University, envisions modeling of the brain as an
obvious approach to answering questions all of us have about the brain: how are
sensations, categorized, how are actions selected from a given repertoire, how is
“motivation” to be conceived (2012)? It was the availability of computers that
allowed academic researchers to construct ever more detailed and complicated
models of the brain. Some neural modelers try actually to mimic neurons and
neuronal systems faithfully, in detail, while others do not; instead, in Reeke’s
words, they just concentrate on devising “rule-based systems.” In all cases, the
equations neuronal modelers use to mimic neurons never match the full sophisti-
cation and flexibility of real neurons; neither are the circuitry properties of the
human brain truly realized, even in the best models. These days, many neuro-
scientists are drawn into modeling, and thus a form of AI, because of the considerable
number of free software modeling packages. The implication is that progress in
neuronal modeling is accelerating. Nevertheless, as Reeke points out, the field is not
without its shortcomings. For example, in some cases, the equations representing
neurons and their connections are so abstract that they lose the properties of real
neural systems. In other cases, neuronal modelers will run large numbers of trials
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and select some in which their favorite ideas work, which, of course, leads to false
conclusions.
The operations of individual nerve cells and individual synapses comprise the
irreducible base of neuronal modeling and have absorbed the attention of William
Lytton, at State University of New York Medical Center. One starts with the nerve
cell membrane. The equations that represent the membrane in the model contain the
elements of electrical circuit theory: resistors and capacitors. Once those equations
and the dynamic changes when electrical current flows, for example through
sodium channels or calcium channels, are in place, you are ready to start building
artificial "circuits." One example would be the modeling of a type of connection
serving the passage of sensory information through the thalamus with its subse-
quent impact on the cerebral cortex, which can be modeled, as Lytton has done,
using five types of “neurons” and nine types of connections between neurons.
A Brief Survey of Emerging Techniques
for Neuromodulation
Electrical
One striking development demonstrated the use of the patient’s own electrical
waveform activity to move artificial limbs. While John Donoghue (Brown) was
given a lot of credit for opening up this field, Miguel Nicolelis (Duke, Sao Paolo)
has reported similar achievements. Dedicated to the use of helping injured war
veterans with artificial limbs, Geoffrey Ling (DARPA) has shown effective control
of artificial limbs in therapeutic settings.
On the sensory side of the CNS, some scientist/engineers are concerned with
age-related macular degeneration. Retinal prostheses to help ameliorate this prob-
lem are a central concern of Sheila Nirenberg (Cornell), but the project has a
dimension that goes well beyond prosthesis construction. Central to the solution
is a deep understanding of the critical features of electrical signaling to the optic
nerve. Working with the computational neuroscientist Jonathan Victor, Nierenberg
is discovering the answer to that intellectual problem now.
Chemical
While the field of microfluidics has been applied extensively to sampling extremely
small volumes of biological fluids, it will now become available for precise, time-
limited local delivery of therapeutic substances in specific brain regions. For similar
purposes, nanoparticles, lipid bilayered to cross blood–brain barrier, can be loaded
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up with chemicals intended for therapeutic purposes. Cationic liposomes, the
positive charge offering the possibility of entry into cells, can be used likewise.
DREADDS—Designer Receptors Exclusively Activated by Designer Drugs—
can be genetically encoded so that they are expressed only in specific subpopulations
of neurons, thus to bind pharmaceuticals..
Genetic
The applicability of optogenetics to the nervous system (Karl Deisseroth, Stanford)
has been proven; it uses brief pulses of light to activate channel proteins that, in
some cases, excite neurons and, in other cases, inhibit neurons. For example,
inhibiting GABA neurons that, in turn, inhibit giant medullary reticular neurons
can enhance recovery of consciousness from anesthesia, as measured by behavioral
activation and by the activation of the cortical EEG.
Viral
Locally delivered by stereotaxically guided microinjection, adeno-associated viral
particles (AAV) are outfitted with cell-selecting promoters to modify synthetic and
electrical activities of selected subsets of neurons in that neuronal group (only).
Computational
In general, the use of temporal and spatial patterns of firing in the human brain’s
“connectome” requires big data computational efficacy. One specific example,
viewing brain activity as a set of non-linear dynamic systems, would involve the
identification and use of “attractor” states of neuronal circuitry. This project is
being carried out in the context of the Obama BRAIN initiative.
Special Opportunities for Manipulating the Unique Products
of Neuroendocrine Neurons
Because neuroendocrine neurons specifically produce small chemicals of surpass-
ing importance for the governance of the physiology of the entire body, the
possibility of using chemical, viral or genetic means to regulate their activity offers
unique therapeutic opportunities. Seven examples:
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• GnRH: Gonadotropin releasing hormone controls all of reproductive physiology
and reproductive behavior.
• GHRH: Growth hormone releasing hormone promotes the release of growth
hormone from the pituitary.
• Somatostatin: Reduces the release of growth hormone from the pituitary.
• TRH: Thyrotropic releasing hormone facilitates the release of TSH from the
pituitary Normal mentation and mood depend on thyroid hormone levels.
• CRH: Corticotropic releasing hormone facilitates the release of ACTH from the
pituitary (stress response). In the brain, CRH (also known as CRF) participates in
circuits that govern stress-related behaviors.
• Oxytocin: In addition to regulating lactation and parturition, oxytocin partici-
pates in the initiation of maternal behavior and prosocial motivation.
• Vasopressin: Regulation of body water, blood pressure, blood volume. Vaso-
pressin expression in certain forebrain neurons is known to facilitate aggression.
This Volume
As illustrated throughout this volume, stem cell biology is a fast-moving, young field
with obvious therapeutic potential as well as technical and legal encumbrances.
Following a didactic chapter intended for readers without a background in this area
of medical science, several chapters will report striking advances. Between invi-
tations for this project and the time of the meeting in Paris, one doctor moved from
having a definite need for stem cell technology to publishing a pair of papers in the
prestigious journals, Science and Cell. The meeting wrapped up with an overview
from the Lovell-Badge group, the lab that 24 years ago reported the basis of sexual
differentiation through the discovery of the SRY gene on the Y chromosome.
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Basics of Stem Cell Biology as Applied
to the Brain
Inna Tabansky and Joel N.H. Stern
Abstract Stem cell technology can allow us to produce human neuronal cell types
outside the body, but what exactly are stem cells, and what challenges are associ-
ated with their use? Stem cells are a kind of cell that has the capacity to self-renew
to produce additional stem cells by mitosis, and also to differentiate into other—
more mature—cell types. Stem cells are usually categorized as multipotent (able to
give rise to multiple cells within a lineage), pluripotent (able to give rise to all cell
types in an adult) and totipotent (able to give rise to all embryonic and adult
lineages). Multipotent adult stem cells are found throughout the body, and they
include neural stem cells. The challenge in utilizing adult stem cells for disease
research is obtaining cells that are genetically matched to people with disease
phenotypes, and being able to differentiate them into the appropriate cell types of
interest. As adult neural stem cells reside in the brain, their isolation would require
considerably invasive and dangerous procedures. In contrast, pluripotent stem cells
are easy to obtain, due to the paradigm-shifting work on direct reprogramming of
human skin fibroblasts into induced pluripotent stem cells. This work has enabled
us to produce neurons that are genetically matched to individual patients. While we
are able to isolate pluripotent stem cells from patients in a minimally invasive
manner, we do not yet fully understand how to direct these cells to many of the
medically important neuroendocrine fates. Progress in this direction continues to be
made, on multiple fronts, and it involves using small molecules and proteins to
mimic developmentally important signals, as well as building on advances in
“reprogramming” to directly convert one cell type into another by forced expres-
sion of sets of transcription factors. An additional challenge involves providing
these cells with the appropriate environment to induce their normal behavior
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outside the body. Despite these challenges, the promise of producing human
neuroendocrine cell types in vitro gives opportunities for unique insights and is
therefore worthwhile.
Introduction
By the beginning of the twentieth century, humanity knew that the basic unit of the
brain was the neuron. We also knew that a person was born with all the neurons she
would ever have, as these neurons could not—under any conditions—regenerate.
This understanding left patients with diseases resulting from neuronal death caused
by injury or autoimmunity with few options. Over the course of the twentieth
century, this dogma has been overturned, driven by two advances: (1) the discovery
of neural stem cells, and (2) reprogramming technology that allows us to make
neurons that are genetically matched to individual people outside the body. While
the opportunities are clear, considerable technical challenges remain before they
can be fulfilled in the clinic.
The Basic Biology of Stem Cells
A stem cell is defined as any cell type with two fundamental capacities (1) self-
renewal and (2) differentiation. Self-renewal refers to a cell’s capacity to divide and
make other cells with the same properties. Differentiation refers to its ability to
make other cell types, performing other biological functions.
For instance, hematopoietic stem cells are found in the bone marrow, where they
generate progenitor cells that give rise to the cells of the immune system and red
blood cells.
Not all stem cells have the same “potency,” the capacity to give rise to similar
cell types. Broadly speaking, they are characterized as totipotent, pluripotent and
multipotent. The hematopoetic stem cells mentioned earlier are a multipotent cell
type: they are able to give rise to many kinds of cells, but only of the blood lineage.
In basic embryology, blood originates from the mesoderm, the middle layer of
an embryo, which forms as the embryo undergoes a process called “gastrulation”
shortly after fertilization. Gastrulation subdivides the cells in the group into three
broad layers: endoderm, which gives rise to the cells of many internal organs,
mesoderm, which gives rise to the muscles and the blood, and ectoderm, which
gives rise to the nervous system and epithelial layers. These three lineages are
referred to as the embryonic germ layers.
For mammals, even before gastrulation occurs, the tissues of the embryo
are classified into two other broad categories: extra-embryonic and embryonic.
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Extra-embryonic tissues are “outside the embryo,” referring primarily to the cells of
the amniotic sac and the placenta: organs that are essential for embryonic devel-
opment but are discarded after birth.
To be classified as “multipotent,” stem cells must make at least two different
lineages, usually from the same embryonic germ layer. In contrast, pluripotent stem
cells can make multiple lineages from all three embryonic germ layers but not from
extra-embryonic tissue. Finally, totipotent stem cells can make all three embryonic
germ layers and the extra-embryonic tissue. The only known indisputably totipotent
cell is the zygote.
Preimplantation Development and Embryonic Stem
(ES) Cells
In most animals, development occurs outside the body and the embryo is not
physically connected to the mother. Mammals, particularly placental mammals,
are an exception. However, even in placental mammals, not all development occurs
in the uterus. During the first few days of its development (exact number of days
varies depending on the species), the early mammalian embryo travels down the
fallopian tubes into the uterus. Once inside the uterus, the embryo invades the
uterine wall and establishes the organs that will support its further development—a
phenomenon known as implantation. Thus, the first days of development within the
fallopian tubes are called “preimplantation development.”
During preimplantation development, several important developmental events
occur. Of the biggest relevance to us is the first cell fate determination, or segre-
gation of the early totipotent cells into two lineages: extra-embryonic and
embryonic.
We will review these events as they occur in the mouse, the most commonly
studied mammalian model of development, and then discuss differences between
human and mouse development. At the first stage of development, the fertilized
zygote undergoes a series of three cell divisions to produce eight cells. At these
early stages, these cells are called blastomeres. The divisions that produce these
blastomeres are thought to be mostly “symmetric” (to produce cells with similar
properties), though blastomeres have been reported to exhibit bias toward particular
developmental lineages (Tabansky et al. 2013). During these early divisions, cells
do not increase in size: every division produces two daughter cells that are half the
size of the mother; they are called “cleavage” divisions.
Until the eight-cell stage, these cleavage stage blastomeres have very few cell
adhesion molecules, and they are separate from each other and readily distinguish-
able under a microscope. However, at the eight-cell stage, the molecules on the cell
membrane start to bind to each other, and the boundaries of the cells become
indistinguishable. This moment in development is called “compaction,” and though
compaction is morphologically striking, it is far from being a mere cosmetic
Basics of Stem Cell Biology as Applied to the Brain 13
change. Instead, it serves a very important role: differentiating the inside of the
embryo from the outside for the first time.
Immediately after compaction, most of the blastomeres are still able to give rise
to embryonic and extra-embryonic lineages. However, as they continue to divide,
some cells become separated from the outside. At the same time, the tight junctions
between the outside cells allow the formation of a fluid-filled cavity within the
embryo. The cells on the outside will now comprise the trophectoderm, which gives
rise to the placenta. Inside of the fluid-filled cavity, known as the blastcoel, the cells
with no contact with the outside of the embryo form a clump that adheres to the
trophectodermal cells. This clump is known as the inner cell mass (ICM). It
contains the pluripotent cells that will give rise to the embryo proper, as well as a
newly formed cell lineage that will give rise to the amniotic sack: the primitive
endoderm, or PE.
The trophectoderm is the cell lineage that will intercalate with the uterine lining
and allow implantation to occur. As this process proceeds, the pluripotent lineage
loses its ability to form PE, becoming another cell type known as the epiblast. The
distinction between ICM and epiblast is very important for understanding the
differences between mouse and human embryonic stem cells.
Derivation and Maintenance of Pluripotent Stem Cells:
Differences Between Mouse and Human
Mouse ES cells have been known and used for years before human embryonic stem
cells were derived (Thomson 1998).
While mouse and human ES cells indubitably share multiple features, including
pluripotency and the capacity to self-renew, they do not grow under the same
conditions in culture. More specifically, mouse ES cells absolutely require activa-
tion of the JAK-STAT3 signaling pathway in order to continue to proliferate,
usually achieved by the addition of the Leukemia Inhibitory Factor (LIF) to the
medium. In contrast, human ES cells absolutely require basic fibroblast growth
factor (bFGF) and Activin A signaling, and they will lose their ability to differen-
tiate and grow without them.
Human ES cells are not unique: ES cells isolated from most species share the
features of human ES cells, but not mouse ES cells. The question then becomes,
why is the mouse the outlier?
Mice have a unique property known as diapause; in times of stress or starvation,
females can delay implantation of blastocysts, which persist in the oviduct until
conditions improve. Most mammals do not have this ability. Diapause is mediated
by LIF; in fact, defects in diapause are the main phenotype of LIF-knockout mice.
These observations led researchers to conclude that conditions for culturing mouse
ES cells mimic the response of the ICM to diapause, whereas the conditions for
culture of ES cells from other animals do not.
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However, this raises an important point: why is it possible to derive ES cells
from other species at all? The currently favored hypothesis suggests that most ES
cultures mimic the conditions that exist in the embryo a little after implantation
but before the cells have begun the process of migration that will separate them into
the three germ layers. At this stage, the pluripotent lineage is called the epiblast, and
the cells derived from it can therefore properly be called “epiblast stem cells.”
The hypothesis described above makes several predictions about the nature of
human and mouse ES cells. One is that they will require different conditions and
display different properties. Indeed, they do: mouse ES cells have different growth
requirements, different differentiation requirements and different morphology than
human ES cells.
A second prediction would be that, if differences between mouse and human ES
in fact reflect different developmental states, then it should be possible to derive
mouse ES cells that have a more human-like phenotype, growth factor requirement
and morphology. Indeed, mouse epiblast stem cells were derived a few years ago,
and they share many of the characteristics of the cell type known as human ES cells
(Tesar et al. 2007). Mouse ES cells can also be converted to mouse epiblast cells,
and vice versa (Greber et al. 2010).
These findings have multiple applications for stem cell research. Of these,
perhaps the most urgent is that testing protocols on cheaper mouse ES cells before
trying them on human ES cells is not a good idea, as mouse ES cells are funda-
mentally different and respond to differentiation cues in a manner highly dissimilar
to human ES cells. However, it is possible to test differentiation protocols on mouse
epiblast stem cells as they respond to differentiation cues in a manner quite similar
to human ES cells.
How to Test Pluripotency?
The definition of stem cells is primarily functional. Therefore, any test to determine
whether a stem cell is in fact a stem cell must also be functional. For pluripotent
stem cells, this functionality encompasses the ability to self-renew and also to
differentiate into any cell type in the body.
The first property is quite easy to test: simply assess whether stem cells continue
to grow and produce more pluripotent stem cells. However, how do you test
whether a cell can differentiate into anything in the body?
In mouse ES cells, there are two tests of increasing stringency. In the less
stringent version of this test, pluripotent ES cells are injected back into the cavity
of the blastocyst, where they aggregate with the inner cell mass and, ideally,
contribute to the germ line and multiple other lineages. Usually the coat color of
the “recipient” blastocyst into which the cells were injected is different than the
color of the original “donor” mouse from which the stem cells were derived. The
chimeric mice therefore have variegated coloring resulting from a mix of two cells
of two different genotypes in their skin.
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This technology is also used to make transgenic mice: stem cells are genetically
modified in an appropriate way, and the chimeric mice resulting from the stem cell
transfer into the blastocyst are crossed to a wildtype mouse. If the stem cells
contributed to the germ line of the chimera, these animals can be expected to
produce at least some progeny where every cell carries the transgene. The presence
of the transgene in these progeny animals can be assessed by analyzing DNA from
their skin cells.
A more stringent test of pluripotency in mice relies on the fact that the embryo
has a form of quality control where only cells with two copies of the genome (one
from the mother, one from the father) can contribute to the adult organism. In using
this approach, people wait for the first division of the recipient embryo and then
fuse the two cells back together into one cell. The embryo continues to develop to
the blastocyst stage, but each of its cells now contains four copies of its genome:
two from the father and two from the mother, a feature called being “tetraploid.”
Due to that feature, the cells in the embryo are only able to form the placenta and
other extra-embryonic lineages and cannot contribute to the adult. However, if the
pluripotent cells with the normal number of genomes are introduced into this
embryo, they will form all the lineages of the adult. Because they are
complementing the function that the tetraploid cells lost in embryonic development,
this technique is known as “tetraploid embryo complementation.” It is considered
the gold standard of pluripotency in the mouse, but it can also be used to generate
transgenic mice more quickly.
However, neither of these techniques is applicable to humans, due to both
technological and ethical reasons. Therefore, the test for pluripotency in human
cells must be something different and less stringent.
One simple test is to remove the bFGF—on which the human ES cells rely to
stay pluripotent—from the media and to allow the cells to differentiate without
trying to influence their path. This test is frequently used as a preliminary charac-
terization of newly derived human pluripotent cell lines.
A more stringent test is to implant the cells into the body cavity of an immuno-
compromised mouse, where they will continue to grow, giving rise to a tumor,
called a teratoma, containing multiple fully differentiated lineages. After the tumor
grows, it is possible to test the number of different cells that were able to develop
within the mouse.
Why not just carry the whole test out in a dish, instead of implanting into a
mouse? Different cell types need different environments to grow, and it is impos-
sible to combine them all in the same preparation of cells and to allow them to
survive until analysis. However, in the mouse, the supply of blood and oxygen from
the body allows the teratoma to develop in a manner somewhat similar to what
might happen in an embryo, but in a more disordered fashion. Since the environ-
ment is more supportive of multiple different cell types, more different kinds of
cells in more mature states can be detected and the test is more stringent.
It is worthwhile mentioning that there are vast numbers of different kinds of cells
within the body, and it would be a daunting task to attempt to detect them all within
a teratoma. Therefore, while the teratoma can detect the ability of a cell to give rise
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to all three germ layers, it cannot be used as evidence that a particular cell line can
give rise to every single kind of cell in the body. Thus, a teratoma is an approxi-
mation of a test for the most stringent definition of pluripotency.
Opportunities and Challenges for Using ES Cells inMedicine
What do we do with pluripotent stem cells once we have them? Multiple uses have
been proposed for these cells, including (1) studying rare cell types, (2) disease
modeling, (3) drug screening and (4) transplantation therapies.
Of these, the most obvious and simple application is studying rare cell types.
While mice are readily accessible and their neurons can easily be isolated from the
brain and cultured in a dish, human cells are not always so easy to isolate and
manipulate. This is especially true in the brain, as death is currently primarily
defined by the cessation of brain function. Therefore, unlike many cells, neurons
cannot be harvested from people who have opted to donate their organs to research,
as the damage to the brain that is necessary to declare a person dead will also affect
the cells.
To study human neurons in detail another source of cells must be found, and
neurons derived from human pluripotent cells constitute one such source. Pluripo-
tent cells from most species tend to be predisposed to make neurons, making such
neurons easy to obtain. Additional protocols have been developed to ensure that
particular kinds of cells—of interest to people from the investigation of diseases
perspective—are preferentially made (Tabar and Studer 2014).
Growing neurons in culture can and has been used to address many questions
about their basic biology and their electrophysiological properties. However, it is
also true that results from experiments on cultured neurons need to be interpreted
very carefully. This caution should particularly apply to human neurons when they
are being studied outside the body and when differences between human and mouse
are revealed by the study. The question will always arise whether the differences
observed have to do with something that happens in the human brain or whether
they arise from the distinct ways that human and mouse neurons adapt to the
environment outside the body. Luckily, if the biochemical basis of the phenomenon
is known, the neurons in culture can be compared to human postmortem brains to
determine whether the phenomenon under study occurs in the body as well as in cell
culture.
Disease modeling builds on the study of normal human cell types, by comparing
cells that are obtained from pluripotent stem cells of patients with a particular
(usually genetic) disorder with cells from patients who do not have this particular
disorder. Prominent examples include amyotrophic lateral sclerosis and schizo-
phrenia (Marchetto and Gage 2012). Disorders where a person with a particular
genetic makeup is highly likely to get a disease are easier to study in culture than
disorders that develop in response to environmental stimuli or involve multiple cell
types, such as autoimmune diseases or Alzheimer’s disease. However, when the
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cells are provided with the proper environmental stimuli to induce a disease-like
state, it may eventually be possible to model a wide range of diseases in culture.
Once a good disease model has been established, drug screening can begin. Drug
screening in culture builds on disease modeling by treating cells with various
potentially therapeutic compounds and attempting to determine which compounds
can reverse or slow down the course of the disease. The simplest approach is to use
cells that express some sort of fluorescent protein or that secrete a particular
metabolite that indicates health and then measure how treatment with compounds
can alter the amount of fluorescence (a proxy for cell number) or metabolite in the
dish. Automated drug screening robots that can measure fluorescence from tens of
thousands of different samples are routinely used for drug screening. In this case, it
is not even necessary to know the mechanism of disease or the mechanism of action
of the compound in order to isolate an effective drug; however, it is desirable to
understand at least a little about the function of the drug before administering it to
patients.
Of all these approaches to using stem cells for medicine, perhaps the most
daunting and fraught with potential side effects is transplantation of stem cells
and cells derived from them back into a patient. Ideally, the cells would be perfectly
genetically matched to the patient, negating the necessity for immunosuppressive
drugs, which are necessary for conventional organ transplantation. This approach
can be risky because cells tend to accumulate abnormalities in culture, potentially
causing some of them to become tumorigenic; also, if the pluripotent cells are
insufficiently differentiated, their inherent tumorigenicity (see above) also becomes
a problem. However, recent phase 1 clinical trials have at least suggested that stem
cells could potentially cause functional improvements—with few adverse effects—
over the course of several years (Schwartz et al. 2012); whether this will hold true
for larger cohorts and longer term trials remains to be determined.
Obtaining Cells Genetically Matched to Patients:
Reprogramming, Cloning, and Induced Pluripotent Stem
Cells
In animals, pluripotent stem cells can be derived from embryos quite easily, but
human preimplantation embryos, while sometimes used in research in very specific
circumstances, are not widely available. In addition, the cells used for modeling
disease, drug screening and transplantation need to be genetically identical to the
patient, necessitating that the cells be derived from the person and not from their
offspring.
Given that a patient is an adult and therefore does not have any more embryonic
cells, some applications require that the cells be induced to revert back to an
embryonic-like state, or “reprogrammed.” While here reprogramming refers to
the conversion to an embryonic-like state, the term can also indicate a direct
18 I. Tabansky and J.N.H. Stern
interconversion of two different cell types into each other: for instance, a muscle
cell into a neuron. It generally refers to the types of interconversion that do not
occur under natural circumstances. In contrast, the term “differentiate” refers to
making a more adult cell type from a more embryonic cell type (or from a
multipotent stem cell), thereby replicating a process that normally occurs in nature.
Historically, there have been three methods for obtaining pluripotent stem cells
from patients: cell fusion, somatic cell nuclear transfer and direct reprogramming.
Of these, cell fusion is the simplest technique. The cytoplasms of the cells are
induced to combine together to form one cell (the nuclei can also combine into a
single tetraploid nucleus). Interestingly, if cells of different type are fused, they do
not produce an intermediate kind of cell. Instead, one of the cell types is “dominant”
over the other, and the resulting cell will have multiple nuclei but will otherwise be
functionally very similar, if not identical, to the dominant cell type. It so happens
that pluripotent cells are dominant over every other kind of cell, allowing
reprogramming by cell fusion.
However, the complication of this method is that, while it may theoretically be
possible to enucleate one of the cells or to remove one of the nuclei after fusion, no
practical method for doing so on a large scale has yet found wide acceptance. Thus,
most products of cell fusion are tetraploid (with the associated problems) and, to
make pluripotent stem cells genetically matched to a patient, you would have to
start with pluripotent cells from that patient, which obviates the usefulness of the
whole endeavor.
An alternate method of reprogramming cells to a pluripotent state first came into
prominence in 1996, when people were able to produce an adult sheep from a skin
cell isolated from another sheep. In this approach, called “somatic cell nuclear
transfer” (SCNT) and referred to colloquially as “cloning,” an egg cell has its
nucleus removed and replaced with a nucleus from a donor cell. In a way, SCNT
is simply a special case of cell fusion of an enucleated totipotent zygote with a
differentiated cell. The egg cell then goes on to develop as though it is an embryo,
producing a blastocyst from which stem cells can be derived and also, potentially,
an adult animal. Blastocysts have been produced by SCNT from multiple animals,
including, quite recently, humans (Chung et al. 2014). However, logistical and
ethical considerations involved with obtaining human eggs and making embryos
preclude this research from being applicable on a large scale to medicine. It may
eventually be possible to make cells resembling human eggs in culture from
pluripotent cells, but there are currently no established protocols for this approach.
Currently the most popular method of reprogramming for drug screening and
disease modeling relies on the delivery of four transcription factors (genes that
regulate expression of other genes) to adult cells in order to convert them into an
embryonic-like state (Takahashi and Yamanaka 2006). Named after Shinya
Yamanaka, who originally discovered this approach, they are also sometimes
known as the “Yamanaka factors.”
The original method relied on a type of genetically modified retrovirus from
which the DNA encoding viral genomes was removed and replaced with DNA
encoding each of the Yamanaka factors. Once the cell infected with the genetically
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modified virus became pluripotent, they were able to activate the intrinsic protec-
tive mechanisms found in pluripotent cells to inactivate this particular kind of virus.
Thus, once reprogrammed, these cells were again differentiated into other cell
types, and Yamanaka and multiple other groups were able to test the pluripotency
of these cells. The caveat is that retroviruses by themselves are carcinogenic, and
their presence is undesirable for any cells being transplanted back into patients,
which is why the cells reprogrammed by the Yamanaka method (called induced
pluripotent stem cells) are used primarily for disease modeling and studies of
diseases processes. However, multiple groups have published papers on alternative
approaches to reprogramming, including pieces of DNA that do not integrate into
the genome, a special kind of RNA molecule called micro-RNA and small mole-
cules (Schlaeger et al. 2015). The Yamanaka method currently remains the most
widespread technique but, going forward, it is quite likely that one of these other
methods will eventually replace it.
Opportunities and Challenges of Producing Hypothalamic
Neurons from Stem Cells
There is wide agreement that investigation of the function of the human hypothal-
amus could be enhanced by the production of hypothalamic-like neurons from ES
cells. Many diseases exist in which particular subpopulations of hypothalamic
neurons are absent or defective, and replicating the disease in culture for testing
of drug candidates or even producing the neurons and transplanting them back into
patients are obvious therapeutic opportunities. However, before neurons can be
investigated or transplanted, they first need to be produced, and that is quite a
daunting challenge.
In embryonic development, every cell needs to know what it has to become. It
would be inappropriate, for instance, for a cell located where the skin will be to
become a liver cell. However, a cell does not necessarily know where in the body it
is located. To inform each cell of its precise position and eventual fate, the
developing embryo relies on complex, overlapping gradients of multiple secreted
proteins (patterning factors) that activate molecules on the surface of the cells that,
in turn, alter the gene expression patterns of these cells. The history of the previous
signals is then recorded in the DNA of the cell by chemical alterations to both the
histones and DNA.
Thus, the fate determination of each cell in development depends on a variety of
inputs, including the timing of exposure to gradients of patterning factors, the cell’s
previous developmental history, and types and concentrations of patterning factors
that the cell experiences. Interactions with other cells and the local microenviron-
ment also play a considerable role, including determining whether a given cell will
survive or die. The cues and responses of the cells can be stunningly complex, and
development is incompletely understood even for the best-studied cell types. Even
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in the cleavage-stage embryo, where the system is quite simple, the signaling
pathway that differentiates inside from outside cells was discovered only in 2009
(Nishioka et al. 2009).
In the context of this complexity, it is stunning that we are at all able to
differentiate cells along particular pathways. Most stem cell differentiation pro-
tocols are far from 100% efficient when it comes to the phenotype of the cells that
they output. When contemplating that we do not actually understand most of the
interactions that occur during development, and that most differentiation protocols
use cell aggregates, it is quite clear that intercellular signaling within the dish is an
important component of stem cell differentiation protocols.
In the hypothalamus, one published protocol indeed relied on self-patterning of
mouse ES cells. In brief, cells were allowed to aggregate and develop with as few
(known) disruptive chemical cues as possible (Wataya et al. 2008). The success of
this protocol suggested that the hypothalamic cell fate is developmentally rather
simple and relies on few cues in order to be induced. Cut off from external
gradients, the cells produced hypothalamus almost by default. This approach
appeared to produce a number of neurons of different types expressing markers
found in the hypothalamus, so no particular peptide-secreting cell was the default
fate. An alternative explanation is that, in the absence of environmental cues, cells
tended towards fates that secreted the molecules necessary to induce the
hypothalamus.
However, in human ES cells, this protocol is considerably less efficient, so two
directed differentiation protocols have recently been published. This protocol
seems to produce a mixture of hypothalamic-like neurons (particularly, neuronal
subtypes found in the ventral hypothalamus; Merkle et al. 2015; Wang et al. 2015).
These neuronal mixtures are as close as we have gotten to producing individual
subtype hypothalamic-like neurons, and while they are a good start, the complex
microenvironment of that brain region creates problems for derivation of more
specific cell types. A lack of information about the developmental cues guiding the
specification of many hypothalamic cell types compounds this problem.
Direct Reprogramming: An Alternative Pathway
to Obtaining Patient-Matched Neuron-Like Cells
The discovery that cells could be induced to acquire an embryonic-like cell fate by
treatment with just four viruses to change gene expression naturally led to the
question of whether specific types of neurons could be obtained in a similar manner.
The answer from the field, thus far, seems to be a resounding “yes.” Multiple papers
have been published showing that infection of various fully differentiated cell types
with viruses is able to produce cells similar to various kinds of neurons (Tsunemoto
et al. 2015). However, not all protocols are as simple as the Yamanaka protocol,
with some requiring 20þ different genetically modified viruses to enter the same
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cell in order to be effective. Even with an efficiency of viral delivery of 95%, such
an approach would produce a conversion rate of less than 36%, assuming every cell
infected with virus is converted (which is very unlikely). In practice, the conversion
rates are often in the single digits.
The unique challenge of trying to obtain neuronal cells using this method, as
opposed to other cell types such as pluripotent cells or hepatocytes, is that neuronal
cells do not replicate. Thus, while for most other cell types it is possible to feed
them media that will allow replication of large numbers of that cell type at the
expense of others, this is not the case in neurons.
An additional concern is that introducing so many different viruses into cells is
likely to induce mutations, which could interfere with the normal function of the
cells and alter their properties. In addition, these mutations would present a high
risk of carcinogenesis when transferred into patients, making neurons obtained in
this manner poor candidates for transplantation therapies. It is possible that direct
conversion of neurons by other means, such as small molecules or delivery of
micro-RNAs, will circumvent both the efficiency and mutagenesis concerns.
Relevance of In Vitro Cell Types to Neuronal Biology
Nearly every discussion of in vitro modeling would have to start with the recogni-
tion that in vitro models lack many of the factors found within an intact organism
and that many aspects of the conditions found in vitro (for instance, high concen-
trations of oxygen and a lack of cell-to-cell contact in three dimensions) could
interfere with cell survival and function, giving rise to artifacts once cells are
studied in culture. It also cannot be denied that certain models in culture reflect
aspects of conditions within organisms better than others. Every batch of cells
differentiated from stem cells needs to be quality controlled to ascertain whether
the cell type being cultured reflects particular aspects of biology within the intact
organism.
Since the purpose of differentiating stem cells is fundamentally to make a
particular kind of cell normally found within the body, it is important to produce
a comprehensive and applicable definition of cell type. This task is complicated by
more and more data from single-cell RNAseq and electrophysiology studies that
are demonstrating considerable molecular and functional variation within cell
populations that would normally be defined as being the same “type.” One possi-
bility is to define a cell type as a population of cells within a range of phenotypes
that perform analogous functions within the intact organism (reviewed Tabansky
et al. 2016). Such a definition would naturally exclude any in vitro cell type, as that
cell type is found outside the organism, and it is philosophically impossible to rule
out the possibility of an undetected difference between a cell in culture and its
counterpart in the organism. Therefore, the aim should not be to faithfully replicate
every aspect of an in vivo cell type in culture but, instead, to produce a number
of models that reflect the interesting features of a cell type as closely as possible.
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This way, each new discovery made with a single model can be subjected to
multiple functional tests before being tested again in an organism. Using this
strategy, false discovery rates from in vitro models should be decreased.
Outlook
In summary, pluripotent stem cells offer a promising path to understanding and
treating neuroendocrine diseases. Considerable challenges remain before we are
able to transplant neurons derived from these cells into patients, but studying them
in culture might be more accessible. Using induced pluripotent stem cells, we can
produce cells that are genetically matched to patients to model development and
disease. However, in creating cells that can be used in culture, it is important to
keep in mind that it may be impossible to faithfully mimic every aspect of the
environment that they encounter in an organism, and thus the cells in culture may
behave differently than they would in a brain. It is, therefore, useful to create
multiple, redundant models of each cell type, so that false discovery can be
minimized. It is likely that the field will continue to advance rapidly, and that it
will produce considerable insights for neuroendocrinology.
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Human Pluripotent-Derived Lineages
for Repairing Hypopituitarism
Lorenz Studer and Viviane Tabar
Abstract Human pluripotent stem cells (hPSCs) present a potentially unlimited
source of specialized cell types for regenerative medicine. Over the last few years
there has been rapid progress in realizing this potential by developing protocols to
generate disease-relevant cell types in vitro on demand. The approach was parti-
cularly successful for the nervous system, where the field is at the verge of human
translation for several indications, including the treatment of eye disorders,
Parkinson’s disease and spinal cord injury. More recently, there has also been
success in deriving anterior pituitary lineages from both mouse and human pluri-
potent stem cells. In vitro-derived pituitary hormone-producing cell types present an
attractive source for repair in patients with hypopituitarism. However, several
hurdles remain towards realizing this goal. In particular, there is a need to further
improve the efficiency and precision with which specific hormone-producing line-
ages can be derived. Furthermore, it will be important to assess the potential of both
ectopic and orthotopic transplantation strategies to achieve meaningful hormone
replacement. The ultimate challenge will be repair that moves beyond hormone
replacement towards the full functional integration of the grafted cells into the
complex regulatory endocrine network controlled by the human pituitary gland.
L. Studer (*)
Developmental Biology, The Center for Stem Cell Biology, Memorial Sloan-Kettering Cancer
Center, New York, NY, USA
e-mail: studerl@MSKCC.ORG
V. Tabar (*)
Department of Neurosurgery, The Center for Stem Cell Biology, Memorial Sloan-Kettering
Cancer Center, New York, NY, USA
e-mail: tabarv@MSKCC.ORG
© The Author(s) 2016
D. Pfaff, Y. Christen (eds.), Stem Cells in Neuroendocrinology, Research and
Perspectives in Endocrine Interactions, DOI 10.1007/978-3-319-41603-8_3
25
Derivation of Human Neural Cell Types for Regenerative
Medicine
The isolation of human embryonic stem cells (ESCs; Thomson et al. 1998) and the
remarkable feat of reprogramming somatic cells back to pluripotency via induced
pluripotent stem cell (iPSC) technology (Takahashi et al. 2007; Takahashi and
Yamanaka 2006; Yu et al. 2007) have set the stage for a new era of regenerative
medicine. Human pluripotent stem cells (hPSCs), a term comprising both human
ESCs and iPSCs, are characterized by their potential to differentiate into any cell
lineage of the body. For many years, the main challenge in the field has been to
capture the broad differentiation potential of hPSCs towards specific cell lineages
relevant to modeling and treating human disease. However, there has been consi-
derable progress recently in establishing differentiation protocol for many key
lineages such as endoderm-derived insulin-producing pancreatic cells (Pagliuca
et al. 2014; Rezania et al. 2014) for the treatment of diabetes or mesoderm-derived
cardiac cells for heart repair (Chong et al. 2014). Some of the most dramatic
successes, however, have involved ectoderm-derived lineages, in particular retinal
and CNS lineages (for review see Tabar and Studer 2014)). In fact, the very first
attempts at translating ESC technology towards the treatment of human patients
was based on the use of oligodendrocyte precursor-like cells in patients with spinal
cord injury (SCI: Alper 2009; Priest et al. 2015). However, SCI patients represent a
challenging target for cell therapy, as the primary defect is a problem of connec-
tivity between the brain and spinal cord rather than the loss of a specific cell type.
Currently, the most widely pursued clinical target is the transplantation of hPSC-
derived retinal pigment epithelial cells (RPEs) in patients with macular degenera-
tion. There are nearly a dozen different RPE-based clinical trials either ongoing or
in the planning phase (Kimbrel and Lanza 2015). Initial results using hESC-derived
RPEs suggest that the approach can be translated safely into humans (Schwartz
et al. 2015).
Beyond eye disorders, there has been particular interest in developing cell-based
therapies for the treatment of various neurodegenerative disorders. In the case of
Parkinson’s disease (PD), several studies demonstrated excellent in vivo survival of
hPSC-derived midbrain dopamine (mDA) neurons in mouse, rat and non-human
primate hosts (Kirkeby et al. 2012; Kriks et al. 2011). The transplantation of mDA
neurons represents an example of replacing a highly specific neuronal subtype and a
strategy that is thought to involve functional integration of the grafted cells into the
existing neuronal networks. Indeed, a recent study from our group used opto-
genetics to demonstrate that functional rescue in the PD host animals depended
on the continued neuronal activity of the grafted hESC-derived mDA neurons, and
“switching-off” the graft led to a reversal of functional benefit within minutes
(Steinbeck et al. 2015). The ability to derive mDA neurons from hESCs and hiPSCs
and the promising pre-clinical data have set the stage for ongoing translational
efforts towards testing this approach in human PD patients. Clinical trials are being
planned in the US, Japan and Sweden, which have led to the formation of G-Force
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PD, a global effort to coordinate hPSC-based cell therapy efforts in PD (Barker
et al. 2015). Another neurodegenerative disease being targeted is Huntington’s
disease where several protocols have been published to generate authentic, striatal
medium spiny neurons and where there is some initial evidence of efficacy in
preclinical models (Arber et al. 2015; Delli Carri et al. 2013; Ma et al. 2012).
Finally, several promising strategies are under development using glial cells. These
include the transplantation of hPSC-derived oligodendrocytes in genetic models of
white matter loss (Wang et al. 2013) and the remyelination of the brain following
radiation-induced brain damage (Piao et al. 2015), a common and serious problem
in cancer patients subjected to cranial irradiation (Greene-Schloesser et al. 2012;
Schatz et al. 2000).
With our increasing ability to generate potentially any neural lineage on demand,
the main challenge in the field has moved beyond making a specific cell type
towards translation and therapy development in regenerative medicine. While the
initial therapeutic targets for cell therapy are focused on replacing highly defined
populations of cells such as RPEs or mDA neurons, it may be necessary in future
studies to replace multiple cell types in combination to achieve meaningful rescue
in a broader range of human disorders. A particular challenge for neuronal cell
therapies is the importance of developing pre-clinical and ultimately clinical evi-
dence that in vitro-derived cells can integrate into the complex circuitry of the
human brain.
Derivation and Application of Human Pituitary Lineages
Replacing endocrine cells is conceptually more straightforward than replacing CNS
neurons because there is no need to re-establish a complex synaptic circuitry to
achieve improved function. However, the pituitary gland is also highly complex
and acts as the master regulator of endocrine function, controlling a diverse range of
responses in the body including stress control, growth and sexual function. Such
complexity makes any treatment of hypopituitarism - the loss of pituitary function –
challenging, as many hormones need to be replaced in a coordinated manner. In the
context of cell therapy, this requires the ability to generate multiple hormone-
producing cells at scale and on demand. To date, the main focus of hPSC-based
approaches for treating endocrine disorders has been on the treatment of type I
diabetes (Bruin et al. 2015). One key rationale for proposing a cell-based approach
in diabetes is successful derivation of functional islet cells from hPSCs (Pagliuca
et al. 2014; Rezania et al. 2014) and the expectation that grafted pancreatic β-cells
will establish a feedback loop sensing glucose and adjusting insulin levels conti-
nuously throughout the day, something that is difficult to achieve by insulin injec-
tions. Furthermore, it appears likely that regulatory control can be achieved with
cells that are not placed orthotopically into the pancreas but injected into a
surgically more accessible tissue with high vascularity, such as the spleen or liver
(Bruin et al. 2015). In contrast, orthotopic placement may be more critical for
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pituitary cells that respond to rapid and short acting signals from the hypothalamus.
The challenge of recreating anterior pituitary lineage diversity in vitro was first
tackled using mouse ESC cells. In a seminal study by the Sasai lab (Suga
et al. 2011), a differentiation protocol was presented that allowed the derivation
of mouse pituitary lineages via a serum-free embryoid body (SFEBq) culture step.
SFEBq conditions were initially developed to generate forebrain lineages from
mouse (Watanabe et al. 2005) and subsequently from human ESCs (Eiraku
et al. 2008). In contrast to the forebrain, which is derived from the CNS, the anterior
pituitary gland is derived from the oral ectoderm, which is part of the cranial
placode lineages during development. To direct cell lineage towards oral ectoderm,
Suga et al. (2011) showed that BMP4 exposure could trigger the induction of
PITX2, an oral ectoderm marker, at the periphery of the differentiating SFEBs.
Subsequent exposure to agonists of sonic hedgehog (SHH) signaling triggered
expression of LHX3, which is a definitive anterior pituitary lineage marker. One
remarkable feature during the induction process is the morphogenetic movements
of the oral ectoderm that mimic the formation of Rathke’s pouch, an invagination of
the oral ectoderm occurring during development that results in anterior pituitary
gland formation. However, the overall efficiency of generating Pitx2+ oral ecto-
derm cells was low and most cells in the SFEBq cultures retained a neural identity.
Approximately 1–7% of the non-neural cells expressed specific hormones, a
number that was dependent on further modulation of WNT activation for induction
of growth hormone- (GH) or prolactin (PRL)-producing cells or inhibition of Notch
signaling for obtaining ACTH+ cells (Suga et al. 2011). For the in vitro-derived
ACTH+ cells, Suga et al. (2011) demonstrated CRH-dependent hormone secretion
in vitro. Furthermore, transplanted cells were able to survive in vivo in an animal
with surgically induced hypopituitarism, and they extended the life span of those
animals, presumably by partially restoring their stress response. Some of the key
questions raised by the Suga et al. study include whether the same technology can
be applied for human ESC and iPSCs, whether the overall yield of anterior pituitary
placode and hormone-producing cells can be improved and whether the 3D culture
step, allowing the interaction of oral ectoderm-like and hypothalamic tissue, is
critical for the efficient induction of anterior pituitary lineage cells.
Some initial answers to these questions came from an independent effort in our
laboratories aimed at inducing cranial placode lineages from hPSCs (Dincer
et al. 2013). Similar to the SFEBq technology, the human placode induction
strategy was based on a protocol, dual-SMAD inhibition (Chambers et al. 2009),
that was initially developed for inducing forebrain fates. Under dual-SMAD inhi-
bition conditions, a monolayer of human ESCs or iPSCs can be converted at nearly
100% efficiency into PAX6+ anterior neuroectoderm within about 10 days of
differentiation (Chambers et al. 2009). Dual-SMAD inhibition involves concomi-
tant exposure of hPSCs to inhibitors of BMP signaling (either Noggin or the ALK2/
3 inhibitor LDN193189) and inhibitors of TGFβ, Activin and Nodal signaling
(commonly via the small molecule compound SB431542). In Dincer
et al. (2013), we showed that the key difference between CNS versus placode
induction was the inhibition versus activation of BMP signaling. In contrast to
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the induction of CNS lineage under conditions of dual-SMAD inhibition, placode
induction requires the timed removal of the BMP inhibitor at 48 h after neural
induction, allowing endogenous BMP signaling to rebound. Under these default
placode induction conditions, the majority of the hPSC-derived cells expressed
PAX3, suggestive of trigeminal placode fate (Dincer et al. 2013). However, upon
activation of SHH signaling, there was a marked increase in oral ectoderm markers
such as PITX1 and SIX6. Further differentiation of these pituitary placode pre-
cursors was shown to yield various hormone-expressing cells, including ACTH+,
FSH+ and GH+ lineages with clear evidence of in vitro hormone release. Finally,
our study demonstrated that subcutaneous injection of hPSC-derived pituitary pre-
cursors into nude rats yielded measurable levels of ACTH and GH secretion in vivo.
The findings of Dincer et al. suggested that the robust induction of human pituitary
hormone-expressing cells did not require a 3D culture step. However, the overall
efficiency of pituitary placode induction remained suboptimal. Furthermore, the
media conditions during differentiation included components such as knockout
serum-replacement (KSR) that are known to introduce batch-to-batch variability
into the differentiation process. Furthermore, the study did not attempt to enrich for
specific hormone lineages that may be required to develop better tailored therapies
for each individual patient. A first step towards optimizing cranial placode induc-
tion in the absence of KSR was achieved by another study that carefully optimized
the timing of BMP4 application (Leung et al. 2013). The results indicated that early
exposure to BMP4 could increase overall cranial placode yield whereas the subse-
quent inhibition versus activation of BMP at later stages of differentiation could
modulate the regional identity of hESC-derived placodal cells from PAX6+ anterior
to PAX3+ posterior placode (Leung et al. 2013). Finally, the study confirmed that
activation of SHH signaling increased the expression of oral ectoderm markers
including PITX1 and PITX2.
More recently, members of the Sasai lab presented a study that adapted their 3D
approach to human cells (Ozone et al. 2016). The study was based on a modified
SFEBq culture system triggering differentiation in the presence of KSR, SHH
agonist and BMP4 to yield 3D structures composed of hypothalamic cells in the
center of the 3D aggregates and oral ectoderm cells at the periphery. In a proportion
of those structures, the authors again observed the spontaneous formation of
Rathke’s pouch-like structures similar to their original data in mouse ESCs, though
at a lower frequency. While the overall induction efficiency of definitive pituitary
lineages remained low, the authors were able to demonstrate both basal and
CRH-induced release of ACTH in vitro that was shown to be suppressed by
hydrocortisone treatment. Similarly, induction of GH could be modulated both
positively and negatively by exposure to GHRH or somatostatin, respectively.
Finally, subcutaneous injection of the 3D aggregates into mice with surgical
hypophysectomy showed evidence of in vivo ACTH production that was respon-
sive to CRH treatment. The transplanted cells also triggered significant, albeit very
low, levels of corticosterone production and led to improved body weight and
survival as compared to sham-grafted animals in hypophysectomized hosts.
Some of the key remaining challenges include further improving the efficiency and
reliability of pituitary lineage differentiation with a greater percentage of hormone-
producing cells.
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Perspectives and Challenges on the Road to Translation
The adenohypophysis (pituitary) is a remarkable endocrine organ that orchestrates
the function of multiple targets via secretion of a set of regulatory hormones in
charge of vital functions such as development, growth, puberty, reproduction,
lactation and, crucially, response to stress. It receives regulatory endocrine input
from the adjacent hypothalamus through a portal circulation system and commu-
nicates with the rest of the organism via an extensive network of vessels. Multi-
tiered feedback is integrated by this master gland, leading to hormonal and meta-
bolic homeostasis (Tabar 2011). The role of regenerative approaches to the adeno-
hypophysis has received very little attention despite the prevalence of pituitary
disorders and the large number of patients requiring pituitary hormone replacement
due to traumatic brain injury, genetic, sporadic or iatrogenic disease. Several
syndromes of pituitary deficiencies are recognized in humans as the result of
mutations of early transcription factors or cell cycle regulator proteins (Melmed
2011). One of the prevalent causes of pituitary deficiency is post-treatment pituitary
and hypothalamic damage. Specifically, and of interest to us, is a group of patients
who suffer from hypopituitarism as a consequence of brain radiation for a variety of
disorders, including hematological malignancies, head and neck cancers, brain
tumors and sellar lesions (Appelman-Dijkstra et al. 2011). In fact, growing interest
in cancer survivorship has identified hypopituitarism as a major contributor to poor
quality of life indices (Darzy 2009). The clinical consequences are extensive and
include fatigue, poor concentration, decreased memory and general cognitive
abilities as well as significantly reduced well-being. In children these consequences
are compounded by more serious learning difficulties and growth and skeletal
problems, as well as a major impact on puberty and sexual function (Chemaitilly
and Sklar 2010). Radiation damage to the hypothalamus and pituitary regions is
progressive and irreversible. Current treatment consists of life-long multiple hor-
mone replacement therapies, a suboptimal solution since static delivery of these
molecules is a poor substitute for normal pituitary gland features such as the
dynamic secretion of hormones in response to circadian patterns, feedback mech-
anisms or stressful conditions. In addition, treatment can be prohibitively expen-
sive, with costs of growth hormone replacement alone exceeding $20,000 per year.
One of the key challenges to restorative strategies, regardless of the etiology of
hypopituitarism, involves decisions regarding orthotopic or ectopic graft implanta-
tion. Grafts of pituitary tissue or primary cell suspensions from human fetal or
rodent sources have been performed extensively using ectopic (Fu and Vankelecom
2012) or more or less orthotopic placement in the pituitary (Falconi and Rossi
1964), hypothalamus (Tulipan et al. 1985) or in the third ventricle (Vuillez
et al. 1989). Overall, pituitary tissue or cells survive very well with the exception
of conditions of immunological mismatch. A major concern with ectopic (i.e.,
subcutaneous or kidney) placement is the absence of hypothalamic control. The
adenohypophysis is connected to the hypothalamus by a portal vein system that
allows the immediate delivery of hypothalamic factors, thus bypassing the systemic
circulation. Data from transplants in the hypothalamus, third ventricle or the
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hypophysis sites suggest that pituitary grafts demonstrate improved function and
response to feedback when they are in immediate contact with the hypothalamus
(Harris and Jacobsohn 1952; Maxwell et al. 1998). Some of the most successful
results have been obtained upon transplantation in hypophysectomized female rats
at the level of the median eminence, with good outcomes including restoration of
estrus cycles, ability to conceive and lactate pups, adequate growth hormone and
ACTH levels, as well as near normalization of body size in comparison to normal
controls (Harris and Jacobsohn 1952). Data from transplantation of mouse
ESC-derived pituitary cells (injected in the renal capsule) suggested statistically
significant elevation of basal ACTH and corticosterone (Suga et al. 2011). From a
translational perspective, ectopic placement in the subcutaneous tissue offers sig-
nificant advantages due to the low risk of the intervention (e.g., in a subcutaneous
location) and easy accessibility in case of complications. The experimental evalu-
ation of ectopic grafts may therefore be a justifiable strategy, though integration
within the hypothalamic-pituitary-target organ axis and homeostatic control is more
likely to be achieved if grafts are placed in the vicinity of the hypothalamus or even
within the gland itself. Interestingly, in humans, placement in the sella is simpler
than in rodents, due to the development of minimal invasive transnasal endoscopic
approaches to the sella and anterior skull base. Experimental evidence of hypo-
thalamic control upon grafting of pituitary cells requires complex assays and
readouts, including stimulation tests [e.g., response to thyrotropin releasing hor-
mone (TSH) or to growth hormone-releasing hormone (GHRH) etc.], physiological
stress tests [e.g., exposure to cold, arginine testing followed by evaluation of
variations in pituitary hormone levels (Akalan et al. 1988; Fisker et al. 1999;
Guillemin 2005)]. Behavioral testing can also contribute to the evaluation of the
integrity of the hypothalamic-pituitary-target organ axis and its feedback loops.
Demonstrating appropriate integration into the neuroendocrine system and its
physiological and homeostatic feedback loops should be considered an important
component of both efficacy and safety of this strategy. Obviously uncontrolled or
random secretion of key hormones such as ACTH or growth hormone can have
serious negative health consequences.
Additional considerations in translational strategies would include the possibil-
ity of grafting specific pituitary sublineages, e.g., ACTH- or growth hormone-
secreting. This approach might require more sophisticated differentiation protocols
and, likely, selection strategies that should be compatible with good manufacturing
practice (GMP) conditions and safety standards.
Conclusion
The recent successful derivation of pituitary placode lineage and the range of
anterior pituitary hormone-producing cells are very exciting advances that will
likely herald the development of restorative strategies in humans. Several chal-
lenges along the road to translation remain to be tackled. Key questions include the
Human Pluripotent-Derived Lineages for Repairing Hypopituitarism 31
ability to develop selective pituitary sublineages that produce a single target
hormone, the development of grafting strategies for human patients, and the
demonstration of integration of the grafted cells into the hypothalamic-pituitary-
peripheral target axis, a goal that is fundamental to the safety assessment of the cell
therapy-based approach to hypopituitarism.
Note Added in Proof
A recent manuscript from our team presents a fully defined and efficient protocol
for the derivation of anterior pituitary hormone producing cells from human pluri-
potent stem cells and demonstrates hormone release in a rat model of hypo-
pituitarism (Zimm et al. 2016).
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Recapitulating Hypothalamus and Pituitary
Development Using Embryonic Stem/
Induced Pluripotent Stem Cells
Hidetaka Suga
Abstract The hypothalamic-pituitary system is essential for maintaining life and
controlling systemic homeostasis. However, it can be negatively affected by vari-
ous diseases, resulting in life-long serious symptoms.
Pluripotent stem cells, such as embryonic stem (ES) cells and induced pluripo-
tent stem (iPS) cells, differentiate into neuroectodermal progenitors when cultured
as floating aggregates under serum-free conditions.
Recent results have shown that strict removal of exogenous patterning factors
during the early differentiation period induces efficient generation of rostral
hypothalamic-like progenitors from mouse ES cell-derived neuroectodermal cells.
The use of growth factor-free, chemically defined medium was critical for this
induction. The ES cell-derived hypothalamic-like progenitors generated rostral-
dorsal hypothalamic neurons, in particular magnocellular vasopressinergic neurons,
which release hormones upon stimulation.
We subsequently reported efficient self-formation of three-dimensional adeno-
hypophysis tissues in aggregate cultures of mouse ES cells. The ES cells were
stimulated to differentiate into non-neural head ectoderm and hypothalamic
neuroectoderm in adjacent layers within the aggregate, followed by treatment
with a Sonic Hedgehog agonist. Self-organization of Rathke’s pouch-like structures
occurred at the interface of the two epithelia in vivo, and various endocrine
cells, including corticotrophs and somatotrophs, were subsequently produced. The
corticotrophs efficiently secreted adrenocorticotropic hormone in response to
corticotropin-releasing hormone. Furthermore, when engrafted in vivo, these cells
rescued systemic glucocorticoid levels in hypopituitary mice.
The present study aimed to prepare hypothalamic and pituitary tissues from
human pluripotent stem cells and establish effective transplantation techniques for
future clinical applications. Preliminary results indicated differentiation using
human ES/iPS cells, and the culture method replicated stepwise embryonic differ-
entiation. Therefore, these methods could potentially be used as developmental and
disease models as well as for future regenerative medicine.
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Introduction
The hypothalamus and adenohypophysis maintain physiological homeostasis by
controlling the endocrine system. A collection of studies exploring their develop-
ment and function has shown that they are essential for the regulation of vital
functions. However, their regeneration remains largely unclear.
Recently, somatic stem cells have been recognized as a major source for tissue
maintenance and regeneration. A 2005 study reported that somatic stem cells exist
in the adenohypophysis (Chen et al. 2005). Subsequent studies have discussed
their functions during early postnatal pituitary maturation (Fauquier et al. 2001;
Kikuchi et al. 2007; Chen et al. 2009; Gremeaux et al. 2012; Mollard et al. 2012),
after pituitary damage (Luque et al. 2011; Fu et al. 2012; Langlais et al. 2013), and
in pituitary tumorigenesis (Gaston-Massuet et al. 2011; Andoniadou et al. 2012;
Garcia-Lavandeira et al. 2012; Li et al. 2012).
In addition to somatic stem cells, studies have focused on embryonic stem
(ES) cells and induced pluripotent stem (iPS) cells. These pluripotent stem cells
exhibit self-renewal properties and pluripotent differentiation. Therefore, they have
attracted attention as a cell source for differentiated tissues in clinical applications.
A Need for Hypothalamus and Adenohypophysis
Regenerative Medicine
The hypothalamus and adenohypophysis are located in adjacent regions, and they
coordinate functions as the center for the endocrine systems. Following dysfunc-
tion, patients experience various systemic symptoms. Current treatment primarily
consists of hormone replacement therapy, but various factors can complicate the
proper dose. Drug administration cannot precisely mimic the circadian or stress-
induced changes of hormone requirements. For example, we have reported that
some patients with central diabetes insipidus show unstable serum Na levels,
resulting in a poor prognosis (Arima et al. 2014). This instability is caused by the
lack of positive and negative control systems, which is characteristic of hormone-
producing cells. As for hypopituitarism, it has been reported that adrenal crisis
occurs in a substantial proportion of society, and adrenal crisis-associated mortality
is not negligible, even in educated patients (Hahner et al. 2015). Furthermore,
adrenocorticotropic hormone (ACTH)-dependent adrenal insufficiency, as well
as high-dose hydrocortisone treatment, serves as a predictor for acromegaly-
associated mortality (Sherlock et al. 2009; Ben-Shlomo 2010). Taken together,




The establishment of mouse pluripotent ES cells significantly contributed to the
advancement of biology and medicine. In 1981, Evans and Kaufman successfully
established mouse ES cells from the inner cell mass of mouse blastocyst-stage
embryos (Evans and Kaufman 1981). Various knock-out and knock-in mice have
been established using genetically modified ES cells, which have contributed to our
understanding of gene functions (Bernstein and Breitman 1989; Babinet and
Cohen-Tannoudji 2001).
There are two reasons for the use of mouse ES cells, rather than human ES cells,
in our recent studies. One reason is the short developmental period; the duration of
mouse fetal development is about 20 days, which is much shorter than the 300 days
of human development. Therefore, mouse ES cells are suitable for establishing
novel differentiation methods with numerous trial-and-error processes. Another
reason is the similarity between mouse and human cells. For example, the retinal
differentiation method from human ES cells (Nakano et al. 2012) was established
based on a previous report using mouse ES cells (Eiraku et al. 2011). Although
the inducing culture methods differ considerably, their key principles are similar.
The fundamental processes of mouse ES cells appear to be applicable to human
ES cells.
Pituitary Gland Embryology
The adenohypophysis, which corresponds to the anterior pituitary gland, contains
several types of endocrine cells that secrete factors including adrenocorticotropic
hormone (ACTH), growth hormone (GH), prolactin (PRL), thyroid-stimulating
hormone, luteinizing hormone, and follicle-stimulating hormone. The posterior
pituitary gland consists of axons and terminals of hypothalamic neurons, i.e.,
vasopressin and oxytocin neurons. The development of the adenohypophysis is a
complex process. During early development, the adenohypophysis anlage origi-
nates as a placode in the non-neural ectoderm adjacent to the anterior neural plate
(Fig. 1a). Both the adenohypophysis placode and hypothalamic anlage interact with
each other. Accordingly, the thickened placode invaginates and subsequently
detaches from the oral ectoderm to form a hollowed vesicle, termed “Rathke’s
pouch” (Zhu et al. 2007; Fig. 1b). The molecular nature of this local inductive
interaction during this initial phase of pituitary formation remains elusive, but
FGF and BMP signals appear to be involved (Takuma et al. 1998; Brinkmeier
et al. 2007).
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Three-Dimensional ES Cell Culture
Organ formation during embryogenesis consists of complicated processes that
involve various local interactions between different tissues or cells. Despite this
complexity, organogenesis can be modeled in vivo. Our colleagues established a
three-dimensional culture method for ES cells called “serum-free culture of embry-
oid body-like aggregates with quick re-aggregation (SFEBq)” (Watanabe
et al. 2005; Eiraku et al. 2008). The culture method is quite simple. First, the
quality of maintenance for undifferentiated ES cells is very important. For SFEBq
culture, maintained ES cells are dissociated to single cells in trypsin or something
similar. The cells are then quickly aggregated using low-cell adhesion 96-well
plates in differentiation medium suitable for each differentiation purpose.
This culture method is suitable for induction of various ectodermal derivatives
from ES cells. In SEFBq cultures, the ES cell aggregates exhibit self-organization
(Sasai et al. 2012) and spontaneous formation of a highly ordered structure or
patterning. This floating culture has revealed intrinsic programs that drive locally
autonomous modes of organogenesis and homeostasis. Using the SFEBq method,
mesencephalic dopamine neurons (Kawasaki et al. 2002; Morizane et al. 2006),
cortex neurons (Eiraku et al. 2008; Danjo et al. 2011; Kadoshima et al. 2013), the
optic cup (Eiraku et al. 2011; Ikeda et al. 2005; Osakada et al. 2008), cerebellar
neurons (Muguruma et al. 2010), and hippocampal neurons (Sakaguchi et al. 2015)
have been generated from mouse and human ES cells.
Induction of Hypothalamic Neurons from Mouse ES Cells
Using SFEBq cultures, hypothalamic neurons such as vasopressin-positive neurons
have been induced from mouse ES cells (Wataya et al. 2008). The differentiation
occurs efficiently when the ES cell aggregates are cultured in growth factor-free,
chemically defined medium (gfCDM). Strict removal of exogenous patterning
Fig. 1 Diagram of mouse pituitary development. (a) Dorsal view of neural plate and placodes. (b)
Sagittal view of pituitary embryogenesis. E embryonic day
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factors during early differentiation steps induces efficient generation of rostral
hypothalamic-like progenitors (Rax(+)/Six3(+)/Vax1(+); these combinations are
characteristic for hypothalamic precursors) in mouse ES cell aggregates. The use
of gfCDM is critical. For example, even the presence of exogenous insulin, which is
commonly used in cell culture, strongly inhibits differentiation via the
Akt-dependent pathway. The ES cell-derived hypothalamic progenitors generate
Otp(+)/Brn2(+) neuronal precursors (characteristic of rostral-dorsal hypothalamic
neurons) and subsequent magnocellular vasopressinergic neurons that release vaso-
pressin upon stimulation. Additionally, differentiation markers of rostral-“ventral”
hypothalamic precursors and neurons have been induced from ES cell-derived Rax
(+) progenitors by treatment with Sonic Hedgehog (Shh).
Thus, in the absence of exogenous growth factors in the medium, ES cell-
derived neuroectodermal cells spontaneously differentiated into rostral (particu-
larly rostral-dorsal) hypothalamic-like progenitors, which generated characteristic
hypothalamic neuroendocrine neurons in a stepwise fashion, as observed in vivo.
These findings indicated that, instead of the addition of inductive signals, minimi-
zation of exogenous patterning signaling played a key role in rostral hypothalamic
specification of neural progenitors derived from pluripotent cells. This work also
showed that the default fate of mouse ES cells is the rostral hypothalamus (Wataya
et al. 2008).
Two-Layer Formation In Vitro Is the First Step
of Adenohypohysis Differentiation
We next established an in vitro differentiation method for the anterior pituitary (38).
Rathke’s pouch is formed as a result of interactions between the hypothalamus and
neighboring oral ectoderm (Zhu et al. 2007). To recapitulate embryonic pituitary
development, we co-induced these two tissues within one ES cell aggregate.
Previous results have shown hypothalamic differentiation from mouse ES cells
(37). Mouse ES cells can be induced to differentiate into hypothalamic cells when
cultured as floating aggregates using the SFEBq method with gfCDM. Therefore,
the present study used a technical modification to co-induce oral ectodermal
differentiation in addition to hypothalamic differentiation.
We attempted to slightly shift positional information so that the oral ectoderm
co-existed with hypothalamic tissues (Suga et al. 2011). As shown in Fig. 1a, the
oral ectoderm is generated from the rostral and midline region adjacent to the
hypothalamic region in the mouse embryo. Therefore, the rostral and midline
shifting information was relevant for mouse ES cell aggregates in the SFEBq
culture. We tested many culture conditions known to affect early ectodermal
patterning. We ultimately identified two conditions that efficiently induced oral
ectoderm. One condition was the addition of bone morphogenetic protein
4 (BMP4). However, treatment with 0.5 μMBMP4 strongly inhibited hypothalamic
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neuron differentiation instead of inducing oral ectodermal differentiation. The other
condition was high-density cell aggregation (10,000 cells per aggregate instead of
3,000 in SFEBq culture), which we refer to as large cell aggregation (LCA; Fig. 2a).
In the LCA culture, both the oral ectoderm (Pitx1/2+) and hypothalamic tissues
co-existed within one aggregate (Fig. 2b).
LCA culture allows for the formation of oral ectoderm epithelium on the surface
of mouse ES cell aggregates as well as hypothalamic neural tissue in the inner
layer adjacent to the oral ectoderm (Fig. 2b). Treatment with a BMP4 antagonist,
dorsomorphin, has been shown to suppress the generation of oral ectoderm (Suga
et al. 2011). Quantitative polymerase chain reaction analyses revealed significantly
higher internal BMP4 expression in LCA aggregates (Suga et al. 2011). Moreover,
Koehler et al. succeeded in differentiating the otic placode (Fig. 1a; Koehler
et al. 2013), which belongs to the head and oral ectoderm, following BMP treatment
of mouse ES cells, which supports the reliability and robustness of this strategy.
Our recent study showed that very low concentrations (picomolar level) of exog-
enous BMP4 treatment facilitated differentiation into non-neural ectoderms, which
contained not only pituitary primordium but also dental germs (Ochiai et al. 2015).
Taken together, these findings appear to indicate that appropriate BMP4 expression
is important for head ectoderm induction (Wilson and Hemmati-Brivanlou 1995;
Basch and Bronner-Fraser 2006; Davis and Camper 2007).
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Fig. 2 In vitro differentiation into anterior pituitary from mouse ES cells (ESCs). (a) Diagram of
SFEBq. (b) Two-layer formation in LCA aggregates. (c) Self-formation of Rathke’s pouches. (d)
Subsequent generation of ACTH+ cells
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Self-Formation of Rathke’s Pouch
In the developing embryo, Rathke’s pouch forms at the midline of the head
ectoderm. Shh is expressed in the ventral diencephalon and oral ectoderm but is
excluded from the invaginating Rathke’s pouch (Zhu et al. 2007; Wang et al. 2010).
Rathke’s pouch receives Shh signals from neighboring tissues in vivo, and Shh is
known to provide positional information to adjust towards the midline (Zhu
et al. 2007). Therefore, we added smoothened agonist (SAG) as a strong Shh signal
to the differentiation medium of mouse ES cell aggregates in vitro. On day
13, multiple oval structures formed in the SAG-treated LCA SFEBq aggregates
(Fig. 2c). The vesicles were situated between the oral ectoderm and hypothalamic
neurons. Lim3 (formal gene name is Lhx3) expression indicated that the vesicles
had similar characteristics to Rathke’s pouch. These Lim3+ tissues appeared as a
thick epithelium on the surface that then invaginated and finally formed hollowed
vesicles. The length of the major axis was about 200 μm, which is almost equal to
the size of the embryonic Rathke’s pouch. The size of Rathke’s pouch seems to be
prescribed.
Interactions between oral ectoderm and hypothalamic neurons appear to be
critically important. Neither isolated surface ectoderm alone, nor isolated hypotha-
lamic tissues alone, formed Lim3+ pouches. Only in cases where the two divided
components were re-assembled did Lim3+ expression recover to some extent (Suga
et al. 2011).
These findings demonstrate self-formation of Rathke’s pouch in mouse ES cell
aggregates. It has also been shown that Rathke’s pouch forms even without
mesenchymal cells, because this model contains only ectodermal cells.
Interestingly, a single aggregate often contains several pouches whereas there is
usually only one pouch in the embryo (Suga et al. 2011). This finding suggests that
several morphogenetic fields for pituitary placodes can be independently generated
within the oral ectoderm epithelium on the surface of the ES cell aggregate, which
is reminiscent of the Vax1 knock-out mouse (Bharti et al. 2011). A second Rathke’s
pouch develops in addition to the orthotopic anlage in the Vax1 knock-out
mouse. Ectopic expression of FGF10, which is expressed in the infundibulum
and implicated in pituitary induction, is also detected in the hypothalamic
neuroepithelium overlying the second pouch. Thus, Vax1 likely limits the hypo-
thalamic neuroepithelium area that generates pituitary-inducing signals. Indeed,
Vax1 expression in vivo is eliminated near the infundibulum, which has inducing
activity for pituitary development. In the mouse ES aggregates used for pituitary
differentiation in the present study, Vax1-positive cells did not exist in the hypo-
thalamic area. Conversely, Wataya’s aggregate for hypothalamic differentiation
(Wataya et al. 2008) has been shown to contain Vax1-positive cells. We speculate
that precise positioning in the hypothalamus slightly shifts as a result of BMP4 and
Shh signals.
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Differentiation Into Hormone-Producing Endocrine Cells
During pituitary development in the embryo, Lim3+ pituitary progenitors commit to
several lineages (Davis et al. 2011), i.e., corticotroph, somatotroph, lactotroph,
thyrotroph, gonadotroph, and melanotroph lineages. Among them, the ACTH-
producing corticotroph lineage expresses the transcription factor Tbx19 prior to
ACTH expression. As Notch signaling inhibits Tbx19 expression (Lamolet
et al. 2001; Zhu et al. 2006; Kita et al. 2007), we evaluated the effect of the
Notch inhibitor DAPT. As a result, DAPT treatment increased Tbx19 expression
in SAG-treated LCA SFEBq aggregates. A substantial number of ACTH+ cells
appeared in the Tbx19+ lesion (Fig. 2d). Without DAPT treatment, corticotroph
differentiation efficiency was decreased, and other lineages were not detected.
Previous reports have shown that canonical Wnt signaling promotes Pit1 expres-
sion (DiMattia et al. 1997; Olson et al. 2006; Sornson et al. 1996). Consistent with
this finding, treatment with the Wnt agonist BIO increased Pit1 expression,
resulting in subsequent GH+ and PRL+ cell differentiation.
Head mesenchyme has been suggested to promote pituitary development in vivo
(Gleiberman et al. 1999). Therefore, we applied conditioned medium from PA6
stromal cells to SAG-treated LCA SFEBq aggregates. As a result, we successfully
induced luteinizing hormone-positive, follicle-stimulating hormone-positive, and
thyroid-stimulating hormone-positive cells. Further investigation is necessary to
identify factors in the PA6-conditioned medium.
Lim3 is essential for these hormone-producing lineages. To suppress Lim3
expression in differentiating mouse ES cells, we used the Tet-inducible shRNA
expression lentivirus vector system (kindly gifted from Hiroyuki Miyoshi at
RIKEN BioResouce Center). Knockdown of Lim3 inhibited subsequent differenti-
ation into hormone-producing cells, which supports altered pituitary development
in Lim3 knockout mice (Sheng et al. 1996).
These results demonstrate the competence of ES cell-derived pituitary progen-
itors to generate multiple endocrine lineages in vitro.
Functionality of Induced ACTH+ Cells
Positive and negative regulations by exogenous stimuli are characteristic for endo-
crine cells. To investigate in vitro functionality, we induced ACTH+ cells for
evaluation because they are most efficiently generated using the SAG-treated
LCA SFEBq method.
After 10 min of stimulation by corticotropin releasing hormone (CRH), substan-
tial amounts of ACTH were secreted from SAG-treated LCA SFEBq aggregates
in vitro (Fig. 3a). The secreted ACTH concentration was similar to levels in mouse








Fig. 3 Functional tests of mouse ES-derived ACTH+ cells. (a) In vitro release from mouse
ES-derived ACTH+ cells. F, glucocorticoid pretreatment. Among the releasing factors, CRH
most efficiently induces ACTH secretion. (b) Negative feedback test. Pretreatment with hydro-
cortisone suppresses CRH-stimulated ACTH secretion from aggregates. (c) In vivo functional test
by ectopic transplantation. All mice, except for the WT mice, received a hypophysectomy;
hypopituitarism was confirmed by CRH loading. S +D+, SAG- and DAPT-treated aggregates.
S-D-, no SAG or DAPT treatment. The values shown on graphs represent mean s.e.m.
*P< 0.05; **P< 0.01; ***P< 0.001 (modified from Suga et al. 2011). (d) Blood ACTH and
subsequent release of corticosterone. (e) Improved activity and survival
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by the downstream glucocorticoid hormone. Consistent with this control principle,
in vitro ACTH secretion as a result of CRH stimulation was suppressed by gluco-
corticoid pre-treatment (Fig. 3b).
Similar to in vivo endocrine systems, these data demonstrate that mouse ES cell-
derived ACTH+ cells respond to both positive and negative regulators. These
hormonal responses to surrounding regulators are indispensable for homeostasis.
For this reason, the generation of anterior pituitary tissue that retains regulatory
hormonal control in vitro is an important step for the development of cell trans-
plantation therapies for pituitary diseases. Furthermore, we suggest that the endo-
crine organoid formed in this three-dimensional culture condition might better
reflect the in vivo microenvironment. Such approaches may be beneficial for
producing other functionally mature endocrine tissues.
Effect of Transplantation Into Hypophysectomized Model
Animals
Finally, we evaluated the transplantation effect of the induced ACTH+ cells.
Because of technical difficulties, we chose ectopic transplantation into the kidney
subcapsule (Fig. 3c) instead of orthotopic transplantation into the sella turcica. At
one week after transplantation, blood ACTH levels were slightly, but significantly,
increased. CRH loading induced a substantial elevation in blood ACTH levels
(Fig. 3d). The downstream glucocorticoid hormone corticosterone was also signif-
icantly increased, indicating that ACTH from the graft sufficiently induced the
downstream hormone (Fig. 3d).
Even without CRH loading, the basal levels of ACTH were higher. Importantly,
corticosterone levels were also increased, suggesting that partial recovery of blood
ACTH had a moderate, but biologically significant, effect (note that ED50 of the
ACTH receptor MC2R for glucocorticoid production is around 9 pg/mL; Melmed
2011). In accordance with this finding, the treated hypophysectomized mice
displayed higher spontaneous locomotor activities and survived significantly longer
(Fig. 3e). Although CRH, which is secreted from the hypothalamus, should be
diluted in the peripheral site, mouse ES cell derived pituitary tissues rescued
survival and spontaneous activities, suggesting that basal secretion from these
tissues was sufficient for those effects.
These findings showed that induced ACTH+ cells derived from mouse ES cells
acted as endocrine tissues and that regenerative medicine for pituitary dysfunction
is feasible.
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Adaptation to Human ES/iPS Cell Culture
The recovery of lost pituitary function is an important issue for medical studies
because the anterior pituitary has poor potential for regeneration. Because some
pituitary dysfunctions cannot be solely treated by drugs (Arima et al. 2014; Hahner
et al. 2015; Sherlock et al. 2009), regenerative therapy employing stem cells should
be considered as a new form of therapeutic intervention. Our SFEBq method (Suga
et al. 2011) induces pituitary cells that can auto-regulate hormonal secretion and
respond to changing circumstances. The application of this culture method to
human ES cells is necessary for clinical purposes. However, poor survival of
human ES cells in SFEB culture might limit the use of these cells for future medical
applications. Our colleagues found that a selective Rho-associated kinase (ROCK)
inhibitor, Y-27632, markedly diminished dissociation-induced apoptosis of human
ES cells and enabled the cells to form aggregates in SFEB culture (Watanabe
et al. 2007). Using this fundamentally important discovery, we attempted to adapt
our pituitary-differentiating culture method for human ES cell culture. We were
able to obtain corticotrophs and somatotrophs from the human ES cells, although
these are still preliminary data.
Results demonstrated that the anterior pituitary self-forms in vitro following
co-induction of the hypothalamic and oral ectoderm (Fig. 4a). The juxtaposition of
these tissues facilitated the formation of the pituitary placode, and their features
were consistent with characteristics of Rathke’s pouch in vivo. The human ES cell-
derived Rathke’s pouch was much larger than the pouch formed by mouse ES cells,
which was in accordance with the size difference between human and mouse
embryonic Rathke’s pouches. These pituitary placodes subsequently differentiated
into pituitary hormone-producing cells. All six types of pituitary hormone-
producing cells were identified (Fig. 4b). Among them, we confirmed that the
human ES-derived corticotroph responded normally to releasing and feedback
signals. Electron microscopy revealed secretory granules stored in the cytoplasm
of these cells (Fig. 4c).
For both mouse and human ES cells, SFEB culture is a favorable method that can
generate functional pituitary cells. Future studies will confirm whether human iPS
cells can differentiate into pituitary cells using the same culture methods.
Future Perspectives
There are two primary uses for human ES/iPS cell-derived pituitary cells. One is the
human model of development or disease. Results from our study showed that the
present culture methods recapitulated embryogenesis, suggesting that it could be
used in the area of developmental biology. In terms of diseases due to gene
mutations, tissues derived from disease-specific iPS cells can be used for therapy
screenings in a human disease model.
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The second major use for human ES/iPS cell-derived pituitary cells is for
regenerative medicine. Although stem cell-based therapeutics provide high expec-
tations for the treatment of diabetes mellitus, the use of regenerative medicine for
hypothalamus-hypophyseal dysfunctions has received little attention.
ES cell-derived ACTH-producing cells function even after ectopic transplanta-
tion. This finding raises the possibility of relatively simple grafting of artificial
ES/iPS cell-derived pituitary tissues into a peripheral site. These cells can function













Fig. 4 Human ES culture. (a): Recapitulation of Rathke’s pouch formation. (b) Differentiation of
corticotrophs and somatotrophs. (c) Secretory granules characteristic of endocrine cells
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or small molecule agonists. However, ectopic transplantation is not perfect because
physiological CRH released from the hypothalamus does not directly affect these
grafts. Orthotopic transplantation of hormone-producing cells that are controlled by
positive and negative regulators is one of the future candidates for complete
therapy.
In future studies, it will be challenging to recapitulate an entire anterior pituitary
gland that contains all endocrine components in three-dimensional cultures of
human ES or iPS cells and to use such artificial pituitary tissues for orthotopic
transplantation into the sella of a large mammal. To achieve this long-term goal,
further studies are needed before pituitary regenerative medicine can be directly
transferred to clinical use.
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Regulation of Body Weight and Metabolism
by Tanycyte-Derived Neurogenesis in Young
Adult Mice
Seth Blackshaw, Daniel A. Lee, Thomas Pak, and Sooyeon Yoo
Abstract The hypothalamus controls many homeostatic and instinctive physio-
logical processes, including the sleep-wake cycle, food intake, and sexually dimor-
phic behaviors. These behaviors are regulated by environmental and physiological
cues, although the molecular and cellular mechanisms that underlie these effects are
still poorly understood. Recently, it has become clear that both the juvenile and
adult hypothalamus exhibit neurogenesis, which modifies homeostatic neural cir-
cuitry. In this manuscript, we report data addressing the role of sex-specific and
dietary factors in controlling neurogenesis in the mediobasal hypothalamus. We
report that a high fat diet (HFD) activates neurogenesis in the median eminence
(ME) of young adult female, but not male mice, and that focal irradiation of the ME
in HFD-fed mice reduces weight gain in females, but not males. These results
suggest that some physiological effects of HFD are mediated by sexually dimorphic
neurogenesis in the ME. We present these findings in the context of other studies on
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the cellular and molecular mechanisms that regulate neurogenesis in postnatal and
adult hypothalamus.
Introduction
Obesity and metabolic disorders are severe public health problems in developed
countries. The pathophysiological effects of metabolic disease are partially medi-
ated by hypothalamic inflammation (Thaler et al. 2012; Cai 2013; Purkayastha and
Cai 2013) and by compensatory changes in hypothalamic neural circuitry triggered
by obesity-induced neural injury. Recent studies have revealed hypothalamic neural
injury in obese patients (Thaler et al. 2012). An understanding of the cellular and
molecular responses to hypothalamic injury induced by dietary factors may identify
new therapeutic targets for treating obesity and metabolic disorders (Lee and
Blackshaw 2012).
Newborn neurons in the postnatal and adult hypothalamus have been described
in multiple vertebrate species, including zebrafish (Wang et al. 2012; McPherson
et al. 2016), chick (Kisliouk et al. 2014), hamster (Mohr and Sisk 2013), mouse
(Lee et al. 2012), rats (Matsuzaki et al. 2015), and sheep (Batailler et al. 2015). This
finding suggests a degree of plasticity that is evolutionarily conserved and likely
extends to humans as well (Batailler et al. 2013; Dahiya et al. 2011; Noguiera
et al. 2014). Both juvenile and adult mammalian hypothalamus exhibit ongoing
neurogenesis that can be regulated by growth and differentiation factors (Pencea
et al. 2001; Xu et al. 2005; Kokoeva et al. 2005; Perez-Martin et al. 2010; Robins
et al. 2013b), diet (Lee et al. 2012; Li et al. 2012; McNay et al. 2012; Gouaze
et al. 2013; Bless et al. 2014), antidepressants (Sachs and Caron 2014), exercise
(Matsuzaki et al. 2015), and hormones (Ahmed et al. 2008; Bless et al. 2014).
Although these studies generally agree that levels of constitutive hypothalamic
neurogenesis are much lower than those seen in well-characterized neurogenic
zones in the adult brain, such as the subventricular zone of the lateral ventricles
or the subgranular zone of the lateral hypothalamus (Lee et al. 2012), they often
report differing effects of extrinsic factors on cell proliferation and neurogenesis in
hypothalamus. In addition, these studies make opposing claims about levels of
neurogenesis and proliferation in certain hypothalamic regions, and the cell(s) of
origin for these adult-born neurons remain controversial (Lee and Blackshaw
2012).
For instance, using a combination of in vitro cell culture and in vivo genetic
lineage analysis, studies have claimed that a population of Sox2-positive
(Li et al. 2012) and/or NG2-positive progenitors in the mediobasal hypothalamic
parenchyma (Robins et al. 2013b) acts as multipotent neural progenitors. Tanycytes
of the hypothalamic ventricular zone have also been reported to act as neural
progenitors (Xu et al. 2005; Lee et al. 2012; Li et al. 2012; Haan et al. 2013; Robins
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et al. 2013a), and it has been variously claimed that dorsal located alpha2 and
ventral beta2 tanycytes of the median eminence show the greatest levels of neuro-
genic potential (Robins et al. 2013a; Lee et al. 2012).
Other studies have reported that a range of extrinsic factors, such as dietary and
hormonal signals as well as growth and differentiation factors, can also modulate
postnatal hypothalamic neurogenesis. High-fat diet (HFD) has been reported to
constitutively inhibit neurogenesis in the mediobasal hypothalamic parenchyma
(Li et al. 2012; McNay et al. 2012) while activating neurogenesis in median
eminence (ME; Lee et al. 2012; Hourai and Miyata 2013). It has also been reported
that neurogenesis occurs in a sexually dimorphic pattern during puberty in hypo-
thalamic regions, such as the preoptic area and anterioventral paraventricular
nucleus that control sexual behavior (Ahmed et al. 2008), although the source of
these young adult-generated neurons was not investigated.
Although these results seem discrepant at first glance, a closer examination
reveals that these observed effects may result from methodological differences
among the studies (Lee et al. 2012; Migaud et al. 2010). For instance, while
multiple groups have reported that long-term administration of HFD inhibits cell
proliferation and neurogenesis in hypothalamic parenchyma (Li et al. 2012; McNay
et al. 2012; Gouaze et al. 2013; Bless et al. 2014), studies investigating acute
responses to HFD have reported increased hypothalamic cell proliferation and
neurogenesis (Thaler et al. 2012; Gouaze et al. 2013). Acute HFD administration
has also been reported to rapidly induce hypothalamic inflammation, increasing
cytokine signaling (Thaler et al. 2012). The physiological response in acute versus
chronic HFD administration may serve different, but equally important, roles in
maintaining metabolic homeostasis.
Hypothalamic progenitor cell populations may likewise respond differentially,
and in some cases with opposite reactions, to dietary signals such as HFD. The ME,
for instance, lies outside the blood–brain barrier; it is thus exposed to higher
effective concentrations of circulating dietary and hormonal cues than the hypo-
thalamic parenchyma (Fry et al. 2007; Langlet et al. 2013b). In contrast, all tanycyte
subtypes directly contact the cerebrospinal fluid (CSF) and can potentially respond
to intracerebral ventricular signals (Bennett et al. 2009; Bolborea and Dale 2013).
The age of the mice used for these studies has ranged from early postnatal (Lee
et al. 2012) to young adult (Lee et al. 2012; Ahmed et al. 2008), to 3–12 months of
age (Lee et al. 2012; Kokoeva et al. 2005; McNay et al. 2012; Kokoeva et al. 2007).
Finally, studies of postnatal and adult neurogenesis in the ventrobasal hypothala-
mus have typically used either only male (Kokoeva et al. 2005, 2007; McNay
et al. 2012; Li et al. 2012; Sachs and Caron 2014) or only female (Lee et al. 2012;
Bless et al. 2014) mice. Neurogenesis in other hypothalamic regions is sexually
dimorphic (Ahmed et al. 2008), making this but one additional methodological
difference that could contribute to differences in the levels, location and dietary
regulation of hypothalamic neurogenesis reported in these studies.
To clarify the extent to which sex-dependent factors might regulate neurogenesis
in different hypothalamic regions, we investigated levels of hypothalamic
neurogenesis in both the arcuate nucleus (ArcN) and ME in male and female
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young adult mice fed normal chow and HFD. We also investigated the effects of
low-protein diet (LPD) and caloric restriction (CR) in these same areas in female
mice. These dietary treatments led to significant and region-specific differences in
neurogenesis. Most notably, HFD treatment inhibited ArcN neurogenesis in both
sexes while selectively stimulating ME neurogenesis in female mice. In mice fed
HFD, we found that inhibiting ME neurogenesis by computer tomography-guided
focal irradiation attenuated weight gain in females but not males. These findings
advance our understanding of extrinsic factors that regulate adult hypothalamic




Five week old female or male C57BL/6 mice were obtained from Charles River and
housed in a 14/10-h light–dark cycle with free access to normal chow (Teklad F6
Rodent Diet 8664:: Protein (kcal): 31%, Carbohydrate (kcal): 50%, Fat (kcal):
19%, Harlan Teklad, Madison, WI) and water. Where indicated, animals were
provided with a high-fat diet (HFD) (Catalog #: D12492i:: Protein (kcal): 20%,
Carbohydrate (kcal): 20%, Fat (kcal): 60%, Research Diets, New Brunswick, NJ)
or low protein diet (Catalog#: D11112203:: Protein (kcal): 8%, Carbohydrate
(kcal): 76%, Fat (kcal): 16%, Research Diets, New Brunswick, NJ). All mice
used in these studies were maintained and euthanized according to protocols
approved by the Institutional Animal Care and Use Committee at the Johns Hopkins
School of Medicine.
Caloric Restriction
Five-week-old female C57BL/6 mice were obtained from Charles River and put on
a high-fat diet (HFD: 60% kcals from fat, Research Diets #D12492). At six weeks
old, mice were separated into two groups: (control group) HFD ad libitum and HFD
caloric restriction (CR). CR is at 70% of the HFD control group’s average food
intake. This was calculated by providing the amount of the control group’s average
food intake, plus an amount equal to the standard error of that group’s intake, to
ensure that mice would have enough food both to eat, and to spill, and maintain
70% of the HFD control group’s average food intake. Food intakes were measured
twice per week and used to calculate the CR levels to be used for 0.5 weeks until the
next food intake assessment.
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Reagents
Bromodeoxyuridine (BrdU)
Where indicated, young adult mice received bromodeoxyuridine (BrdU; Sigma)
administrated in the morning and evening by intraperitoneal injection at 50 mg/kg
of body weight from P45 to P53.
Tissue Processing and Antibodies
Adult mice were sacrificed, perfused with 4% PFA/PBS, and cryoprotected as
previously described (Lee et al. 2012). Serial sections (40 μm thick) were collected
and stored at 20  C. Free-floating sections were immunostained using the
following primary antibodies and working concentrations: mouse monoclonal
anti-phospho-H2AX, Ser139, clone JBW301 (1:700, Millipore), rat monoclonal
anti-BrdU (1:200, Accurate, Westbury, NY), mouse monoclonal anti-Hu (5 μg/ml,
Molecular Probes, Carlsbad, CA). Double staining was visualized with Alexa Fluor
555-, and Alexa Fluor 488 (1:500, Molecular Probe, Carlsbad, CA). 40,6-diamidino-
2-phenylindole (DAPI) was used as a nuclear counterstain.
Immunohistochemistry
γH2AX immunostaining was performed as previously described (Lee et al. 2013).
For BrdU immunostaining, sections were first incubated in 2 N HCl at 37 C for
30 min, and rinsed in 0.1 M boric acid (pH 8.5) at room temperature for 10 min.
Sections were then rinsed in PBST, blocked for 5 min in SuperBlock (ScyTek), and
incubated overnight with in anti-BrdU antibody in 5% normal horse serum in
PBS/0.16% Triton X-100 at 4 C in blocking solution. Sections were washed in
PBST, incubated with secondary antibodies in blocking solution at RT for 2 h,
washed in PBST, mounted on Superfrost Plus slides (Fisher, Hampton, NH), and
coverslipped with Gelvatol mounting medium.
Cell Quantification
All tissue sections used for quantification were imaged using confocal microscopy
(Meta 510, Zeiss Microscopy). ME cells were counted. The dorsal-ventral bound-
ary of the cells counted was the third ventricle (3 V) floor and the ventral edge of the
external layer of the ME. The lateral boundaries were a 20 μm medial inset off the
corner of the 3 V. ME dorsal and ventral boundaries remained identical to as
previously described. Seven 40-μm coronal serial sections (280 μm) were counted
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between1.515 mm and1.875 mm from Bregma. On the rare occasion, a section
would be lost in the collection process. If available, the next section in the mouse
sample was taken and counted (seven sections were counted total). For analysis of
newborn Hu+ neurons, for each section analyzed, Hu+DAPI+ and Hu+BrdU+DAPI+
neurons within the ME were counted in the region defined above, excluding cells of
the uppermost focal plane to avoid oversampling. To determine the frequency of
BrdU+ cells expressing Hu, dual fluorescence-labeled sections were examined by
confocal microscopy using a 20 objective and 1.5 digital zoom. For each marker
and treatment condition, seven representative serial sections from each animal were
examined. Sections were scored for double labeling by manual examination of
optical slices. Cells were considered positive for a given phenotypic marker when
the marker-specific labeling was unambiguously associated with a BrdU+ nucleus.
Cells were spot-checked in all three dimensions by Z-stack using a 63x objective.
Images of Hu+BrdU+DAPI+ labeling in feeding conditions (Fig. 1b) were blinded
prior to counting. Cell counts are described in the text and figure legends as mean of
several samples s.e.m., total cell counts, and the number of samples examined to
derive those total cell counts.
Focal Irradiation of Ventrobasal Hypothalamus
Radiation (10 Gy) was delivered using the Small Animal Radiation Research
Platform (SARRP), a dedicated laboratory focal radiation device with CT capabil-
ities (Xstrahl, Inc.). A detailed video and protocol describing this focal irradiation
methodology is available online (http://www.jove.com/video/50716/functional-
interrogation-adult-hypothalamic-neurogenesis-with-focal) (Lee et al. 2013).
Sham controls were performed in parallel. Mice in this cohort were caged,
transported to the procedure room, received the same anesthesia, and received
similar amounts of ambient radiation coming from the SARRP as the irradiated
cohort. Sham controls differed only in that they did not receive a direct radiation
beam and CT scan.
Longitudinal Collection of Weight Data
Weight data from each mouse subject was collected at the time of sham or
irradiation treatment. Longitudinal weight gain was normalized to weight at the
time of treatment for each subject. Weight data was taken every 0.5 weeks for each
mouse subject. Female mice were group housed. Male mice were all group-housed
initially, but were separated if they were observed to fight. To reduce variation
resulting from changes in housing, the numbers of male mice that were individually
and group housed were matched at all times between the sham and irradiated
cohorts. For one experiment, HFD-fed female sham or irradiated cohorts, blood
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samples were collected 1 week following treatment and a standard complete blood
count panel was taken. There was no statistically significant difference in any of
blood components.
Fig. 1 Dynamic alteration of hypothalamic neurogenesis in response to different dietary condi-
tions. (a) Experimental design schematic. Female mice were either continuously fed on normal
chow (NC) or switched to the low protein diet (LPD) or high fat diet (HFD) at postnatal day
(PD) 42. After 3 days, BrdU was injected intraperitoneally twice per day for 9 days. Mice were
sacrificed 1 month after the onset of BrdU administration. (b) Representative high magnification
image of BrdU and Hu double-positive P75 adult-born neurons (white arrows) located in median
eminence (ME) of female mice fed HFD. (c) Quantitative comparison of diet-dependent
neurogenesis (Hu+BrdU+/Hu+ neurons) in the arcuate nucleus (ArcN) and ME. (d) Schematic
summarizing opposite effects of dietary change on neurogenesis between ArcN and ME. (e)
Scheme of experimental design for calorie restriction. After 1 week initial adjustment to HFD
(red striped square), female mice were fed either ad libitumHFD or were calorie restricted (CR) on
the HFD to 70% of the ad libitum-fed mice, from PD42 onward. After 3 days, BrdU was injected
intraperitoneally twice per day for 9 days. Mice were sacrificed 1 month after BrdU administration
onset. (f, g) Quantitative comparison of ME neurogenesis (Hu+BrdU+/Hu+ neurons) or prolifera-
tion (BrdU+DAPI+/DAPI+ cells) in CR HFD-fed (HFD-CR) mice or ad libitum HFD-fed
(HFD-AL) mice. (h) Schematic summarizing significant reduction of cell proliferation in the
ME of mice fed on HFD-CR. *P< 0.05, **P< 0.003. Scale bar: 5 μm
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Statistical Analysis
Figures are shown as mean standard error of the mean. Two-tailed Student’s t-test
was applied. A p-value 0.05 indicated significant group difference.
Results
Dietary Signals Differentially Regulate Neurogenesis and Cell
Proliferation in ME and ArcN
Our group previously demonstrated that feeding young adult female mice HFD led
to significantly increased ME neurogenesis (Lee et al. 2012). We set out to test
whether additional dietary conditions could also alter neurogenesis in the ME and
whether these conditions led to comparable changes in neurogenesis in the ArcN,
which lies inside the blood–brain barrier within the hypothalamus proper. Young
adult female mice were switched onto control normal chow (NC), HFD or LPD
beginning at postnatal day (P) 42. Cell proliferation was tracked using twice-daily
intraperitoneal (i.p.) injections of BrdU from P45-53 (Fig. 1a). Mice were eutha-
nized at P75, and brains were immunostained for BrdU and the pan-neuronal
marker HuC/D. The fraction of Hu+ cells that were also BrdU+ was quantified to
assess levels of neurogenesis.
Baseline levels of hypothalamic neurogenesis [(Hu+BrdU+)/Hu+ neurons] in
mice fed NC were low and did not differ significantly between the two regions
(NC ArcN [0.012 0.002, n¼ 5] vs NC ME [0.015 0.004, n¼ 7], p¼ 0.47, equal
variance; Fig. 1c). Both HFD-fed mice (0.0072 0.0012, n¼ 5, p¼ 0.044, equal
“n”) and LPD-fed mice (0.0048 0.0004, n¼ 5, p¼ 0.0022, equal “n”) showed a
substantial reduction in the fraction of Hu+BrdU+ ArcN neurons. In contrast, both
HFD-fed mice (0.058 0.008, n¼ 9, p¼ 0.0005, unequal “n,” equal variance) and
LPD-fed mice (0.055 0.019, n¼ 4, p¼ 0.025, unequal “n,” equal variance)
showed a significant increase in the fraction of Hu+BrdU+ ME neurons (Fig. 1c).
The differences in neurogenesis levels between the ArcN and ME following both
HFD (ArcN [0.0072 0.001, n¼ 5] vs. ME [0.058 0.008, n¼ 9], p¼ 0.0005,
equal variance) and LPD (ArcN [0.0048 0.0004, n¼ 5] vs. ME [0.055 .019,
n¼ 4], p¼ 0.021, equal variance] were significant and implied that neural progen-
itor populations in these two regions responded differentially to these dietary cues
(Fig. 1c, d). The HFD-induced inhibition of ArcN neurogenesis was similar to
observations of adult male mice made by other groups (McNay et al. 2012; Li
et al. 2012).
Because previous studies reported that CR could reverse the effects of HFD on
ArcN neurogenesis (McNay et al. 2012), we next tested whether CR could likewise
modulate HFD-induced ME neurogenesis. For these studies, female mice were
housed individually and allowed either ad libitum or restricted access to HFD
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starting at P45. Restricted HFD access was at 70% of the caloric intake of animals
fed ad libitum (Fig. 1e). BrdU labeling and immunohistochemistry were conducted
as described above. CR HFD-fed mice trended towards a decrease in neurogenesis
levels in ME (HFD ad lib [0.039 0.011, n¼ 4] vs HFD-CR [0.022 0.006, n¼ 6]
p¼ 0.19, equal variance), but this effect did not reach significance (Fig. 1f).
However, we observed that overall BrdU incorporation in ME cells was signifi-
cantly reduced (HFD ad lib [0.08 0.02, n¼ 4] vs HFD-CR [0.035 0.007, n¼ 6],
p¼ .043, equal variance) (Fig. 1g). We thus conclude that CR inhibits proliferation
of progenitor cells within the ME (Fig. 1h).
Sex-Specific Differences in Diet-Induced Hypothalamic
Neurogenesis
Since these studies were all performed in young adult females, we next tested
whether the levels of baseline and HFD-induced ME neurogenesis were different
between the sexes. We used diet and BrdU labeling conditions identical to those in
Fig. 1a to measure levels of neurogenesis in male mice fed either NC or HFD. We
observed that young adult males fed NC showed levels of neurogenesis in both
ArcN and ME that were low and not significantly different from age-matched
females (NC-fed: Male ArcN [0.0119 0.0012, n¼ 3] vs Male ME
[0.020 0.009, n¼ 3], p¼ 0.40, equal variance; Fig. 2a). We likewise observed
that male mice fed HFD showed reduced levels of ArcN neurogenesis relative to
male mice fed NC (NC ArcN [0.0119 0.0016, n¼ 3] vs HFD ArcN
[0.0070 0.0011, n¼ 5] p¼ 0.036, equal variance). However, in sharp contrast
to what we observed in females, male mice showed no increase in ME neurogenesis
when fed HFD (0.020 0.009, n¼ 3, vs 0.025 0.006, n¼ 4: NC vs HFD,
p¼ 0.36; Fig. 2a), implying that neural progenitor populations in the ME showed
sex-specific increases in neurogenesis in response to HFD (Fig. 2b).
Fig. 2 Sex differences in neurogenic response to HFD. (a) Quantification of hypothalamic
neurogenesis (Hu+BrdU+/Hu+ neurons) in the ArcN and ME of young adult male mice fed HFD
or NC. (b) Schematic summarizing sexual dimorphism of dietary challenge on ME neurogenesis
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Blocking Neurogenesis in ME Attenuates HFD-Induced
Weight Gain in Young Adult Female, But Not Male, Mice
We previously demonstrated that computer tomography-guided focal irradiation
could selectively inhibit cell proliferation in the ME while sparing proliferation in
ArcN (Lee et al. 2012, 2013). Our radiological approach reduced ME neurogenesis
by ~85% (Lee et al. 2012), in line with previous approaches that used focal
irradiation in other mammalian neurogenic niches (Ford et al. 2011). We next
tested whether selective radiological inhibition of ME neurogenesis (Fig. 3a) in
both males and female mice fed HFD led to sex-specific differences in regulation of
body weight. The specificity of the focal irradiation was demonstrated using
γH2AX immunostaining (Fig. 3b; Lee et al. 2012, 2013). Longitudinal body weight
measurements were then taken for male and female mice that underwent either
focal irradiation or sham treatment and that were fed either NC or HFD. Weight
changes were normalized to the starting weight of each mouse at the time of sham
or irradiation treatment.
Fig. 3 Sex differences in diet-induced weight gain after focal inhibition of ME neurogenesis.
Mice received either NC or HFD at 5 weeks of age. Sham treatment or 10 Gy of computer
tomography-guided focal radiation was applied to the ME of young adult mice (P42) as previously
described (Lee et al. 2013). (a) Superimposition of dosimetry-film acquired with 1-mm radiation
beam in phantom with an X-ray of a real mouse subject (blue line).White circle (arrow) indicates
10-Gy radiation dose focally targeted to hypothalamic proliferative zone (HPZ). (b) Confirmation
of radiation targeting accuracy by γH2AX immunostaining, an indicator of DNA double strand
breaks and radiation localization. (c) Weight gain was assessed from the time of either sham or
focal irradiation treatment in NC- and HFD-fed mice of both sexes
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We observed no long-term changes in body weight between sham and irradiated
animals fed NC in either our male (sham treatment: n¼ 8; irradiation treatment:
n¼ 12) or female (sham treatment: n¼ 12; irradiation treatment: n¼ 12) cohorts
(Fig. 3c). In contrast, HFD-fed female mice showed a significant reduction in
weight gain following irradiation relative to sham controls, as previously reported
(Lee et al. 2012). At 9 weeks post-treatment, irradiated female mice receiving HFD
(n¼ 10) had a 32 4% increase in weight gain relative to sham controls (n¼ 9),
which showed a 52 6% increase in weight gain (p-value¼ 0.028, Fig. 3c). In
sharp contrast, no significant differences in weight gain were observed in irradiated
HFD-fed males relative to sham controls (59 7% increase, n¼ 11, vs 71 7%
increase, n¼ 12, p¼ 0.27; Fig. 3c). These data confirm previous reports that
neurons generated in the female ME in response to HFD act to promote energy
storage (Lee et al. 2012, 2013).
Discussion
Several recent studies have reported that neurogenesis occurs in the adult hypo-
thalamus (Migaud et al. 2010; Lee and Blackshaw 2012, 2014), a central regulator
of metabolism and energy balance. We investigated how changes in diet can
modulate hypothalamic neurogenesis by presenting young adult mice with different
diets. We observed that HFD, LPD, and CR HFD all differentially modulated
proliferation and neurogenesis in the hypothalamic ME and ArcN, hypothalamic
regions that regulate energy balance (summarized in Fig. 4b). We observed an
increase in ME neurogenesis and a decrease in ArcN neurogenesis in response to
both HFD and LPD (Fig. 1c, d). In contrast, HFD selectively activated neurogenesis
in the female ME. These differential region-specific changes in neurogenesis may
lead to differential generation of orexinergic and anorexinergic neurons in response
to dietary cues and may serve as a mechanism that allows adaptation to long-term
changes in energy balance homeostasis.
These region-specific changes in adult hypothalamic neurogenesis most likely
are mediated by differing exposures to secreted peptide, growth factors, and
neurotrophic factors that signify feeding status and long-term energy availability.
The ME, by virtue of its access to the third ventricle and status as a
circumventricular organ, is exposed to a variety of these secreted factors via the
CSF and the blood. By comparison, the ArcN, a structure protected by the blood–
brain barrier (Mullier et al. 2010), has less access to circulating satiety signals and
hormones. The permeability of hypothalamic blood–brain barrier to blood-borne
factors has been proposed to be differentially regulated in fed and fasting conditions
through a VEGF-dependent mechanism (Langlet et al. 2013a). Continuous integra-
tion of these peripheral signals by neurons belonging to both the ArcN and the ME
of the hypothalamus is critical for central regulation of energy balance and neuro-
endocrine function (Schaeffer et al. 2013). Our data suggest that adult-generated
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neurons in both hypothalamic regions may show differing sensitivities to dietary
and hormonal signals that help maintain energy homeostasis.
Several secreted factors that signal feeding status and long-term energy avail-
ability regulate adult neurogenesis in various neurogenic niches, including the
hypothalamus (Sousa-Ferreira et al. 2014). For instance, compared to NC-fed
controls, HFD-fed mice exhibited substantially higher ciliary neurotrophic factor
(CNTF) mRNA in tanycytes and multi-ciliated ependymal cells, whereas CR mice
showed substantially lower expression levels; this coincided with similar changes
in CNTF receptor (CNTFR) mRNA (Severi et al. 2013). Taken together with
previous findings that CNTF delivered by i.c.v. cannulation stimulates adult hypo-
thalamic neurogenesis (Kokoeva et al. 2005), this finding suggests that dietary
signals may regulate hypothalamic neurogenesis in the ME through altered CNTF
Fig. 4 Regulation of hypothalamic neurogenesis by dietary factors. (a) In mammals, constitutive
adult neurogenesis is primarily confined to three brain regions (highlighted in orange). The
hippocampal dentate gyrus and the subventricular zone of the lateral ventricles are canonical
neurogenic niches. Additionally, recent observations demonstrate that the ventrobasal hypothala-
mus serves as a neurogenic niche, engaging in low but constitutive levels of neurogenesis in adults.
(b) Hypothalamic tanycytes and parenchymal Sox2+ cells represent potential hypothalamic neural
progenitor populations that give rise to adult-born neurons. In the hypothalamic ME, tanycytes are
a convincing neurogenic source for the ArcN and ME. In females, both HFD and low protein diet
(LPD) increase ME neurogenesis in the ME, while concurrently decreasing ArcN neurogenesis in
the ArcN. Several lines of evidence suggest that this dynamic change in neurogenesis is mediated
between a tanycytic neural progenitor pool and factors present in the cerebrospinal fluid (CSF)
and/or those circulating through the fenestrated capillaries of the ME
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signaling. This hypotheses is supported by observations that beta2 tanycytes of the
adult hypothalamic proliferative zone (HPZ) are enriched with CNTFR, as com-
pared to alpha 1,2 tanycytes (Kokoeva et al. 2005). In that study, mice receiving
intracerebroventricular infusion of CNTF demonstrated hyperplasia within the HPZ
of the ME, as indicated by particularly high levels of BrdU incorporation (Kokoeva
et al. 2005). The development of inducible Cre mouse lines specific for hypotha-
lamic neural progenitors will help identify additional signaling pathways that are
critical for the regulation of hypothalamic neurogenesis (Robins et al. 2013a, b; Pak
et al. 2014).
In female mice fed a NC diet, we observed relatively low levels of hypothalamic
neurogenesis in the ME. Interestingly, upon presentation of a dietary challenge such
as HFD, ME neurogenesis was increased in females. Moreover, computer
tomography-guided radiological inhibition of ME neurogenesis (Lee et al. 2013)
reduced HFD-induced weight gain in females, but not in males (Fig. 3b). These
intriguing results suggest that weight gain in females can be attributed in part to
additional adult-generated neurons in the ME and that the neural circuitry regulat-
ing body weight differs in some respects between females and males. These
findings are consistent with previous studies demonstrating that sex hormones can
regulate hypothalamic neurogenesis in a region-dependent manner (Ahmed
et al. 2008; Cheng 2013). Taken together with our results, this body of work
highlights the importance of examining both the regional differences in hypotha-
lamic neurogenesis and the sex-specific differences. Such differences likely at least
partially account for differences in the levels and diet dependence of adult hypo-
thalamic neurogenesis observed by different groups.
Factors that mediate these sex-dependent differences in hypothalamic
neurogenesis have not yet been identified but could involve numerous levels of
regulation, such as hormone-dependent plasticity (de Seranno et al. 2010), differ-
ences in blood-barrier access between the sexes (Hoxha et al. 2013), and hormone-
specific induction of feeding behavior (Sieck et al. 1978). Lastly, it is possible that it
is the survival of newborn neurons, rather than (or in addition to) their proliferation,
that is sexually dimorphic, as has been previously demonstrated for prenatally
generated hypothalamic neurons (Waters and Simerly 2009; Forger et al. 2004;
Tobet and Hanna 1997; Park et al. 1998).
In addition to being a means of regulating energy homeostasis in response to
long-term changes in diet, adult hypothalamic neurogenesis may be triggered in
response to environmental injury. The hypothalamic ME, in contrast to other
hypothalamic regions, lies outside of the blood–brain barrier and is thus directly
exposed to circulating toxins and pathogens, as well as nutrients that can lead to
cellular injury when in oversupply. Hypothalamic neural injury and inflammation
are seen in obese animals and humans (Thaler et al. 2012, 2013; Li et al. 2012). The
increased neurogenesis in adult female ME may serve to replace damaged neurons
in this region. Indeed, at least one study has reported that neurons important for
energy balance regulation can be regenerated in adult hypothalamus in response to
neurodegenerative-like injury (Pierce and Xu 2010). Further studies to determine
the role of environmental and physiological factors in regulating adult
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hypothalamic neurogenesis may yet reveal new mechanistic approaches towards
the treatment of obesity and metabolic disorders.
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Genetic Dissection of the Neuroendocrine
and Behavioral Responses to Stressful
Challenges
Alon Chen
Abstract Dysregulation of the stress response is implicated in many psychopathol-
ogies. Data gathered over the past two decades have proposed a rather dualistic view
of the central corticotropin-releasing factor (CRF)-urocortin system. Originally, it
was thought that CRF/CRF receptor type 1 (CRFR1) signaling mediated stress-
initiated effects and increased anxiety-like behavior, whereas activation of
urocortins/CRFR2 ensured adequate recovery from stress and restoration of homeo-
stasis. However, this viewwas based on data gained from geneticallymodifiedmouse
models and pharmacological approaches; now, with the emergence of new and more
specific biological tools, it has become clear that this is an over-simplistic proposal. It
is becoming apparent that the function of the CRF-urocortin system’s components
relies profoundly on the spatial and temporal patterns of activity of the CRF family
members. Here, we provide an overview of recent work that proposes a more
dynamic, modulatory role for the CRF system’s central pathways in the modulation
of stress-linked behaviors. Recent findings suggest that the CRF system’s actions are
brain-region specific and dependent on the type of neuronal cell involved.
In 1955, Hans Seyle recognized that the hypothalamic-pituitary-adrenal (HPA) axis
orchestrates the stress response (Selye 1955). However, it took until 1981 for the
structure of its principal regulatory peptide, corticotropin-releasing factor (CRF), to
be characterized (Vale et al. 1981). Neurons in the paraventricular nucleus (PVN)
of the hypothalamus secrete CRF, which binds to receptors in the pituitary, which,
in turn, secretes adrenocorticotropic hormone (ACTH) into the circulation. The
circulating ACTH binds at the adrenal cortex stimulating the synthesis and secre-
tion of glucocorticoids: cortisol in humans and corticosterone in rodents. Gluco-
corticoids are the downstream biological effector of the neuroendocrine stress
response and also provide negative feedback in the HPA axis.
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The CRF family of peptides includes the 41 amino acid peptide CRF and the
more recently discovered urocortin (UCN) 1, 2 and 3. As shown in Fig. 1, this
family of peptides binds to two distinct receptors: the CRF receptor type 1 (CRFR1)
and type 2 (CRFR2). CRF is a high-affinity ligand for the CRFR1, whereas UCN1
binds with equal affinity to both receptors. UCN2 and UCN3 preferentially bind the
CRFR2. However, specificity seems to be lost at higher concentrations of the
ligand, with CRF activating CRFR2. CRFR1 and CRFR2 are produced from
distinct genes and have numerous splice variants (CRFR1α,β, and CRFR2α,β,γ),
some of which are nonfunctional (Perrin and Vale 1999; Grammatopoulos and
Chrousos 2002).
CRF receptors are Gs protein-coupled receptors. They stimulate a cascade of
events, firstly adenylate cyclase, which subsequently activates cyclic AMP
(cAMP). Cyclic AMP stimulates protein kinase A (PKA) to phosphorylate sub-
strates such as the cAMP responsive-element–binding (CREB) protein, thereby
inducing transcription of downstream target genes. In addition, cAMP binds to
exchange proteins, which then activate the extracellular signal-regulated kinase-
mitogen-activated protein kinase (ERK-MAPK) cascade (Gutknecht et al. 2009).
The ERK/MAPK pathway regulates synaptic plasticity, including dendrite stabili-
zation, ion channel transmission, transcription of CREB and other genes, and
receptor scaffolding, trafficking, and crosstalk. Coupling to Gs is the dominant
mechanism for stimulating intracellular calcium mobilization by CRFR1 and
CRFR2. However, CRF receptors also interact with other G protein systems,
including Gq, Gi, Go, Gil/2, and Gz (Grammatopoulos et al. 2001). Coupling to Gq
Fig. 1 The CRF family of neuropeptides and their action on the CRFR1 and CRFR2 (Kuperman
and Chen 2008, with permission). Colored arrows indicate the receptors with which each ligand
preferably interacts; dashed lines indicate a lower affinity binding. CRFR2 has two apparent
membrane-bound splice variants in rodents, resulting in two receptor proteins, CRFR2α and
CRFR2β
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activates PLCβ, which cleaves the phospholipid phosphatidylinositol
4,5-bisphosphate into diacyl glycerol (DAG) and inositol 1,4,5-trisphosphate
(IP3). IP3 then diffuses through the cytosol to bind to IP3 receptors to increase
intracellular calcium levels, whereas DAG activates protein kinase C (PKC), which
activates ERK1/2 via Ras, Raf and MEKs. Gi/0 mediated activation of Gβγ subunits
activates the ERK1/2 by PI-3 kinase and induces PLCγ activation, which increases
intracellular calcium release. Thus, depending on their localization and cellular
context, CRF receptors are able to modulate a wide variety of signaling pathways
(Hauger et al. 2006, 2009) and kinases [including PKA, protein kinase B (PKB),
PKC (Gutknecht et al. 2009), mitogen activated protein (MAP) kinases (e.g.,
ERK1/2), and intracellular Ca2+ concentrations]. CRF receptors activate these
various G-protein systems in a concentration-dependent manner (Grammatopoulos
and Chrousos 2002).
Besides the activated pathway, the desensitization and internalization following
receptor activation seems to depend on the specific ligand bound. Desensitization of
CRFR2 cAMP signaling was shown to occur more rapidly and to a greater extent in
response to UCN2 binding compared to UCN3, whereas CRF is a relatively weak
desensitizing agonist (Gutknecht et al. 2008). Additionally, the internalization of
CRFR2 was shown to be greater upon exposure to UCN2 (Markovic et al. 2008).
In situ hybridization histochemical studies (and recently generated reporter
mice; Justice et al. 2008; Kuhne et al. 2012) have shown that CRFR1 is widely
distributed throughout the brain. The highest expression levels are seen in neocor-
tical, limbic, brain stem regions and the cerebellum (Fig. 2). Moderate levels are
found in the dorsal and median raphe nuclei, and only low levels are found in the
PVN of the hypothalamus (Chalmers et al. 1995; Van Pett et al. 2000). CRFR1 is
expressed in diverse neuronal subpopulations. They have been found on cell bodies,
dendritic shafts and dendritic spines of hippocampal neurons (Chen et al. 2004a,b,
2010). Compared to CRFR1, CRFR2 mRNA has a much more localized distribu-
tion pattern throughout the brain, which is virtually confined to subcortical struc-
tures. The highest levels of CRFR2 expression are found in the lateral septum, the
Fig. 2 The distribution of CRFR1 (yellow) and CRFR2 (pink) mRNA expression in the rodent
brain. AMYG, amygdala; BST, bed nucleus of the stria terminalis; RAPHE, raphe nucleus; SEPT,
lateral septum; VMH, ventromedial hypothalamic nucleus
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ventromedial hypothalamic nucleus, and the choroid plexus (Fig. 2). Moderate
levels are seen in the olfactory bulb, nuclei of the extended amygdala, hippocam-
pus, the PVN and supraoptic nuclei of the hypothalamus, the inferior colliculus and
the raphe nucleus (Chalmers et al. 1995; Van Pett et al. 2000). Only a limited
amount of data is available on brain region-specific modulation of CRFR2 signal-
ing. Among the most investigated regions are the extended amygdala, hippocam-
pus, lateral septum, medial prefrontal cortex, and brain stem nuclei. Additionally,
all four CRF family neuropeptides have been detected in the periphery, in particular
UCN2 and UCN3, which have been recognized as novel modulators of centrally
and peripherally controlled metabolic function (Chen et al. 2004a; Kuperman and
Chen 2008).
Alterations in HPA axis function, attributed to centrally elevated CRF levels,
were observed in depressed patients (Nemeroff et al. 1984; Holsboer 1999; Reul
and Holsboer 2002) and in patients with post-traumatic stress disorder (PTSD;
Bremner et al. 1997; McEwen 2002). These findings stimulated huge interest into
the functioning of the CRF family. CRFR1 and CRFR2 seem to modulate anxiety-
like behavior in a brain region-dependent manner. One obvious explanation for the
differential behavioral effects of CRF receptor activation is that distinct brain
regions simply serve distinct behavioral functions, and their activation would thus
induce a distinct behavioral phenotype. Activation of brain regions implicated in
emotional arousal, such as the extended amygdala, would be expected to increase
anxiety, whereas activation of cognitive control regions, such as the medial pre-
frontal cortex, would contribute to stress coping and reduce anxiety. However, both
the behavioral and electrophysiological effects of CRF receptor activation impli-
cate a more complex underlying mechanism of region dependency and suggest
specificity due to the cell type and ligand concentration.
Since specific CRF receptor antibodies are lacking, much about the action of the
CRF family has been learned from transgenic mice, overexpressing or knocked out
for the various members. Increased central levels of CRF [induced by either CRF
administration (Britton et al. 1986; Dunn and File 1987; Dunn and Berridge 1990)
or its overexpression in transgenic mice (Stenzel-Poore et al. 1994; Heinrichs
et al. 1997; van Gaalen et al. 2002; Binneman et al. 2008)] produces anxiogenic
behavior, whereas suppression induces anxiolytic effects (Skutella et al. 1994) and
reduced stress-induced anxiety (Skutella et al. 1994). This action was attributed to
CRFR1 activation specifically, since CRFR1 blockage by antisense treatment
(Skutella et al. 1998; Liebsch et al. 1999) or selective antagonists (i.e., antalarmin;
Habib et al. 2000; Valdez et al., 2002) prevented CRF/stress-induced anxiety.
Furthermore, CRFR1 knock-out mice displayed reduced anxiety-like behavior
(Smith et al. 1998; Timpl et al. 1998; Contarino et al. 1999; Muller et al. 2003).
Taken together, these data suggested a critical role for CRFR1 activation in eliciting
stress-induced anxiety. However, although these findings suggest a causative role
for CRFR1 over-activation in stress-related psychopathologies, clinical trials of
CRFR1 antagonists as potential next-generation anxiolytics/antidepressants have
unfortunately met with little success.
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In contrast to CRFR1, the role of CRFR2 in the mediation of psychopathologies
is less clear, and two prominent theories are currently circulating that explain its
role. The most popular view is that CRFR2 activation is responsible for ensuring
homeostasis and counteracts the stress response-provoking effects and anxiety-like
behavior induced by CRFR1 activation (Coste et al. 2001; Bale and Vale 2004;
Heinrichs and Koob 2004; Muller and Holsboer 2006). This theory is primarily
based on the increased corticosterone stress response observed in CRFR2 KO mice
(Bale et al. 2000; Coste et al. 2000), and the anxiogenic phenotype observed in
some (but not all; Coste et al., 2000) of the CRFR2 KO mouse lines (Bale
et al. 2000; Kishimoto et al. 2000). However, the increased levels of anxiety and
stress-related behaviors observed in a mouse line displaying (chronic)
overexpression of UCN3 (Neufeld-Cohen et al. 2012), as well as the observed
reduction in shock-induced freezing in response to reduced CRFR2 expression
(by administration of CRFR2 mRNA antisense oligonucleotides; Ho et al. 2001)
contradict this theory.
UCN1 neurons are mainly localized in the Edinger Westphal nucleus where they
constitute the centrally projecting part of the nucleus to the lateral septum. UCN1
mRNA is also found in the lateral olivary and supraoptic nucleus (Bittencourt
et al. 1999). UCN2 expression has been shown in several regions that are involved
in the physiological and behavioral responses to stress, such as the PVN, locus
coeruleus, and it partly overlaps with CRF and UCN1 expression in the hypothal-
amus and brainstem. UCN2 is thought to be the primary ligand for CRFR2s in the
bed nucleus of the stria terminalis (BNST), PVN, central amygdala, parabrachial
nucleus and nucleus tractus solitarii (Reyes et al. 2001). UCN3 also shows a distinct
expression pattern and is mainly found in the medial preoptic area, rostral
perifornical area, the posterior part of the BNST and the medial amygdala, with
projections observed in the intermediate lateral septum (Lewis et al. 2001) and in
the BNST (Deussing et al. 2010). However, although the sites of mRNA expression
of these ligands are pretty well established, it is still largely unknown at which exact
sites (i.e., axonal, dendritic, synaptic) the ligands are in fact released.
UCN1 neurons are recruited following chronic stress exposure and stay active
for a prolonged period of time, suggesting that this peptide plays a prominent role in
the later, adaptive phase of the stress response (Korosi et al. 2005; Xu et al. 2010;
Ryabinin et al. 2012). The UCN family members’ involvement in stress-related
behavior was assessed in UCN1/UCN2 (dKO) double and UCN1/UCN2/UCN3
(tKO) triple knockout mice. Although the dKO knockout mice displayed no
changes in basal HPA axis activity, they had elevated corticosterone levels follow-
ing acute stress exposure (Neufeld-Cohen et al. 2010b). HPA axis function was
unchanged in tKO mice compared to controls (Neufeld-Cohen et al. 2010a). The
dKO knockout mice displayed decreased anxiety-like behavior under basal and
acute stress conditions, which was accompanied by elevated serotonin concentra-
tions in a number of brain regions, including the dorsal raphe nucleus, hippocam-
pus, basolateral amygdala and subiculum (Neufeld-Cohen et al. 2010b). In contrast,
tKO mice exhibited increased anxiety-like behavior, but only 24 h after restraint
stress. Moreover, tKO mice displayed an increased stress-induced startle response
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(Neufeld-Cohen et al. 2010b). As opposed to dKO mice, the behavioral phenotype
in tKO mice was associated with decreased serotonergic metabolism in regions
such as the septum, central and basolateral amygdala (Neufeld-Cohen et al. 2010a).
Again, the effect of compensatory changes in CRF expression on emotional behav-
ior cannot be excluded in many of the UCN mouse models, as shown in dKO mice
(Neufeld-Cohen et al. 2010b). Overall, the data suggest that the UCN’s binding to
CRFR2 is able to regulate specific aspects of stress-related emotional behavior,
complementing the effects of CRF to CRFR1.
Another great advance in the understanding of the CRF system’s actions can be
accredited to the specificity of genetic or viral-mediated loss-of-function
approaches. For example, deletion of the CRFR1 in glutamatergic neurons reduces
anxiety-related behavior, whereas deletion in dopaminergic neurons increases
anxiety-related behavior (Refojo et al. 2011). Lentiviral-mediated knockdown of
CRF in the central amygdala attenuated stress-induced anxiety-like behavior and
altered HPA axis activity, reinforcing a role for amygdalar CRF in the modulation
of fear and anxiety (Regev et al. 2011). Lentiviral knockdown of CRFR1 in the
basolateral amygdala was also shown to decrease anxiety-like behavior and mim-
icked the anxiolytic effect of environmental enrichment (Sztainberg et al. 2010).
Using stereotactic delivery of lentiviruses into the paraventricular nucleus, Elliott
et al. (2010) targeted CRF by using lentiviral constructs that carried shRNA against
CRF. This approach enabled the site-specific manipulation of gene expression. The
knockdown attenuated chronic stress-induced social avoidance, which was shown
to result from demethylation of the CRF promoter (Elliott et al. 2010).
The BNST is thought to be involved in the regulation of anxiety. It is positioned
as a relay center between the limbic structures and mediates anticipatory stress.
Lentiviral-mediated knockdown of CRFR2 in the BNST increased anxiety-related
behavior both immediately and 24 h after restraint stress. Studying the knockdown
and overexpression of CRFR2 specifically in the BNST revealed an important role
of this receptor in PTSD-like behavior (Lebow et al. 2012).
In some of our most recent work, we have used optogenic regulation of posterior
BNST CRFR2 neurons using bilateral fiber optic implantation. CRFR2 Cre
mice were crossed with conditional channelrhodopsin (ChR2) mice, in which
blue light activates CRFR2-expressing neurons specifically, or with conditional
halorhodopsin (NpHR2) mice, in which yellow light inhibits CRFR2-expressing
neurons specifically. Using this tool, we found that specific activation of CRFR2
neurons in the posterior BNST reduced anxiety-related behavior and, conversely,
their suppression increased anxiety-related behavior (Henckens et al. 2016). Similar
viral-mediated loss-of-function tools were used to knockdown CRFR1 in the globus
pallidus, revealing a previously unknown anxiolytic effect of the receptor in this
brain region, which was further confirmed with site-specific CRFR1 antagonist
administration (Sztainberg et al. 2011). The relevance of CRFR1 receptors in
addiction and reward processes was investigated in the ventral tegmental area
using lentiviral-mediated knockdown. Knockdown of CRFR1 reduced
cue-induced and acute food deprivation, stress-induced cocaine seeking, but had
no effect on self-administering behavior. CRFR1 signalling in the ventral tegmental
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area presents a target for convergent effects of both cue- and stress-induced
cocaine-seeking pathways (Chen et al. 2014).
In summary, recent advances in methodological approaches have begun eluci-
dating the site-specific actions of the CRF system. Most notably, they suggest that,
via the CRFR2, UCNs might be the central system involved in coping with stress.
Improved understanding of the CRF system holds the promise of better treatment of
stress-related psychopathologies.
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Pituitary Stem Cells: Quest for Hidden
Functions
Hugo Vankelecom
Abstract The pituitary is the core endocrine gland, ruling fundamental processes
of body growth, metabolism, reproduction and stress. Over the past decade, it has
progressively become clear that the pituitary, like many adult tissues, harbors a
population of stem cells. While the molecular depiction of these cells is constantly
expanding, their function remains essentially hidden. From recent studies, the
picture is developing that the stem cells of the adult pituitary are highly quiescent
and mainly come into play during pathological conditions.
Upon transgenic cell-ablation damage in the pituitary, the stem cell compart-
ment is promptly turned on with expansion and expression of the missing hormone.
This activation is accompanied by substantial regeneration of the lost hormonal
cells, a restorative competence that was unexpected in the mature gland. This
regenerative skill, however, rapidly disappears with aging, together with a decline
in the number and fitness of the stem cells. One function of the adult pituitary stem
cells may thus be hidden in the regenerative toolbox of the gland, at least during a
specified and limited time window.
Recent work also showed activation of the pituitary stem cell compartment
during tumor formation in the (mouse) gland. Moreover, pituitary tumors (from
patients and mice) contain a candidate ‘tumor stem cell’ (TSC) population. The
pathogenetic steps of initiation, expansion, invasion and recurrence of pituitary
tumors remain far from understood. A link between the tumor-driving TSC and the
pituitary stem cells may shed new light on this tumorigenic darkness.
To conclude, decoding the hidden functions of pituitary stem cells will not only
lead to better fundamental insights into their role but may also expose (novel)
targets for treating pituitary tumors and for regenerative intervention in pituitary
deficiency, as caused by damage, tumors or aging. Yet, the journey in the ‘hidden
valley’ of pituitary stem cell functions has only just begun, and a long distance still
has to be walked.
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Introduction
The pituitary gland, in unison with the hypothalamus, constitutes the hub of our
endocrine system, governing fundamental processes of growth, metabolism, sexual
development, procreation and coping with immune and stress challenges (Melmed
2010; Vankelecom 2012; Willems and Vankelecom 2014). Due to this strategic
position, malfunctioning of the pituitary leads to important morbidities that can be
life-threatening (Schneider et al. 2007; Willems and Vankelecom 2014). In the past
decade, mounting evidence has been presented that the endocrine gland contains a
population of stem cells, purportedly sitting there to deal with renewal of cells that
are worn out or have been damaged (Vankelecom 2012; Vankelecom and Chen
2014). However, like in comparable adult tissues that do not turn over very actively
such as the brain and lung (Alvarez-Buylla and Lim 2004; Rando 2006; Slack 2008;
Vankelecom 2012; Wabik and Jones 2015), the function of the stem cells residing
in the pituitary remains enigmatic. Compared to the expanding molecular stripping
of the pituitary stem cell phenotype, functional characterization of the cells clearly
lags behind. In general, stem cells in ‘lazy’ low-turnover tissues are highly quies-
cent, and activation only clearly emerges in conditions of disease or damage
(Barker et al. 2010; Huch et al. 2013a,b; Rando 2006; Slack 2008; Vankelecom
2012; Vankelecom and Chen 2014; Wabik and Jones 2015). Regarding the yet
hidden functions of the pituitary stem cells, recent studies have shed some light on
this obscure domain, particularly in the context of early postnatal maturation,
damage repair and tumor growth. In this review, recent findings are summarized
and emerging views presented. In addition, some brief perspectives are offered
regarding therapeutic implementation of this new knowledge.
Primer on Pituitary Biology and Pathology
The pituitary gland consists of the anterior pituitary (AP), the posterior pituitary
(PP) and the intermediate lobe (IL; Fig. 1), the latter being only rudimentary in
humans (Melmed 2010; Vankelecom 2010, 2012). The AP represents the major
endocrine segment of the gland, containing different cell types that each produce
(a) specific hormone(s). Growth hormone (GH) is produced by the somatotropes,
prolactin (PRL) by lactotropes, adrenocorticotropic hormone (ACTH) by
corticotropes, thyroid-stimulating hormone (TSH) by thyrotropes, and luteinizing
hormone (LH) and/or follicle-stimulating hormone (FSH) by gonadotropes (Fig. 1).
Hormone production by the AP is regulated by signals from the hypothalamus, such
as growth hormone-releasing hormone (GHRH) and somatostatin, which stimulate
and inhibit, respectively, pituitary GH synthesis and secretion. The pituitary hor-
mones act on distal target organs where they mainly control the production of
peripheral hormones (such as glucocorticoids from the adrenal cortex and estradiol
or testosterone from the gonads), which in turn negatively feed back on the
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hypothalamus and pituitary. This multilayered interplay between hypothalamus,
pituitary and target organs eventually generates tightly controlled, pulsatile secre-
tion of hormones by the pituitary.
Because of its master position, disturbed function of the pituitary causes severe
clinical complications (Schneider et al. 2007; Willems and Vankelecom 2014). For
instance, GH deficiency causes growth disturbances and mental retardation in
children and distorted fat metabolism, weakened muscles, osteoporosis and
Fig. 1 Proposed model of pituitary stem cells and their functions. A cross-section of the (mouse)
pituitary gland (upper left) shows the AP stem cell niche around the cleft (MZ; red) with the
projected germinative wedge regions, and the putative secondary niches distributed all over the AP
parenchyma (red clusters). The MZ stem cells and the in-gland stem cell clusters appear to be
wired into a 3D network (see dotted lines in section and zoom-in drawing). The total stem cell pool
is heterogeneous, encompassing stem (and further-advanced progenitor) cells in different phases
of cell cycle, activation and maturation (indicated by different shapes and red tints), supposedly
typified by different fingerprints of markers (of which the most dominant ones are indicated). To
contribute to the pituitary endocrine cells, the stem/progenitor cells may move from the various
niches into the glandular area (arrows), and EMT may be involved in this migration process. The
pituitary stem cells are only modestly implicated in the low-rate turnover of the gland (see text) but
appear to primarily pop up in the actively remodeling pituitary, as occurring during neonatal
maturation (left), regeneration after cell/tissue destruction (middle), and development of tumors
(with candidate TSC; red) (right). AP anterior pituitary, FS folliculo-stellate, IL intermediate lobe,
MZ marginal zone, PP posterior pituitary
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cardiovascular anomalies in adults, together strongly diminishing quality-of-life
and life expectancy (Gasco et al. 2013). Pituitary deficiency (generally referred to
as hypopituitarism) may be congenital or acquired during life, the latter accounting
for the majority of cases (Mehta and Dattani 2008; Schneider et al., 2007; Willems
and Vankelecom 2014; Zhu et al. 2005). Tumor growth in the pituitary (with a
prevalence for clinically observed tumors of 1:1000) can compress the healthy
endocrine tissue, thereby compromising pituitary function (Melmed 2011;
Vankelecom 2012). Also the treatment procedures of surgical resection or irradia-
tion inflict damage on the pituitary, resulting in hypofunction. In addition, traumatic
brain injury, ranging from car accidents to sport-related impacts (e.g.,by boxing),
represents an important cause of pituitary deficiency (Gasco et al. 2012; Tanriverdi
et al. 2015). The current approach to treat hypopituitarism symptoms is by hormone
replacement therapy (HRT) (Gasco et al. 2013; Schneider et al. 2007; Van Aken
and Lamberts 2005; Willems and Vankelecom 2014). However, the exogenous
hormones also cause side effects, further adding to the reduced quality-of-life.
Moreover, a fundamental shortcoming of HRT lies in its failure to mimic the
natural pulsatility of hormone release by the pituitary. Therefore, restoring deficient
pituitary tissue and function would represent a more ideal tactic (Willems and
Vankelecom 2014). Interestingly, it has recently been shown that the pituitary
gland has the capacity to regenerate cells after destruction (Fu and Vankelecom
2012; Fu et al. 2012). Moreover, the local stem cells appear to participate and
function as activated restorers (see below). This new finding may open the door
toward regenerative opportunities.
The process of tumorigenesis in the pituitary is largely uncomprehended, and
treatment remains suboptimal in up to two-thirds of patients (Melmed, 2003, 2011).
A better understanding of the underlying mechanisms is essential to improve
clinical management. In particular, the question arises whether pituitary tumors
contain a driver population of ‘tumor stem cells’ (TSC), as has been discovered in
other types of tumors (Clevers 2011; Dalerba et al. 2007; Sergeant et al. 2009;
Wouters et al. 2009). Generally speaking, TCS are considered to power the devel-
opment, growth, local invasion, metastasis, therapy resistance and/or recurrence of
tumors. TSC thus represent a very appealing target to understand, treat and erad-
icate the tumor.
Pituitary Stem Cells: Expanding Molecular Portrayal
Stem cells have now been identified in many adult organs. They are considered the
master builders of the tissue, replacing cells that have grown old and finished their
task (homeostatic turnover), producing surplus cells when needed, or regenerating
cells that were destroyed by physical or pathological insults (Alvarez-Buylla and
Lim 2004; Rando 2006; Slack 2008; Vankelecom 2012; Vankelecom and Chen
2014; Wabik and Jones 2015). The tissue stem cells not only give rise to new
specialized cells of the organ but must also perpetuate by producing at least one
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‘selfie.’ Differentiation potential (ranging from uni- to multipotency) and self-
renewal capacity indeed represent the core hallmarks of adult tissue stem cells
(Barker et al. 2010; De Los Angeles et al. 2015; Rando 2006; Wabik and Jones
2015). On the other hand, the degree of activity of adult stem cells is clearly
dependent on the tissue. Some organs show rapid cell turnover within days and
contain highly energetic stem cells that drive this renewal (as, for instance, intestine
and skin). Other organs are more static in their cell composition and only need cell
replacement at a very low pace (such as the brain, heart, liver, pancreas, lung;
Alvarez-Buylla and Lim 2004; Barker et al. 2010; Huch et al. 2013a,b; Rando 2006;
Slack 2008; Vankelecom 2012; Wabik and Jones 2015). The pituitary belongs to
the latter group, undergoing turnover in terms of months rather than days (Levy
2002, 2008; Nolan et al. 1998; Rando 2006; Vankelecom 2012; Vankelecom and
Chen 2014). Stem cells in organs with low turnover appear highly dormant (quies-
cent) and are only jolted awake by strong triggers like loss of cells by damage. Stem
cells, together with their further progressed progenitor cells (that have set off for
differentiation), are typically housed in a dedicated setting of the tissue, the niche,
containing cellular and molecular ‘housemates’ that control the maintenance, self-
renewal and differentiation of the stem cell inhabitants (Alvarez-Buylla and Lim
2004; Rando 2006; Roskams 2006; Slack 2008; Vankelecom 2012; Vankelecom
and Chen 2014; Yin et al. 2013).
The discovery of stem/progenitor cells in the pituitary was launched a decade
ago by the identification of a side population (SP) in the adult gland of rodents and
chicken (Chen et al. 2005). SP cells exhibit high efflux capacity, a property
considered characteristic and important for stem cells to defend themselves against
toxic substances. Meanwhile, the existence of stem cells in the pituitary has been
clearly established (Chen et al. 2009; Fauquier et al. 2008; Garcia-Lavandeira
et al. 2009). Their molecular portrayal is steadily expanding; a compact overview
is provided here (for extensive reviews, see Vankelecom 2010, 2012; Vankelecom
and Chen 2014).
Like stem cells of other tissues, pituitary stem cells in general express two
classes of markers, i.e., broad stemness markers and pituitary embryogenesis-
associated factors. Within the first group, the key stem-cell regulatory transcription
factors SOX2 [SRY (sex determining region Y)-box 2] and SOX9 (Arnold
et al. 2011; Jayakody et al. 2012; Pevny and Nicolis 2010) occupy a well-
recognized position. The SOX factors ‘color’ cells that reside in the marginal
zone (MZ), which borders the cleft (Fig. 1), a lumen that is left from the early-
embryonic pituitary structure known as Rathke’s pouch (RP; Vankelecom 2012). In
addition, SOX2-immunoreactive (SOX2þ) cells are present as scattered clusters in
the AP parenchymal area (Fig. 1; Chen et al. 2005, 2009; Fauquier et al. 2008; Fu
et al. 2012; Garcia-Lavandeira et al. 2009; Gremeaux et al. 2012). The several
locations of SOX2þ cells may point to the existence of multiple stem cell niches in
the pituitary, encompassing a major (primary) niche around the cleft and many
secondary parenchymal niches, together taking care of dynamic and/or subtle cell
adaptations in the gland. Interestingly, the SOX2þ cell clusters and MZ cells appear
to be connected (Fu et al. 2012; Gremeaux et al. 2012; Mollard et al. 2012;
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Vankelecom and Chen 2014), thereby forming a three-dimensional (3D) network
throughout the gland (Fig. 1), as also occurs among the different hormonal cell
types (Le Tissier et al. 2012; Mollard et al. 2012). Such an integrated circuit would
allow communication between the stem cells throughout the gland and promote
coordinated actions. Of note, the pituitary stem cells seem to be part of the formerly
identified heterogeneous population of folliculo-stellate (FS) cells within the gland
(Allaerts and Vankelecom 2005), since the stem cells also express the FS cell
marker S100 (Fig. 1). Thus, the SOX2þ cell network may be part of the FS cell
network, the first interconnected functional circuitry identified in the pituitary
(Fauquier et al. 2001). In addition, the cell adhesion molecule E-cadherin
(CDH1) is strongly expressed in the MZ, as well as in S100þ cell patches spread
over the AP lobe (Fauquier et al. 2008), and may participate in stitching the stem
cells together (Fig. 1). Additional general stemness markers found in pituitary stem
cells, although sometimes less well-defined, include OCT4, NANOG, glial cell
line-derived neurotrophic factor receptor alpha 2 (GFRA2), NESTIN and Kr€uppel-
like factor 4 (KLF4; reviewed in Vankelecom and Chen 2014). Of interest, SOX2,
OCT4, NANOG and KLF4 constitute the transcription-factor core of embryonic
stem (ES) and induced pluripotent stem (iPS) cells, the prototypical stem cells
(De Los Angeles et al. 2015; Hyslop et al. 2005; Takahashi and Yamanaka 2006).
Finally, the chemotactic receptor CXCR4 (C-X-C chemokine receptor type 4),
which is more and more classified as a general stemness marker, is also upregulated
in the pituitary stem cell compartment (Horiguchi et al. 2012; Vankelecom 2010,
2012; Vankelecom and Chen 2014).
Within the group of embryonic pituitary-related factors, expression of PROP1
(Prophet of Pit1) seems to be best defined. This transcription factor, which – among
others - is essential for the regulation and migration of RP progenitor cells during
pituitary embryogenesis (Himes and Raetzman 2009; Ward et al. 2005; Zhu
et al. 2005, 2007), is expressed in the SOX2þ cells, although it is not clear yet
whether postnatal expression in the MZ stops after the first postnatal weeks or is
continuous throughout life (Garcia-Lavandeira et al. 2009; Yoshida et al. 2009,
2011). In general, there is no co-localization of PROP1 or SOX2 with hormones
(Chen et al. 2009; Fauquier et al. 2008; Fu et al. 2012a,b; Garcia-Lavandeira
et al. 2009; Gremeaux et al. 2012; Yoshida et al. 2009), supporting the general
notion that stem cell conservators must be downregulated before differentiation
starts. The NOTCH pathway is another essential regulator of pituitary embryogen-
esis (Kita et al. 2007; Monahan et al. 2009; Raetzman et al. 2004; Zhu et al. 2005,
2007), of which several components are upregulated in the adult (mouse) pituitary
stem cell fraction (Chen et al. 2006, 2009; Vankelecom 2010) and are found
expressed in some of the MZ and parenchymal S100þ cells of the (rat) AP
(Tando et al. 2013). Some other transcriptional regulators that play an important
role in pituitary embryonic development (such as Hesx1, the earliest known gene
expressed in the pituitary primordium, Lhx4, Pax6, Otx2, Ascl1 and the Six/Eya/
Dach genes; Kelberman et al. 2009; Zhu et al. 2005, 2007) are also higher
transcribed in the adult pituitary stem cell fraction (Chen et al. 2006, 2009;
reviewed in Vankelecom 2010, 2012), as well as the cyclin-dependent kinase
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inhibitor p57 that, during embryogenesis, emerges in the RP progenitor cells that
stop cycling to embark on differentiation (Bilodeau et al., 2009; Vankelecom 2010;
Vankelecom and Chen 2014). Finally, components of the fibroblast growth factor
(FGF) and bone morphogenetic protein (BMP) pathways, having important roles in
the specification and proliferation of RP progenitor cells (Ericson et al. 1998; Zhu
et al. 2005, 2007), are also upregulated in the adult stem cells (Vankelecom 2010;
Vankelecom and Chen 2014). Together, this expression portrait suggests that the
stem cells of the adult pituitary (re-)use the embryonic developmental programs for
their maintenance and progression toward differentiated cells (as also found in
other tissues; Alvarez-Buylla and Lim 2004; Jensen et al. 2005; Roskams 2006;
Slack 2008; Wagers and Conboy 2005).
Finally, a battery of new candidate markers has emerged from recent studies
(extensively reviewed in Vankelecom 2010 and Vankelecom and Chen 2014),
including the retinoic acid-producing retinal aldehyde dehydrogenase 1 (Raldh1;
Fujiwara et al. 2007) and the retinoic acid receptor Rarb (Vankelecom 2010;
Vankelecom and Chen 2014); the transcription factors PRRX1 and PRRX2
(expressed in proliferating RP progenitor cells until cell-cycle exit and start of
differentiation; Susa et al. 2012); the cell-adhesion molecule cadherin-18
(expressed in the MZ in a different pattern than CDH1; Chauvet et al. 2009); the
coxsackievirus and adenovirus receptor (CAR; Chen et al. 2013); the Kr€uppel-like
factor 6 (KLF6; Ueharu et al. 2014); and the juxtacrine signaling molecule ephrin-
B2 (Yoshida et al. 2015). A number of the pituitary stem cell markers identified
may be involved in constructing and maintaining the 3D network, in particular the
cadherins, ephrins and CAR.
An intriguing question is how the multiple markers are distributed within the
stem cell population. Regarding the embryonic markers, it can be assumed that
different stages along the stem cell differentiation path are typified by different
factors in a sequence similar to the embryogenic process. Accordingly, it is
proposed that the pituitary stem cell compartment represents a heterogeneous
pool of cells in different stages of life cycle and activation (Fig. 1), with the
different markers, alone or in combination, designating the different phases, vary-
ing from quiescent stem cell states to committed precursor steps (reviewed in
Vankelecom 2010, and Vankelecom and Chen 2014). Such heterogeneity within
the stem cell population has also increasingly been demonstrated in other organs
(Bond et al. 2015; Donati and Watt 2015). Single-cell transcriptomic analysis of
brain stem cells identified the presence of four subgroups in different stages of
activation (most prominently in response to injury), ranging from dormant to
primed-quiescent, active and active-dividing stem cells (Llorens-Bobadilla
et al. 2015). Of note, pituitary and brain stem cells show striking similarities, in
particular regarding their localization around a lumen (cleft and ventricle, respec-
tively) and their expression of common markers (such as SOX2, NESTIN and
S100; Kriegstein and Alvarez-Buylla 2009). In addition, different stem cell sub-
populations may be distributed over the different proposed niches in the pituitary.
For instance, stem cells in the parenchymal SOX2þ cell clusters may be further
advanced in their ‘priming’ (as compared to the MZ cells) to allow swifter
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contribution to the neigboring parenchymal endocrine tissue, or they may only form
specific cell types more prevalent at the particular parenchymal spots.
Apart from their labeling value, the factors mentioned must, of course, also have
a function in the pituitary stem cells. Not much is known yet about these duties, but
ideas may be inferred from other stem cells or from pituitary embryogenesis. The
transcription factors SOX2, OCT4, NANOG and KLF4 most likely play a role
similar to the one in ES and iPS cells (De Los Angeles et al. 2015; Hyslop
et al. 2005; Takahashi and Yamanaka 2006), i.e., to keep the pituitary stem cells
in an undifferentiated, multipotent state. Genetic disruptions of SOX2 leads to
certain forms of hormonal cell deficiency and pituitary hypoplasia (Jayakody
et al. 2012; Kelberman et al. 2008), at least partly due to a reduced expansion and
function of the RP progenitor cells, thereby giving some hint toward the importance
of SOX2 in adult stem cell regulation. NOTCH signaling is likely also involved in
the control of stem cell proliferation in the adult gland, since NOTCH
downregulation in the embryonic pituitary coincides with cell cycle exit of the
RP progenitor cells and genetic ablation of NOTCH signaling in the developing
pituitary results in severe AP hypoplasia due to reduced proliferative capacity of RP
progenitors (Kita et al. 2007; Monahan et al. 2009; Raetzman et al. 2004; Tando
et al. 2013; Zhu et al. 2005, 2007). In addition, stem cells increase in number in AP
cell cultures upon NOTCH activation (Chen et al. 2006; Tando et al. 2013). SOX2
and NOTCH (together with PROP1) may form an interacting signaling network
within the stem cell compartment (reviewed in Willems and Vankelecom 2014).
In the adult pituitary, PROP1 may be required in the progressing stem/progenitor
cells to enable migration from the MZ or the in-gland stem cell clusters toward the
parenchyma for further differentiation. This proposed role is based on knowledge
from embryogenesis, where genetic inactivation of PROP1 results in failure of RP
progenitors to migrate from the proliferative progenitor region to the developing
AP, resulting in extensive pituitary hypoplasia and absence of nearly all AP cell
lineages (Himes and Raetzman 2009; Ward et al. 2005; Zhu et al. 2005, 2007). The
prominent presence of the epithelial marker CDH1 and the tight-junction protein
CAR suggests a role for these factors in stitching the marginal and parenchymal
niches of stem cells together in a 3D network (Fig. 1). Escape from this ‘imprison-
ment’ would require conversion of the organized connected epithelial cell type to
the untied and motile mesenchymal cell phenotype through the process of
epithelial-mesenchymal transition (EMT; Kalluri and Weinberg 2009; Vankelecom
and Chen 2014). PROP1 may be required for EMT since it downregulates CDH1 by
activating the expression of the CDH1 repressor SNAI2/SLUG in the RP progenitor
zone (Himes and Raetzman 2009). Stem cell migration in the adult gland may
further be regulated by CXCR4, which is known for its chemotactic activity and
regulation of EMT (Hu et al. 2014; Kalluri and Weinberg 2009). Also NESTINþ
pituitary cells have previously been shown to possess motile capacity (in vitro) as a
possible result of EMT (Krylyshkina et al. 2005). Finally, ephrin signaling may play
a role in the formation and organization of the proposed 3D stem cell network
through actions of attraction and repulsion (Solanas and Batlle 2011). Taken
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together, a number of the factors identified seem to be involved in regulating the
balance between movement and bonding of the pituitary stem cells.
In conclusion, the pituitary stem cell phenotyping list is progressively
expanding. Although one can speculate on the role these markers play in adult
pituitary stem cell regulation, a firm foundation remains to be provided.
Pituitary Stem Cells: Uncovering the Hidden Functions
As mentioned above, new tissue cells can be generated by the resident stem cells
during homeostatic turnover, adaptive responses to body requirements and regen-
erative reactions to tissue damage (Alvarez-Buylla and Lim 2004; Rando 2006;
Slack 2008; Vankelecom 2012; Vankelecom and Chen 2014; Wabik and Jones
2015). Whether stem cells in the pituitary also form or renew hormonal cells during
postnatal life is a tempting question. Given the slow turnover rate of the adult gland
(Levy 2002, 2008; Nolan et al. 1998; Rando 2006; Vankelecom 2012; Vankelecom
and Chen 2014), the involvement of stem cells would be most evident in situations
of more activated cell remodeling in the tissue. Recently, studies have started to
explore the functional position of pituitary stem cells in more dynamic conditions,
including neonatal maturation, adaptation to endocrine demands, regeneration after
damage, and tumor formation.
Neonatal Pituitary Maturation
The (rodent) pituitary undergoes a substantial growth phase immediately after birth,
with increasing numbers of hormonal cells developing during the first neonatal
week(s) (Melmed 2010; Vankelecom 2010, 2012; Vankelecom and Chen 2014).
During this period, the pituitary stem cell population resides in a state of activation
as compared to later in life, showing higher cell numbers, higher proliferation rate
and higher stem cell functionality (i.e., sphere-forming and multipotent differenti-
ation capacity; Chen et al. 2005, 2009; Gremeaux et al. 2012). Moreover, stemness
and embryonic markers are prominently expressed in neonatal stem cells (Chen
et al. 2009; Gremeaux et al. 2012; Kikuchi et al. 2007). The topography of the
SOX2þ cells further underlines this higher activation status, with increased num-
bers of clusters in the neonatal AP lobe and higher abundance of SOX2þ cells at the
junctions of the AP and IL (wedges), with signs of SOX2þ cells sprouting from
these putative germinal regions (Gremeaux et al. 2012; Fig. 1). Neonatal SOX2þ
cell clusters in the vicinity of the MZ are clearly connected to the MZ (Gremeaux
et al. 2012), supporting the idea that the cell clusters observed in the AP lobe
originate from this zone (Fig. 1). Of note, SOX2 is mainly not observed together
with hormones, which may be interpreted again as mutual exclusion, i.e., with
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differentiation only occurring when the guardians of multipotency like SOX2 are
downregulated or extinguished.
Tracing of SOX2þ cells from embryonic to neonatal age (technically speaking,
by tamoxifen induction in pregnant Sox2CreERT2/R26YFPflox/flox mice) revealed
traced ‘yellow fluorescent protein’-positive (YFPþ) cells in the neonatal pituitary
that express early and late differentiation markers of hormonal cells, indicating that
embryonic SOX2-expressing cells contribute to neonatal hormonal cells
(Andoniadou et al. 2013; Rizzoti et al. 2013). It should be realized that this finding
does not automatically mean that the neonatal stem cells per se drive the early
expansion phase (by forming new hormonal cells) during those first weeks after
birth. Short-term SOX2þ lineage tracing should, therefore, be done within the
neonatal period itself. YFP was also found together with SOX2, indicating that
the embryonic SOX2þ progenitor cells persist after birth (e.g., by themselves or
after self-renewal). Also in other tissues, SOX2þ postnatal (stem) cells originate
from fetal SOX2þ (progenitor) cells (Arnold et al. 2011). This idea is also in line
with the embryonic phenotype of the postnatal pituitary stem cells, as supported by
the marker expression profile (see above).
Taken together, the activated nature of the stem cell compartment during the first
weeks after birth suggests a dynamic participation in the neonatal maturation
process of the gland, although most evidence so far is circumstantial.
Basal and Adapting Adult Pituitary
Basal Turnover The contribution of stem cells to the slow homeostatic turnover in
the postnatal gland was only recently demonstrated (Andoniadou et al. 2013;
Rizzoti et al. 2013). Tamoxifen-induced SOX2þ or SOX9þ lineage tracing starting
from four to eight weeks of age revealed the existence of hormoneþ cells derived
from the traced (YFPþ) cells as analyzed 8 to 14 months later. However, their
number was small, which in the first place reflects the low turnover rate of the adult
gland under physiological conditions but at the same time suggests that the contri-
bution of stem cells to new hormonal cells is only very limited under basal
conditions. Endocrine cell turnover in the basal pituitary would thus mainly rely
on proliferation of differentiated hormonal cells (Langlais et al. 2013; Vankelecom
and Chen 2014). The vast majority of the YFPþ cells were still SOX2þ/SOX9þ
after the long-term tracing, supporting a long-lived stem cell phenotype of high
quiescence and/or a persistent (but slow) self-renewal activity. Taken together, the
findings from lineage tracing do not support a major input of stem cells in adult
pituitary homeostatic turnover, which is in line with findings in other ‘lazy’ tissues
(Barker et al. 2010; Huch et al. 2013a,b; Rando 2006; Slack 2008; Vankelecom
2012; Wabik and Jones 2015).
Plastic Cell Adaptations In contrast to the quite immeasurable cell neogenesis
under basal conditions, the pituitary’s cell composition more actively changes in
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response to peripheral signals conveying endocrine needs. As a prominent example,
the number (and activity) of lactotropes rises during pregnancy and lactation to
meet the heightened demand for PRL (Haggi et al. 1986; Vankelecom 2012). This
expansion is at least partly due to elevated estrogen levels in these conditions. The
involvement of stem cells may be concluded from the recent observation that short-
term estradiol treatment (of male mice) causes a 10-fold increase in dividing SOX2þ
cells. The total number of SOX2þ cells, however, did not change, suggesting that the
generated daughter cells immediately stopped expressing SOX2 to differentiate into
the demanded lactotropes (Rizzoti et al. 2013). To underpin a direct contribution of
stem cells to the expanding lactotrope population, lineage-tracing experiments are
further needed. Whether the stem cells also play a role in the rise of somatotropes
during puberty, or in the (continuous) adaptation of gonadotropes during sexual
maturation and estrous cycling, is at present unknown.
Other forms of enhanced pituitary cell remodeling are seen when negative
feedback dissipates because of ablation of target organs. Adrenalectomy causes a
swift, transient rise in corticotropes, whereas gonadectomy triggers a fast and
transitory increase in gonadotropes. Previous studies provided circumstantial evi-
dence that ‘hormonally null cells’ (the at that time postulated pituitary stem cells)
contribute to the new corticotropes and gonadotropes (Levy 2002, 2008; Nolan
et al. 1998; Nolan and Levy 2006). Recent studies provided more direct evidence
that pituitary stem cells are involved. The SOX2þ cells along the cleft expand after
adrenalectomy (Langlais et al. 2013). In addition, SOX9þ lineage tracing showed
that ~20% of the newborn corticotropes are derived from the SOX9þ stem cells
(Rizzoti et al. 2013). The other new ACTHþ cells may be produced by corticotrope
proliferation (see also Langlais et al. 2013). After gonadectomy, dividing SOX2þ
cells increase by four-fold but total SOX2þ cell numbers do not change (Rizzoti
et al. 2013), again suggesting that the generated progenitor cells immediately
differentiate with prompt disappearance of SOX2.
Taken together, recent studies provide supportive evidence that adult pituitary
stem cells have the capacity to differentiate into hormonal cells in vivo under
challenging physio- and pathological conditions.
Pituitary Regeneration and Impact of Aging
A number of adult tissues are capable of restoring cells following destruction by
physical or chemical impacts (Rando 2006; Vankelecom 2012; Vankelecom and
Chen 2014; Willems and Vankelecom 2014; Wabik and Jones 2015). In several of
these regenerative responses (like in muscle), stem cells are mobilized and directly
involved to generate the new cells (Conboy and Rando 2005). Also in slow-
turnover organs like liver and pancreas, hidden (‘facultative’) stem cells are acti-
vated under certain damaging conditions to drive the regenerative reaction (Barker
et al. 2010; Huch et al. 2013a,b; Rando 2006; Slack 2008; Vankelecom 2012;
Wabik and Jones 2015; Xu et al. 2008).
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Regarding the pituitary, it has only recently been established that the adult,
mature gland has the potential to regenerate cells after destruction. Through a
transgenic mouse approach, damage was inflicted in the pituitary by killing the
somatotrope (GHþ) cells using diphtheria toxin (DT; Fu et al. 2012; Luque
et al. 2011). The injury triggered an immediate response of the pituitary stem
cells, which started to expand in number and to co-express GH (Fu et al. 2012).
Five to six months after ablation, the somatotrope cell number was significantly
restored (up to 60%). The study for the first time showed that the pituitary, when
suffering damage at adult age, has the potential to regenerate destroyed tissue
(Fu et al. 2012). In addition, it advanced the stem cells as the likely drivers of
regeneration (Fig. 1) and source of the newborn somatotropes. Meanwhile, this
regenerative capability appeared more general and not limited to somatotropes. In
an analogous model in which lactotropes were destroyed with DT (Fu and
Vankelecom 2012), restoration was also observed (up to ~60%) although clearly
faster (already after four to six weeks), which may be due to the involvement and
cooperation of more than one process. Stem cell participation with expansion and
PRL co-expression was again observed, but in addition there was enhanced prolif-
eration of the surviving (or newly formed) PRLþ cells as well as increased numbers
of double PRLþ/GHþ cells, suggestive of an activated transdifferentiaton process
of somatotropes toward lactotropes (Fu and Vankelecom 2012). Finally, pituitary
stem cells also expanded in number following gonadotrope ablation by DT, but
detailed analysis of this mouse model was not possible because of cardiotoxicity
(Vankelecom, unpublished observations).
A recent follow-up characterization study of the somatotrope ablation-and-
regeneration model revealed some interesting features of the pituitary’s regenera-
tive capacity (Willems et al. 2016). First, the regeneration level appeared to be
capped (at ~60%, or in other words, restoration to ~70% of the normal GHþ cell
number), even if the recovery period was largely extended from 0.5 to 1.5 year.
Either the regenerative power of the pituitary does not go beyond certain levels or
higher restoration is not needed to reach sufficient ‘physiological’ GH activity.
Serum GH concentrations were restored to about one-third of normal values, at the
same time indicating that regeneration does not only occur at the morphological
level but also, although in a more limited fashion, at the functional (hormone-
secretory) level. Furthermore, and rather surprisingly, the restorative capacity of the
pituitary fades very fast at aging; middle-aged mice (eight months old) no longer
showed recovery (as compared to eight-week-old mice), not even after long recu-
peration periods (Willems et al. 2016). Interestingly, this disappearance of regen-
erative competence coincides with a decline in pituitary stem cell number.
Moreover, the stem cells of the older pituitary are less talented in generating
spheres (as a functional characteristic of stem cells), which decrease in number
and size, although differentiation to hormonal cell lineages still occurs in the
spheres. SOX2þ signals in the spheres from the older pituitaries were most of the
time found in the cytoplasm and not in the nucleus of the cells, where SOX2 should
be present to maintain the stem cell phenotype (Willems et al. 2016). Taken
together, these findings suggest a decrease in overall fitness of the pituitary stem
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cells at aging - not being maintained in a primitive state - which may lead to fast
(-er) exhaustion of their potential during differentiation and regenerative attempts.
In other tissues (e.g., muscle and heart), the stem cell population is also negatively
affected by age, undergoing a decline in number and regenerative capacity (Blau
et al. 2015; Hariharan and Sussman 2015).
Further intriguingly, restoration was not observed anymore when the injury
impact was prolonged by extending the DT injection period (from 3 to 10 days),
although the somatotrope ablation grade obtained was identical (Willems
et al. 2016). The stem cell compartment still reacted to the prolonged injury by
promptly expanding (although somewhat less than after the short-term injury
impact), but no co-expression of GH was found despite the fact that the stem
cells were still capable of differentiating into all hormonal cell types when assessed
in vitro (using pituispheres; Willems et al. 2016). As found in other tissues (like the
hippocampus and the hematopoietic system), the regenerative power may become
exhausted when subsequent attempts are over and again suffocated during the long-
term impact (Botnick et al. 1979; Sierra et al. 2015). Stem cells may have reached
their expansive limit or crossed their threshold of restorative competence, or the
reacting, regenerating stem cell pool may become depleted while possibly other,
more quiet, stem cell populations remain unaffected (which would explain the
preservation of sphere-forming and multipotent capacity). Alternatively, the obser-
vation of a remaining intrinsic functionality after prolonged DT treatment may
suggest that a deficiency in stem cell regulatory networks, as emanating from the
niche, pituitary parenchyma or systemic circulation, may lie at the basis of the
regenerative failure.
Finally, our recent characterization study started to search for molecular mech-
anisms underlying regeneration and exposed some embryonic, stemness and
repairing pathways that may be involved in the stem cell reaction to injury, in
particular EMT, growth factor (FGF and epidermal growth factor, EGF) and Hippo
pathways (Willems et al. 2016). Activation of FGF and EGF can lead to increased
pituitary stem cell numbers, as has been demonstrated in AP cell aggregate cultures
(Chen et al. 2006).
Taken together, recent studies support a function for pituitary stem cells in
pituitary regeneration (Fig. 1). Activation of the stem cells and movement to the
site of injury may be steered by embryonic, proliferative (growth factor), migratory
(EMT) and restorative (Hippo) signaling pathways. This regenerative capacity
appears not boundless but limited both in age-related terms and final efficacy.
Pituitary Tumorigenesis
As mentioned, the process of tumorigenesis in the pituitary remains far from
understood (Melmed, 2003, 2011; Vankelecom and Gremeaux 2010; Vankelecom
2012). An appealing but largely untouched question is about the position of the
pituitary stem cells during the tumorigenic event in the tissue. Furthermore, are
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TSC present in pituitary tumors, and if so, are they linked to the resident stem cells?
Previous studies regarding this subject have been extensively reviewed before
(Florio 2011; Lloyd et al. 2013; Vankelecom and Gremeaux 2010; Vankelecom
2012; Vankelecom and Chen 2014). Some candidate TSC were proposed, for
instance, based on spheroid formation (Xu et al. 2009) and marker expression
(Barbieri et al. 2008), but convincing evidence was not provided and some results
remained questionable (discussed in Vankelecom and Gremeaux 2010;
Vankelecom 2012; Vankelecom and Chen 2014).
A recent study of our group found that pituitary adenomas (as obtained from
human patients) contain a SP with prominent expression of tumor stemness markers
(like CXCR4) and stemness signaling pathways (like EMT) and that enriches for
cells that form tumorspheres in a self-renewing sequence (Mertens et al. 2015). The
pituitary tumor SP (as analyzed for the AtT20 cell line) showed tumor-growth
advantage in vivo in immunodeficient mice. Thus, the pituitary tumor SP holds
molecular and functional characteristics supporting a TSC phenotype. In addition,
CXCR4 signaling may be involved in AtT20 tumorigenesis since inhibition of the
pathway reduced tumor size in vivo as well as EMT activity (cell motility) in vitro
(Mertens et al. 2015). Moreover, the AtT20 SP showed resistance to the chemo-
therapeutic drug temozolomide (Mertens and Vankelecom, unpublished observa-
tions), further supporting a TSC phenotype. Also interestingly, the SP of pituitary
tumors displays some appealing molecular differences with the candidate TSC
(SP) of malignant cancer types (melanoma and pancreatic cancer; Van den Broeck
et al. 2013; Wouters et al. 2013) such as an upregulated senescence program, which
might explain why pituitary tumors typically remain benign (Mertens and
Vankelecom, unpublished observations).
The pituitary tumor SP also shows upregulated expression of SOX2 (Mertens
et al. 2015), which may indicate either a link between the stem cells and the putative
TSC or simply activation of SOX2 expression in the candidate TSC. Moreover,
pituitaries from a mouse model in which pituitary (PRLþ) tumors develop in situ
(i.e., the dopamine receptor D2 knockout or Drd2-/- mouse) contains more SP and
SOX2þ cells than wildtype glands (Mertens et al. 2015). This observation is in
accordance with the presence of a TSC (characterized by SP and SOX2þ pheno-
type) in the mouse pituitary tumors, adding up to the SP and SOX2þ cells of the
surrounding normal tissue. In addition, or alternatively, the observation may point
to an activated and expanded ‘normal’ stem cell compartment when tumorigenesis
is occurring in the gland. Regarding the latter idea, it is not known yet what the
consequence of pituitary stem cell activation may be. As already mentioned above,
it is assumed that disappearance of SOX2 from the nucleus (by exclusion or active
expulsion) is needed to allow differentiation (Chen et al. 2009; Fu et al. 2012;
Vankelecom and Chen 2014; Willems and Vankelecom 2014), as has been dem-
onstrated in ES cells (Baltus et al. 2009). The observation in Drd2-/- pituitaries of a
predominant increase in SOX2þ cells in which SOX2 is present in the cytoplasm
(Mertens et al. 2015) might support a high(-er) differentiation rate toward the tumor
PRLþ cells.
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Alternatively, stem cell activation may represent a defence reaction or may
paradoxically activate the TSC or feed the tumor by paracrine influences. An
indirect role of SOX2þ stem cells as paracrine tumor-activating cells has also
been suggested in a mouse model of adamantinomatous craniopharyngioma
(Andoniadou et al. 2013; Gaston-Massuet et al. 2011; see also Andoniadou
2016), a pituitary tumor that originates from ectopic remnants of RP and in that
way clearly differs from the typical AP tumors. On the other hand, resident stem
cells may directly generate the TSC, as has been shown in some other tumor types
(e.g., of intestine, skin and brain; Barker et al. 2009; Chen et al. 2012; Lapouge
et al. 2011; Schepers et al. 2012). Stem cell lineage tracing in mouse models
developing typical pituitary tumors is now needed to explore the link between
tumorigenesis, TSC and stem cells in the pituitary.
Taken together, another hidden function of the pituitary stem cells may reside in
the process of tumorigenesis (Fig. 1), either as the direct creators of the TSC or as
the reacting compartment activated in response to the tumorigenic assault occurring
in the tissue, resulting in a paracrine impact that likely is intended to defend the
tissue but may eventually fuel the tumor.
Conclusion and General Perspectives
Recent studies have started to unveil the hidden functions of pituitary stem cells.
Their job appears to primarily emerge in the active or challenged pituitary, i.e.,
during neonatal maturation, tumorigenesis and repair of damage (Fig. 1). The stem
cells seem much less involved in the more subtle adaptations during basic turnover.
Aging has an early and negative impact on the number and fitness of the pituitary
stem cells, likely explaining the regenerative failure with advancing age. From the
currently available data, embryonic programs appear to be recycled for postnatal
stem cell regulation, activation and differentiation. Further efforts are needed to
pinpoint the molecular mechanisms underlying the stem cell functions. An addi-
tional intriguing aspect to be deciphered is how the newborn endocrine cells
topographically and functionally integrate into the (existing) hormonal cell
networks.
More insight into the pituitary stem cell role and regulation may in the end
advance the treatment of hypopituitarism patients, particularly within the context of
regenerative medicine (extensively reviewed in Vankelecom and Chen 2014 and
Willems and Vankelecom 2014). Pituitary stem cells may provide life-long cures
for mutation-, surgery- and/or trauma-induced pituitary deficiencies. The endoge-
nous stem cells may be stimulated to restore or repair the defective tissue, or the
missing hormonal cells may be generated from stem cells ex vivo and implanted.
The approaches are expected to be superior to HRT, which generates artificial
hormone levels and cannot mimic hormone secretory cyclicity and pulsatility.
However, many pressing issues remain, particularly regarding functional
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integration and safety, before moving to translational applications to cure condi-
tions of hypopituitarism.
In sum, pituitary stem cells represent potential protagonists in the gland with still
mysterious functions in pituitary biology and pathology, although recent studies
have started to ‘write’ some possible scripts. Clearly, there remains a long way to go
in the still under-explored domain of pituitary stem cell functions and associated
clinical opportunities.
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Pituitary Stem Cells During Normal
Physiology and Disease
Cynthia L. Andoniadou
Summary The homeostatic maintenance and functional modification of tissues
require a combination of regulated proliferation and differentiation by somatic stem
cells and more committed progenitors. Of relevance to regenerative medicine
approaches, the endogenous stimulation of cell types for replenishment of damaged
tissues requires an understanding of the signals that promote proliferation and direct
appropriate differentiation to specialised cell types. We recently showed that pitui-
tary stem cells expressing the transcription factor SOX2 are able to contribute to
the generation of new hormone-producing cells during postnatal life. The signals
controlling proliferation in the anterior pituitary are poorly understood and little is
known about the influences supporting the choices between proliferation and quies-
cence among stem cells. The WNT signalling pathway is a major regulator of
proliferation and influences stem cells in multiple tissues throughout the body
as well as cancer stem cells in tumorigenesis. Forced up-regulation of the
WNT pathway specifically in SOX2-positive pituitary stem cells by transgenic
approaches in mouse stimulates a transient burst of proliferation, maintaining
their uncommitted phenotype. These mutated stem cells subsequently induce
tumorigenesis in a non-cell autonomous manner, as they promote proliferation of
surrounding cell types through the secretion of paracrine factors. The studies
presented here aim to provide insights into pituitary stem cell behaviour and their
possible roles during disease states.
“If there were no regeneration there could be no life. If everything regenerated there would
be no death. All organisms exist between these two extremes.” Richard J. Goss, Principles of
Regeneration (1969).
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Introduction
Over the last few years, compelling evidence has demonstrated the presence of
adult somatic stem cells in the murine pituitary gland of mice. In this chapter I will
summarise the critical in vitro and in vivo evidence demonstrating the presence and
functional properties of these cells. In addition, I will highlight how pituitary stem
cells can be involved in tumour formation, as has been shown for stem cell
populations of other organs.
The regulation of stem cell populations is of interest to regenerative medicine
and cancer therapy approaches. Being able to studying the behaviour of stem cells
in their tissue niches can lead to a better understanding of how these behave and
how they are regulated. An abnormal expansion or depletion of such populations
may contribute to neoplasias or organ failure, respectively. In the case of the
pituitary gland, this would manifest as hypopituitarism or pituitary tumours.
Recently, we (Andoniadou/Martinez-Barbera labs) and other groups have provided
evidence that a long-lived, tissue-specific population of undifferentiated progenitor/
stem cells exists within the anterior pituitary gland. Pituitary stem cells (PSCs) are
undifferentiated and are able to generate cells of three main progenitor lineages,
characterized by expression of the transcription factors, PIT1 (POU1F1), TPIT
(TBX19) and SF1 (NR5A1), the expression of which is necessary for terminal
differentiation into hormone-secreting cell types. PIT1-positive progenitors are the
major lineage of the anterior pituitary and give rise to somatotrophs expressing
growth hormone (GH), lactotrophs expressing prolactin (PRL) and thyrotrophs
expressing thyroid stimulating hormone (TSH). Progenitors positive for TPIT
give rise to ACTH-expressing adrenocorticotrophs and MSH-expressing melano-
trophs (refer to Jacques Drouin 2016 for the transcriptional mechanisms regulating
these fate choices). Finally, progenitors expressing SF1 cells give rise to gonado-
trophs that express LH or FSH. All of these populations need to be precisely regu-
lated to ensure appropriate homeostasis and adequate response for hormone
secretion dependent on physiological demand, a process that is very dynamic
throughout life.
To be considered PSCs, the cells need to demonstrate both self-renewal and
differentiation in vivo. Initial studies pointing towards PTCs relied on in vitro
approaches. These identified that there are cells in the postnatal pituitary gland
that have the capacity to expand as colonies in culture, i.e., they have clonogenic
capacity, demonstrating self-renewal in vitro. One population was characterized by
the uptake of the fluorescent dipeptide AMCA and included cells expressing S100
calcium-binding protein B (S100β; Lepore et al. 2005), which have been described
as folliculostellate cells of the anterior lobe (Vila-Porcile 1972). Cells among this
population were able to form adherent colonies in culture. The second population
was characterized by marker expression similar to stem cells of other tissues (Sca1,
Nanog and Oct4) and could form floating spheres (Chen et al. 2005). In later
studies, the same research group showed that there was enrichment in this popu-
lation for the expression of SOX2, SOX9, CD44 and CD133 (Chen et al. 2009).
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Additionally, these cells had active function of ABC transporters, which rendered
them capable of effluxing the vital dye Hoechst 33342, leading to a discrete ‘side
population’ during flow cytometry when analysing levels of expression of Hoechst.
This is a typical property of many cell types that possess properties of stem or
progenitor cells. This side population has since been described for pituitaries of
other vertebrates (Chen et al. 2005, 2006; van Rijn et al. 2012). In time, additional
markers of cells with this in vitro self-renewal capacity have been put forward to
refine the characterisation of PSCs, including Nestin, PROP1, SOX9, GFRα2 and
PRX1/2 (Gleiberman et al. 2008; Yoshida et al. 2009; Rizzoti et al. 2013; Garcia-
Lavandeira et al. 2009; Higuchi et al. 2014). In the postnatal rodent gland in vivo,
SOX2-positive cells displayed a high degree of overlap with other proposed stem
cell markers such as SOX9 (Rizzoti et al. 2013), PROP1 (Yoshida et al. 2009,
2011), and PRX1/2 (Higuchi et al. 2014). We confirmed that SOX2-positive cells
did not overlap with differentiation markers but we sought to determine if they were
able to give rise to all the differentiated lineages in vivo.
The Lovell-Badge lab reported that floating spheres forming from anterior
pituitary cells, were positive for SOX2 (Fauquier et al. 2008), in line with Sox2
expression in the side population (Gremeaux et al. 2012). Our group utilised a
knock-in mouse strain expressing enhanced yellow fluorescent protein (EYFP)
from the SOX2 locus, allowing identification of SOX2-positive cells (Andoniadou
et al. 2012). We isolated SOX2-EYFP-positive and -negative populations sepa-
rately and plated these under conditions promoting the clonogenic expansion of
single cells as adherent colonies. Only cells within the SOX2-positive fraction were
capable of colony formation. This was also the case when clonogenic potential was
assessed via the generation of floating spheres, as reported by the Lovell-Badge
group (Rizzoti 2010). In the adherent cultures, time-lapse imaging of singe cells
plated at clonal density confirmed that they gave rise to single colonies that
contained multiple EYFP-positive cells, demonstrating self-renewal. Withdrawal
of growth factors and prolonged culture in differentiation conditions promoted the
expression of markers of the three main pituitary lineages and the expression of
differentiation markers, as detected by qPCR (Andoniadou et al. 2012). Interest-
ingly, only a small percentage of SOX2+ cells were able to form colonies (up to 5%
depending on age), possibly reflecting heterogeneity within this population in terms
of their potential; alternatively, the culture requirements allowed for expansion of a
restricted subset of cells, where more cell types could have self-renewal capacity. In
either case, the requirement for a better-defined combination of markers was clear.
To address this issue, we investigated S100β as an additional marker of the pituitary
stem cell population, as these had a significant overlap with SOX2+ cells in vivo
(Fauquier et al. 2008; Andoniadou et al. 2013). We purified this population from
transgenic mice expressing S100β-GFP and found that plating GFP-positive and
-negative cells resulted in the enrichment in colonies forming in the GFP-positive
compartment. Since this property lies solely within the SOX2-positive cells in our
assay (Andoniadou et al. 2013), pituitary stem cells are likely to be enriched within
the double-positive population. Double SOX2/S100β are located along the mar-
ginal zone, the epithelium lining the remnants of Rathke’s pouch lumen, and also in
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the parenchyma of the anterior pituitary, often in groups distributed amongst
hormone-secreting cells. We isolated SOX2 cells expressing GFP from these two
regions by microdissection, and demonstrated that their in vitro clonogenic poten-
tial did not differ between the two locations (Andoniadou et al. 2012). Recent
studies from rat have revealed that double-positive SOX2+/S100β+ cells may be
further refined through in vivo expression of the gene Cxadr, which codes for
coxsackievirus and adenovirus receptor (CAR; Chen et al. 2013). Furthermore,
expression of E-cadherin and the juxtacrine factor ephrin-B2 reportedly define
SOX2+/S100β+/CAR+ cells, both in the marginal epithelium and throughout the
parenchyma (Chen et al. 2013; Yoshida et al. 2015). Analysing the side population,
the Vankelecom group (2010) also reported enrichment in ephrin-B expression in
this stem cell-rich compartment; together the data suggested that ephrin-B expres-
sion was a hallmark of the population containing PSCs.
The Long-Term Maintenance of the Anterior Pituitary
Until recently, evidence to support that cells in the pituitary could act as stem cells
in vivo was lacking. This evidence has now been provided through genetic tracing
of SOX2+ cells, enabled by the generation of inducible mouse strains expressing
CreERT2 under the regulation of the SOX2 promoter, where Cre recombinase is
expressed in SOX2+ cells but will not be active until the administration of tamox-
ifen, allowing temporal control of recombinase action (Andoniadou et al. 2013;
Arnold et al. 2011). We lineage traced cells expressing Sox2 both during gestation
and postnatally (Andoniadou et al. 2013). Similarly, the Lovell-Badge group traced
Sox2-expressing and Sox9-expressing cells from embryonic stages (Rizzoti
et al. 2013). In all cases, these populations gave rise to all committed progenitor
cell types (PIT1, TPIT, SF1) and hormone-secreting cells of the anterior lobe (GH,
PRL, TSH, ACTH, LH/FSH). A similar capacity by both SOX2+ and SOX9+
populations is not surprising since Sox2 and Sox9 are co-expressed in the majority
of cells from late embryonic stages (Rizzoti et al. 2013). What remains unknown is
the extent of heterogeneity within this population. Our assay does not distinguish if
a SOX2+ cell capable of proliferation is multipotent or if there are several distinct
oligopotent SOX2+ sub-populations that collectively cover the different popu-
lations. It is, however, able to demonstrate that the population of SOX2+ cells is
long-lived and does not become depleted over time, something that would be
expected of a transit-amplifying progenitor population. We activated CreERT2 in
postnatal SOX2+ cells, enabling expression of R26R-EYFP, and traced the cells for
six months. We assessed the clonogenic potential of EYFP+ cells at the end of this
period, i.e., the SOX2+ cells as well as their derivatives. We flow sorted for EYFP
expression and cultured the positive and negative populations under adherent
clonogenic conditions. Even after six months, the majority of cells with clonogenic
potential (subpopulation of SOX2+) resided within the EYFP+ fraction, indicating
either that SOX2 cells were long-lived, hence persisting long-term after initial
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labeling, or that the pool of SOX2+ cells was maintained through self-renewal.
Importantly, it excluded the possibility that the SOX2+ pituitary stem cell pool
became depleted. Immunofluorescence staining confirmed that, even after a year of
tracing following tamoxifen administration, EYFP+ cells included SOX2+ uncom-
mitted cells. The above experiments relied on repeated administration of a high
dosage of tamoxifen to ensure that the majority of SOX2+ cells were initially
labelled. We have further analysed the behaviour of SOX2+ cells by labelling
sparse cells through low dosage administration. The above experiments demon-
strate the presence of a long-lived population that retains pituitary stem cell prop-
erties throughout normal life. Ongoing efforts focus on the signals that regulate
activity of this stem cell compartment and on how the potential of PSCs is
maintained during life.
Stem Cells and Pituitary Tumours
Similar to organ-specific stem cells, analyses of many tumours and cancers have
revealed the presence of multipotent cells, which are often thought to drive tumour
formation. Many of the properties of ‘cancer stem cells’ (CSCs) are shared by
normal tissue-specific stem cells: slow cycling status, self-renewal and differenti-
ation capacity and even resistance to cytotoxic drugs. For some tumours, it has been
shown that normal stem cells are transformed into CSCs when targeted to express
oncogenic proteins. For example, intestinal crypt stem cells transform into CSCs
when the WNT/β-catenin pathway is over-activated (Barker et al. 2009; Zhu
et al. 2009). However, progenitor cells or even differentiated cells could give rise
to cells fulfilling CSC criteria upon transformation (Valent et al. 2012; Clevers
2011). Several groups have reported the presence of putative CSCs in human
pituitary adenomas and from mouse pituitary tumour models (Chen et al. 2014;
Xu et al. 2009; Donangelo et al. 2014; Lloyd et al. 2013; Mertens et al. 2015;
Orciani et al. 2015; van Rijn et al. 2013; Yunoue et al. 2011; Hosoyama et al. 2010).
It remains unknown if CSCs arise from PSCs, although their properties can be
similar; for example, both are capable of in vitro self-renewal and differentiation
and PSCs are likely to be chemoresistant like CSCs, since PSCs are found within
the ‘side population’ generated by dye efflux, utilising the same transporter prop-
erties as chemoresistance (Chen et al. 2009).
In our quest to determine if PSCs are transformed to CSCs following expression
of an oncogenic protein, we uncovered a non-cell autonomous role for these cells in
tumour formation through the expression of paracrine factors that promote tumour
formation by a different cell population. We focused on mutations in CTNNB1, the
gene encoding β-catenin; these mutations have been identified in numerous tumours
and in the pituitary, identified in the majority of adamantinomatous cranio-
pharyngioma (ACP) tumours (Buslei et al. 2005). ACPs are aggressive tumours
with a tendency to infiltrate the brain, vascular structures and optic tracts (Muller
2014). They represent the most common pituitary tumour type in children and are
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mostly paediatric (Muller 2013). The mutations responsible for the generation of
ACP activate the WNT/β-catenin pathway by preventing the degradation of
β-catenin and resulting in its accumulation (Martinez-Barbera 2015). A hallmark
of ACP is the presence of small cell clusters that strongly accumulate nucleo-
cytoplasmic β-catenin, as revealed by immunohistochemistry (Buslei et al. 2007;
Hofmann et al. 2006). We expressed this mutation embryonically throughout the
developing pituitary primodium, from the early specification of Rathke’s pouch
using the Hesx1-Cre driver. Hesx1Cre/+; Ctnnb1lox(ex3)/+ animals develop tumours
very similar to human ACP and contain the hallmark β-catenin-accumulating cell
clusters that activate the WNT/β-catenin pathway (Gaston-Massuet et al. 2011). We
assessed the mouse tumours for the presence of cells reminiscent of CSCs, which
have self-renewal and differentiation properties in vitro, and found an increase of
clonogenic cells, up to three times the number compared to normal pituitaries
(Gaston-Massuet et al. 2011). These cells expressed markers of stem cells such as
Sox2; however, immunofluorescence experiments showed that these predominantly
co-localised within the β-catenin-accumulating clusters. This population of SOX2+
cells was expanded compared to normal numbers. In an effort to identify if these
cells acted as CSCs in this neoplasm to generate the tumour mass, we pursued a
different approach. We expressed the oncogenic β-catenin specifically in SOX2+
stem cells of postnatal pituitary glands using a mouse model where timing of
expression of the oncogenic protein is dependent upon administration of tamoxifen
(Sox2CreERT2/+; Ctnnb1lox(ex3)/+ mouse model). This approach resulted in tumours
that were similar to human ACP and the previous embryonic model (Andoniadou
et al. 2013). The advantage of this approach was that it allowed us to lineage-trace
the fate of the PSCs carrying the oncogenic mutation and determine their contri-
bution to the tumour mass. As done previously for normal PSC lineage tracing,
SOX2+ cells were targeted simultaneously to oncogenic β-catenin and EYFP,
allowing identification of daughter cells derived from the mutated SOX2+ PSCs
(Sox2CreERT2/+; Ctnnb1lox(ex3)/+;R26EYFP/+). These experiments confirmed that the
typical cell clusters derived from SOX2+ cells but, intriguingly, they revealed that
the bulk of the tumour mass did not. Therefore, mutated SOX2+ PSCs were not
transformed into CSCs by oncogenic β-catenin; instead, the cell clusters that they
generated were found to have the capacity to induce tumours through paracrine
signalling (Andoniadou et al. 2013). Through isolating the cluster cells and
performing gene expression analyses, we identified that they expressed a vast
array of growth factors, chemokines and cytokines including members of the
TGF, FGF and PDGF families of growth factors among many others. These cells
could therefore act as signalling centres, likely changing the microenvironment and
facilitating tumorigenesis (Andoniadou et al. 2012, 2013). An observation that was
indicative of the potential of these cluster cells was that actively proliferating cells,
as marked by immunofluorescence of Ki67, were readily detected in close proxim-
ity to the cell clusters in both mouse and human ACP (Gaston-Massuet et al. 2011).
Several of the identified cytokines and growth factors have been shown to play a
role in normal pituitary physiology as well as in pituitary adenomas (Arzt
et al. 1999, 2009; Graciarena et al. 2004). Future work aims to reveal the
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mechanisms whereby cell clusters may induce paracrine cell transformation and
promote tumour growth as well as the cell of origin of the ACP tumour mass. Taken
together our data reveal that pituitary gland stem cells have the potential to contri-
bute to tumorigenesis when mutated. In the case of ACP, they can instigate tumour
formation in a non-cell autonomous manner, but this does not preclude the possi-
bility of them acting as CSCs in other tumours.
Further research will better characterise PCS to reveal their defining features and
potential as well as the mechanisms that regulate their activities, which can only
enhance our ability to understand their possible role in disease and future regener-
ative medicine approaches, leading to more effective prognoses and treatments.
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Epigenetic Mechanisms of Pituitary Cell Fate
Specification
Jacques Drouin
Abstract Pituitary progenitor or stem cells present in the pituitary primordium
during development are the source of hormone-producing cells of the adult pitui-
tary. These stem cells are maintained in the adult tissue and they can be recruited to
maintain or replenish differentiated pituitary cells. We currently have only limited
insight into the mechanisms that trigger progenitor engagement into one or the
other pituitary differentiation pathway. While transcription factors that drive ter-
minal differentiation have been identified for different lineages, current evidence
suggests that initial engagement of progenitors into differentiation may be due to
earlier-acting factors. One such factor expressed at the transition between progen-
itor and differentiated state was identified in the intermediate lobe; this factor, Pax7,
exerts its action through a pioneer factor activity. Pioneer transcription factors have
the unique ability to bind target sequences in compacted chromatin and to initiate
chromatin “opening” for recruitment of other transcription factors. Pax7 accom-
plishes this process on about 2500 enhancers genome-wide, allowing for Tpit
recruitment at a subset for implementation of the melanotrope-specific program
of gene expression. Current knowledge about this process is reviewed here, together
with a discussion of future challenges in order to understand the unique properties
of pioneer transcription factor action and cell reprogramming through chromatin
remodelling.
Introduction
The last decade was rich in surprising discoveries about the organization and
function of the pituitary. Indeed, we realized that pituitary cells are organized in a
series of intimately associated homotypic cell networks that serve to coordinate
tissue response (Mollard et al. 2012). Further, the pituitary, like many other tissues,
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was found to contain a population of stem or progenitor cells that are maintained in
adult tissues (Rizzoti 2015); this population of pituitary progenitors itself forms a
homotypic network that is primarily organized around the cleft between the inter-
mediate and anterior pituitary (Gremeaux et al. 2012). Signals that activate the
progenitors to either proliferate or differentiate are still being investigated, but
clearly these mechanisms provide a unique opportunity to think about new thera-
peutic perspectives to treat pituitary hormone deficiencies.
To capitalize on the properties of pituitary stem or progenitor cells for any kind
of replacement therapy requires that we understand the unique properties of these
cells and, most importantly, the mechanisms that engage stem cells into differen-
tiation pathways. Pituitary progenitors can differentiate into each of the pituitary
lineages (Fauquier et al. 2008); the challenge is then to understand the precise
requirements for differentiation into each lineage. While a number of critical
transcription factors have been identified for their role in terminal differentiation
of most lineages (Rizzoti 2015), such as Pit1, Tpit and SF1, the initial events of
entry into differentiation are the ones that we least understand presently.
This review will focus on one particular factor that appears to represent such an
initial event for engagement into the differentiation pathway, Pax7, which selects
intermediate lobe identity. Pax7 is unique among the transcription factors presently
identified for a role in pituitary cell differentiation in that it possesses pioneer
activity (Budry et al. 2012). Few transcription factors have the pioneer ability to
bind “closed” or compacted chromatin and to trigger chromatin remodeling of
regulatory sequences, thus opening not only chromatin structure but, most impor-
tantly, a new program of gene expression (Iwafuchi-Doi and Zaret 2014).
Escaping Stemness
Stem cells, whether pluripotent or tissue-specific, have unique properties with
regards to basic cell physiology compared to differentiated cells (De Los Angeles
et al. 2015). The engagement of stem cells into a differentiation pathway thus
implies an important switch for many cellular functions in addition to the gain of
expression for the unique genetic program of the chosen differentiation path. For
example, this can include a switch in energy metabolism (Kohli and Passegue
2014); for pituitary progenitors, it was shown that the control of cell cycle
re-entry is very different in progenitors compared to differentiated cells (Bilodeau
et al. 2009). Indeed during normal mouse development, pituitary progenitors
marked by expression of Sox2 (Fauquier et al. 2008) exit the cell cycle under the
action of the Cip-Kip inhibitor p57Kip2 whereas, upon differentiation, the role of
keeper of cell cycle re-entry is taken over by the related p27Kip1 (Fig. 1a). Although
replacing one inhibitor by a related one may appear as switching between redundant
regulators, the situation is likely more complex, since knockout mice for p57Kip2 do
eventually switch-on expression of p27Kip1 with rescue of some differentiated cells;
however, in the delayed progenitor compartment where this switch has not
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Fig. 1 Role of Pax7 in pituitary development. (a) The role of Pax7 in normal pituitary develop-
ment is depicted in the context of the engagement of Sox2-positive pituitary progenitors into
differentiation pathways. Pituitary progenitors are present throughout the pituitary primordium,
Rathke’s pouch, and the early pituitary depicted here at day e11.5 of mouse embryonic develop-
ment. The Sox2-positive progenitors (green) proliferate and, starting at e12, a group of Sox2-
negative, p57Kip2- and cyclinE-positive cells (white) appears on the ventral side of the pituitary
cleft: these cells have features of transitory precursors. The first differentiated cells appear on the
ventral surface of the developing anterior lobe: these are Tpit-positive corticotropes (blue) that no
longer express p57Kip2 and CyclinE but rather p27Kip1. Starting at e14, intermediate lobe (IL) cells
express Pax7 followed by Tpit and later POMC. Anterior lobe (AL) corticotropes never express
Pax7 and differentiate following expression of Tpit. (PL is posterior lobe). (b) Gain-of-function for
Pax7 performed in corticotrope AtT-20 cells reveals the pioneer transcription factor activity of
Pax7. The expression of Pax7 in AtT-20 cells reprograms the cells to become melanotrope-like
(Budry et al. 2012). The action of Pax7 on the AtT-20 epigenome results in activation of 2508 new
enhancers that have all the expected chromatin hallmarks; 824 of them can then recruit Tpit
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occurred, massive apoptosis occurs, which is suggestive of a critical role for p57Kip2
in leaving the stem status.
Little is known about this switch from stem to differentiated state but, during
development, it appears as sequential steps that are separated by a transitory period/
state where cells have lost markers of stemness such as Sox2 but not yet gained
markers of differentiation such as expression of terminal differentiation factors like
Pit1 and Tpit (Bilodeau et al. 2009). Cells undergoing this transitory period have
been highlighted in the developing anterior pituitary but effectors of this transition
remain to be identified. The big question is thus: what is happening to the genetic
program of these transitory precursors? Are they being pre-programmed for leaving
the stem state and for entry into one or the other pituitary differentiation pathway?
Is their epigenome being set for establishment of a differentiation program?
In the intermediate pituitary, a transcription factor essential for intermediate lobe
identity and melanotrope differentiation was identified and it appears to act within
this gap between stem and differentiation states. Indeed, the transcription factor
Pax7 is expressed immediately after extinction of Sox2, such that a small number of
co-expressing cells can be visualized in the developing mouse pituitary (Budry
et al. 2012). It is only about a half-day later that the driver of terminal differenti-
ation, Tpit, is expressed in Pax7-positive cells, leading to expression of
melanotrope genes (Fig. 1a).
Pax7 thus has the hallmark of a factor that would engage progenitors into a
differentiation pathway and prepare transitory precursors for implementation of the
terminal differentiation program that is itself directed by the Tbox factor Tpit. A
factor with similar properties has yet to be discovered in the anterior pituitary.
Intermediate Pituitary Identity
The intermediate lobe melanotropes are one of the two pituitary lineages that
express the single copy POMC gene. Terminal differentiation of both POMC
lineages, the melanotropes and the corticotropes of the anterior lobe, requires the
action of the Tbox transcription factor Tpit (Lamolet et al. 2001; Pulichino
et al. 2003). Consistent with this role of Tpit as driver of terminal differentiation,
Tpit is required for transcription of the POMC gene in both lineages and it acts
genome-wide on an extensive program of gene expression (Langlais et al. 2011).
Obviously by playing this role for both POMC lineages, Tpit cannot explain the
unique features of melanotrope compared to corticotropes, the two lineages fulfill-
ing entirely different biological functions and, accordingly, being regulated by very
different signals.
The quest for transcription factor(s) that may account for the unique program of
each lineage led to identification of Pax7 for its unique expression in the interme-
diate lobe melanotropes (Budry et al. 2012). The differentiation of most cell
lineages requires the combinatorial action of many transcription factors that
together control cell-specific gene expression. While it is in this context that Pax7
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was initially investigated, it rapidly became clear that Pax7 has far more reaching
actions on the epigenome and that it reprograms intermediate lobe cells for their
unique purpose. Hence in Pax7 knockout pituitaries, intermediate lobe cells still
differentiate under the action of Tpit but, being deprived of Pax7, the cells switch
fate and differentiate into corticotropes (Budry et al. 2012). This process is exem-
plified by the failure to activate melanotrope-specific genes such as the PC2 gene,
which encodes the protein convertase responsible for cleaving ACTH into αMSH,
and also by repression of corticotrope-specific genes such as those for CRH and
vasopressin receptors. This situation is very different in comparison to the Tpit
knockout intermediate lobe, where cells fail to differentiate into either melanotrope
or corticotrope but stay, for the most part, in a limbo between stem and differentiated
states; for example, these cells co-express the two cell cycle inhibitors p57Kip2 and
p27Kip1, a situation that is never observed normally. Thus, Pax7 itself does not drive
expression of the differentiation program but rather sets the stage for Tpit action.
Pax7 Opens a New Enhancer Repertoire
The unique property of Pax7 to act as a pioneer transcription factor allows it to
pre-program intermediate lobe precursors towards the melanotrope identity that
will be later implemented by Tpit (Budry et al. 2012). The picture that is emerging
with regards to pioneer factor action is still fragmentary, but the few pioneers that
have been characterized may operate at different levels to remodel chromatin.
Whereas the pluripotency factors Sox2, Oct4 and Klf4 initiate chromatin
remodeling over large spans of the genome (Soufi et al. 2012), factors like FoxA
(Cirillo et al. 2002), C/EBPα (van Oevelen et al. 2015), Ascl1(Wapinski et al. 2013)
and Pax7 that are involved in specific-tissue programming act primarily on the
enhancer repertoire by both locally opening chromatin at some enhancers and
closing others for activity. The opening or priming of a new enhancer repertoire
will de facto implement the possibility for a new program of gene expression and,
indeed, this is what is observed in pituitary cells following Pax7 action: Tpit now
gains access to a completely new set of enhancers (Fig. 1b). In gain-of-function
experiments performed in AtT-20 cells, Pax7 triggered the local appearance of
active chromatin marks at ~2500 enhancers and, of those, 824 became new targets
of Tpit. Genome-wide, Pax7 targeted an enhancer repertoire that largely (73%)
overlapped the Tpit target repertoire (Budry et al. 2012). The PC2 (PCSK2) locus
provides a good example of this: indeed in normal corticotrope AtT-20 cells, this
gene is inactive and its enhancer bears no mark of active chromatin. Following Pax7
action, an enhancer located 146Kb upstream of the PC2 transcription start site
became active, as revealed by a variety of chromatin marks. Indeed, the enhancer
acquired a bimodal distribution of histone H3K4me1 and the enhancer DNA
became accessible where it was depleted of nucleosome. Also, the general
co-activator p300 was recruited to the enhancer together with Tpit (Fig. 1b). This
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evolutionarily conserved enhancer thus has all the hallmarks of a Pax7- and Tpit-
dependent enhancer (Budry et al. 2012).
In contrast to the pluripotency factors that have large-scale effects on chromatin
organization, the action of Pax7 is restricted to a subset of enhancer domains. It is
interesting that, in the AtT-20 cell gain-of-function experiments, Pax7 also partially
repressed expression of corticotrope-specific genes and this was accompanied by a
quantitative decrease in chromatin marks. However, the extinction of corticotrope-
specific enhancers was at best partial in this model. Nonetheless, these observations
indicate that Pax7 has the ability to not only activate a subset of enhancers but also
to repress others, a property that is shared with other pioneer factors (Watts
et al. 2011; Wang et al. 2015).
The Essence of Pioneering
The critical property of pioneer factors is that they can access their target DNA
sequence in so-called “closed” or compacted heterochromatin. This unique prop-
erty was well illustrated for Pax7 in comparison to Tpit at the PC2 gene -146Kb
enhancer, where Tpit could not gain access to its well-conserved palindromic target
sequence if Pax7 had not previously directed local chromatin remodeling of the
enhancer (Budry et al. 2012). How pioneer factors gain access to their sites in
“closed” chromatin remains largely open to question. While some target binding
sites may find themselves exposed on the surface of nucleosomal DNA, the random
possibility of such positioning argues against this sole mechanism in view of the
high selectivity exerted by pioneer factors. Some pioneers such as FoxA may
initially bind its targets with decreased specificity to scan the genome and then
bind more firmly at pioneering sites (Soufi et al. 2015), but this still does not explain
why a specific subset of sites is selected. The winged helix DNA binding domain of
FoxA factors may mimic the structure of the histone H1 linker that interacts with
DNA to stabilize interaction with nucleosomal DNA (Cirillo and Zaret 2007), but
this model will not apply to all pioneers such as for Pax7. Some factors interact with
core histones, which may stabilize their association with chromatin (Cirillo
et al. 2002; Fiedler et al. 2008). Other factors like the Sox family interact with
the minor groove of DNA and that may facilitate recognition of target sequences on
nucleosomes, but again, this property is not relevant for all pioneers.
For the melanotrope-specific enhancers pioneered by Pax7, the analysis of
enhancers that contain only one sequence motif for Pax7 binding showed that the
group of enhancers that have a so-called composite motif was specifically associ-
ated with pioneering sites (Budry et al. 2012). This composite target site contained
each of the DNA sequences corresponding to the two DNA binding domains of
Pax7, the paired and the homeo domains. In contrast, the enhancers that contained
only the paired or homeodomain target sequence were primarily associated with
enhancers that were already accessible and targeted by Pax7 for transcriptional
activation without pioneering (Budry et al. 2012). Since the composite site was
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longer than either paired or homeodomain target sites, it is possible that higher
affinity for this site may contribute to the ability to pioneer chromatin remodeling.
Alternatively, it may also be that Pax7 interaction with the composite site involves a
unique conformation of the Pax7 DNA binding domains that is itself required to
initiate pioneering events.
Indeed, a unique conformation of the pioneer may be needed to recruit chroma-
tin remodeling complexes that initiate the replacement of modified histone from
repressive to active forms of histones. The sequence of biochemical changes
required to establish a new stable chromatin environment at active enhancers
remains poorly defined. In some systems, changing the chromatin environment
requires passage through DNA replication, hence stripping of chromatin to
re-establish a new chromatin environment (MacAlpine and Almouzni 2013;
Nashun et al. 2015). It is an open question whether passage through DNA replica-
tion is needed for all pioneers (Iwafuchi-Doi and Zaret 2014), but for Pax7, the
activation of target genes that require pioneering is far slower than for transcrip-
tional activation of enhancers/genes that are already in an open active chromatin
conformation. Hence, the action of Pax7 on chromatin remodeling may require
passage through DNA replication.
Succeeding at Multiple Choices or Avoiding Cellular
Schizophrenia
Pax7 is an interesting study case for pioneering. Indeed, we have shown a critical
role for Pax7 in the establishment of intermediate pituitary identity and setting-up
of the melanotrope program of gene expression, but the same Pax7 is also critical
for the myogenic program of gene expression, where it is expressed at the transition
between progenitor and differentiated skeletal muscles (Buckingham and Rigby
2014). These two entirely different functions of Pax7 are not compatible with each
other and, despite the ability of Pax7 to recognize its target DNA sites in hetero-
chromatin, it would need to distinguish the pituitary versus muscle targets in order
to appropriately play its role in each tissue. How is this achieved? There is currently
no clue on how this discrimination is exerted! The myogenic targets of Pax7 are not
bound by Pax7 in pituitary cells, despite the fact that a large group of Pax7 target
sites present in heterochromatin (marked with high levels of histone H3K9me3, the
hallmark of heterochromatin) are bound by Pax7 in pituitary cells. Unexplainably,
the myogenic targets of Pax7 exhibit lower levels of the repressive H3K9me3 in the
same pituitary cells and yet are not bound by Pax7. Without providing an explana-
tion, these observations nonetheless clearly indicate that we have much to learn
about the nature of so-called “closed” chromatin and that there likely are many
flavors of heterochromatin that remain to be defined.
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Future Challenges
The above discussion has illustrated how pioneer transcription factors are important
to implement the developmental program through their unique properties to (1) rec-
ognize their DNA targets on “closed” chromatin and (2) initiate chromatin
remodeling either in a localized fashion at specific enhancers or more broadly on
large genomic domains. It is critical to understand these processes in order to master
cellular reprogramming for therapeutic uses.
In the context of pituitary development, we have reason to believe that there may
be one or more pioneer factors that establish competence towards anterior pituitary
lineages, and we would expect these factors to exert their critical function during
the developmental window when fetal pituitary progenitors have lost expression of
stem cell markers such as Sox2 but not yet gained expression of terminal differen-
tiation drivers such Tpit or Pit1. Is there one pioneer for anterior pituitary identity
that allows differentiation toward each of the five anterior lobe lineages or are there
two for each of the related subgroups of lineages, the gonadotrope and corticotrope
subgroup and the Pit-dependent subgroup? These are important questions that
demand investigation.
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Advances in Stem Cells Biology: New
Approaches to Understand Depression
A. Borsini and P. A. Zunszain
Abstract Depression is a highly prevalent complex neuropsychiatric disorder,
which ranks first among all mental and neurological disorders as a contributor to
the global burden of disease. However, available treatments are still far from ideal,
for their specificity as well as their efficacy. This situation can now be improved by
the increasing availability of stem cells, which allows the development of in vitro
human neural systems to model the brain. These models complement observations
from animal models and patients with depression, allowing for a better understand-
ing of the complexity of this psychiatric illness and potential treatments. Cells
derived from the olfactory neuroepithelium, multipotent fetal hippocampal progen-
itor cells (HPCs) and human induced pluripotent stem cells (iPSCs) have shown
promising leads. Using HPCs and iPSC-derived forebrain neurons, we managed to
provide further insights into the action of drugs with antidepressant action as well as
on molecular mechanisms underlying the effect of stress and inflammation, both
linked to the pathophysiology of depression. Particular attention has been paid to
the complex pathways by which the immune and stress systems differently deter-
mine the final developmental fate of HPCs and the synaptic plasticity of iPSCs. The
combination of accessibility and validity of the available stem cells models will
allow further work to increase our insights into the biology of depression and
support the identification of novel therapeutic targets.
Introduction
How Can We Best Study Depression?
Depression ranks first among all mental and neurological disorders as a contributor
to the global burden of disease and causes a heavy load on patients and their
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families. However, available treatments are far from ideal. Only a third of patients
respond to the initial treatment, another third will get better only after several
changes of medication and the rest will go on to be treatment resistant (Rapaport
et al. 2003; Trivedi et al. 2006). Why is this? We still do not know why depression
happens; neither do we clearly understand how antidepressants work. Much of the
current understanding about the pathogenesis of major depression has come from
animal models (Krishnan and Nestler 2011) as well as from peripheral (Felger
et al. 2012) and central nervous system (CNS; Raison et al. 2010) circulating
measurements from patients with depression. Due to the unique and complex
features of human depression, the generation of valid and more insightful depres-
sion models has been less straightforward than modeling other disabling diseases
(Krishnan and Nestler 2011). One possible approach is that of focusing on brain
models, using neural cell lines. Undifferentiated or differentiated tumor-derived
cells have been used as a translationally valid experimental model for several
psychiatric disorders, including depression (Donnici et al. 2008; Alboni
et al. 2013). However, such lines are limited in the cell types they can be made to
resemble and may have major chromosomal abnormalities (Bray et al. 2012). Into
this breach come new brain models of neural stem cells. Using multipotent fetal
hippocampal progenitor cells (HPCs) and human induced pluripotent stem cells
(iPSCs), we have mimicked clinically pertinent conditions to depressive disorders
by combining depressogenic insults and antidepressant strategies (Anacker
et al. 2011b, 2013a, b; Zunszain et al. 2012; Horowitz et al. 2015). Indeed, our
outcomes provided evidence for the efficacy of such models in understanding the
disorder as well as for giving more insights into antidepressants and their mecha-
nisms of action. Particularly, we focused on neurogenesis as a potential candidate
mechanism for the etiology of this condition as well as a substrate for antidepres-
sant action.
The Neurogenesis Theory of Depression
A reduction in hippocampal neurogenesis, that is the birth of neurons from stem
cells, has been suggested as one of the neurobiological alterations mediating the
development of depressive-like behavior in animals, particularly under conditions
of stress (David et al. 2009; Snyder et al. 2011; Surget et al. 2011). In the absence of
effective neurogenesis, the depressive-like behavior elicited in animals by stress
includes the hallmark abnormalities of clinical depression: increased hypothalamic-
pituitary-adrenal (HPA) axis activity, glucocorticoid resistance (that is, impaired
suppression of HPA axis activity by dexamethasone), anhedonia (assessed using the
sucrose preference test), and behavioural despair (assessed using the forced swim
test) (David et al. 2009; Snyder et al. 2011; Surget et al. 2011). Moreover, it has
been suggested that an impaired neurogenesis may also precipitate depressive
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symptoms because of the lack of neurogenesis-dependent cognitive functions, such
as the ability to enhance encoding of new memories and responding to contextual
changes, which may be protective against behavioural despair in the face of
repeated stressors (Sahay et al. 2011). Recent studies showing that the magnitude
of adult neurogenesis in humans is probably larger than generally believed (Snyder
and Cameron 2012; Spalding et al. 2013) provided even stronger support for the
importance of neurogenesis and its proposed involvement in the association
between stress and depression (Snyder et al. 2011).
Increased inflammation can also cause reductions in neurogenesis. Immune
molecules, including interleukin-1beta (IL-1β), IL-6, interferon-alpha (IFN-α) and
tumor necrosis factor-alpha (TNF-α) have been shown to be significantly
upregulated in the peripheral blood of depressed patients (Howren et al. 2009;
Dowlati et al. 2010). Particularly in the context of depression, IL-1β, IL6, IFN-α
and IFN-γ have also been shown to easily move from the periphery into the brain
(Dantzer et al. 2008; Najjar et al. 2013). Once they cross the brain-blood barrier,
these molecules can alter distinct molecular and cellular mechanisms, including cell
proliferation and neuronal maturation (Pickering and O’Connor 2007; Alboni
et al. 2014) associated with complex cognitive processes, such as mood and
learning functions (Makhija and Karunakaran 2013; Shigemoto-Mogami
et al. 2014). In particular, using animal models, IL-1β, IL-18, IFN-α and TNF-α,
have been shown to contribute to inhibition of synaptic plasticity and memory
consolidation (Pickering and O’Connor 2007), causing similar impairments to those
often reported in patients with major depressive disorder or in experimental models
of depression (Pollak and Yirmiya 2002; Capuron and Miller 2004; Zunszain
et al. 2013).
Furthermore, stress and inflammation interact. For example, in response to
chronic IFN-α administration, patients with Hepatitis C Virus showed a hyper-
reactivity of the HPA axis (Capuron et al. 2002; Raison et al. 2010). Most inter-
estingly, around 30% of those patients developed clinically significant depression
(Raison et al. 2009), strengthening the notion that stress and inflammation might be
among the crosstalk pathways leading to the pathogenesis of the depressive disor-
der. Indeed, it is of relevance in this context that stress and inflammation are among
the different downstream molecular mechanisms that distinct antidepressants acti-
vate. Particularly, antidepressants from the selective serotonin reuptake inhibitor
(SSRI) class, such as fluoxetine, have shown to normalize stress-induced HPA
hyperactivity in rodents (Perera et al. 2011; Surget et al. 2011), whereas other
serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressants, such as
venlafaxine, have normalized inflammatory alterations in cytokine-treated
depressed patients (Capuron et al. 2002). However, irrespective of which distinct
downstream molecular mechanisms specific antidepressants activate, those path-
ways may ultimately converge to stimulate neurogenesis, which is proposed as an
essential substrate for antidepressant action (Schloesser et al. 2010).
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Experimental Approaches
Among the approaches available to investigate the complexity of depressive disor-
ders, immortalized cell lines and patient-derived stem cell lines have proved to be
relevant in vitro human neural cell models (Fig. 1). Immortalized cell lines allow
molecular, developmental and pathophysiological mechanisms to be studied with
considerable reliability. Examples of immortalized cell lines are region-specific
neural stem cells and tumour-derived cells. An alternative cell-based approach is to
derive and compare neural cells from patients and control individuals, particularly
using iPSCs or olfactory neuroepithelium-derived cell lines. Indeed, the use of cells
from patients allows a more attentive analysis of the pathological processes arising
from the whole range of genetic susceptibility variants characterizing each indi-
vidual (Srikanth and Young-Pearse 2014). Evidence has shown the significant
incidence of distinct genetic polymorphisms in patients with psychiatric conditions,
including depression (Cao et al. 2015; Chen et al. 2015; Wang et al. 2015),
suggesting the importance of using such models to investigate genetic differences,
which may allow for a predictive diagnosis of this disorder (Pasca et al. 2014). For
the purpose of this chapter we will focus on immortalized stem cells and iPSC
models. We will subsequently report our findings, providing evidence for their
efficacy in understanding depressive disorders and antidepressant mechanisms of
action.
Immortalized Human Neural Cell Lines
Neural Stem Cell Lines
Stem cells derived from human fetal brain are multipotent (i.e., they can give rise to
a range of neurons and glia) and allow developmental and physiological processes
Neural Cell Models
Immortalized human 











stem cell lines 
Fig. 1 The different range of neural cell models used to study depressive disorder and mecha-
nisms of action of antidepressants
126 A. Borsini and P.A. Zunszain
to be studied more faithfully. Particularly, clonal neural stem cell lines can be
generated by conditional immortalization, whereby a regulated gene that drives cell
division is introduced into the cell’s genome, allowing controlled expansion and
differentiation (Pollock et al. 2006). Indeed, neural stem cell lines with normal
chromosomes have been established from several human fetal brain regions,
including cerebral cortex, hippocampus and striatum. This approach has several
unique advantages. First, it delivers data from living human brain cells, not easily
accessible in clinical samples; second, it can mimic a multitude of clinically
relevant conditions within a tightly controlled experimental environment, providing
a model system with which to explore the mechanisms of drug treatments for a
variety of psychiatric disorders; and finally, it generates findings that are directly
translatable in clinical samples (Bray et al. 2012). Using this approach, we have
modeled “depression in a dish” using the cell line HPC0A07/03C (provided by
ReNeuron Ltd, London), derived from the hippocampus, which allowed us to
translate findings from bench-to-beside-and-back (Anacker et al. 2011b, 2013a, b;
Zunszain et al. 2012; Horowitz et al. 2015). We will describe our observations in
further detail.
Modeling the Role of Stress
As a first example of our translational approach, we managed to provide
evidence for the detrimental role of stress on hippocampal neurogenesis. Impaired
neurogenesis in rodents has recently been shown to contribute to the development
of depressive-like behaviours, including anhedonia and behavioural despair in
response to acute and chronic stressful insults (Zhu et al. 2014). Using our human
hippocampal model, we showed that cortisol caused a reduction in the generation
of new neurons via glucocorticoid receptor (GR)-dependent mechanisms, an effect
which could be fully reverted by treatment with the SSRI sertraline. Indeed,
subsequent stimulation with a GR-antagonist completely abolished the increase
in neurogenesis induced by the antidepressant (Anacker et al. 2011b). Our model
proved to be effective in providing further details from the complex interaction
between stress and neuronal generation, proposing GR-dependent mechanisms as
possible future targets of antidepressant drug treatment to overcome neurogenesis-
related disturbances in depression (Anacker et al. 2011a).
Modeling the Role of Inflammation and Oxidative Stress
As a second example of the use of our model, we demonstrated the involvement of
inflammation on hippocampal neurogenesis. Previous evidence had reported that
in vitro stimulation with distinct cytokines, including IL-1β, IL-6, IFN-α and
TNF-α, caused a significant alteration in both proliferation and neuronal maturation
of human and animal cells (Borsini et al. 2015). Using our in vitro human neuronal
model, we investigated the effect of two pro-inflammatory cytokines, IFN-α
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(our unpublished observation) and IL-1β (Zunszain et al. 2012), on neurogenesis.
Findings showed that, upon treatment with both cytokines HPCs developed a
“depressive phenotype” comprising reduced neurogenesis. Moreover, IL-1β was
responsible for alterations in transcription pathways regulating the metabolism of
tryptophan. Indeed, the inhibitory effects of IL-1β on neurogenesis were mediated,
at least in part, by activation of the neurotoxic branch of the kynurenine pathway,
one of the main pathways postulated to be involved in the development of depres-
sive disorders (Baranyi et al. 2015).
A third example involved the use of tert-butylhydroxiperoxide (TBHP) to model
oxidative stress. High levels of reactive oxygen species, shown in depressed
patients, are known to affect cellular constituents, leading to neoepitopes and
damage-associated molecular patterns that promote further immune responses
(Bakunina et al. 2015). Cells treated with TBHP showed a dose-dependent increase
in lipid peroxidation as well as reduced cell viability.
Studying Mechanism of Action of Antidepressants
Finally, we used this model to investigate the immunomodulatory properties of
distinct compounds with antidepressant actions. We explored the effects of several
conventional monoaminergic antidepressants and the omega-3 polyunsaturated
fatty acids (n-3 PUFAs), eicosapentanoic acid (EPA) and docosahexanoic acid
(DHA), on HPCs treated with the inflammatory and depressogenic IL-1β. In
contrast to sertraline and DHA, which had pro-inflammatory properties,
venlafaxine and EPA were shown to have anti-inflammatory effects via decreasing
distinct cytokines, including IL-6, IL-8 and IP-10 (Horowitz et al. 2015). In
addition, these compounds showed differential effects on neurogenesis. Again,
the findings demonstrate the efficacy of this model for studying specific mecha-
nisms of action of drugs with antidepressant action.
Tumour-Derived Cell Lines
These lines, with an ability to expand quite readily in culture, provide a standard-
ized and potentially limitless alternative to study intracellular mechanisms of
antidepressant action. Currently, the most commonly used human neural cell line
is SH-SY5Y. This line displays neuronal properties, including neurite outgrowth,
neurotransmitter synthesis and relevant receptor expression. The SH-SY5Y line has
been widely used to study intracellular mechanisms of different antidepressant
action, including the SSRI sertraline, the selective norepinephrine reuptake inhib-
itor (SNRI) desipramine and the norepinephrine–dopamine reuptake inhibitor
(NDRI) bupropion (Lin 2015).
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Patient-Derived Neural Cells
IPSCs
Among the patient-derived cell models, iPSC technology provides distinct cell
types that are considered to be central to psychiatric disorders, such as those of
the cortex and the hippocampus (Jaworska et al. 2015). Indeed, primary somatic
cells, typically from skin, can be taken from an individual and reprogrammed into
pluripotent stem cells that can give rise to all of the cell types that characterize the
body, including those of the CNS. By capturing a patient’s entire genome and any
possible epigenetic variations, iPSCs constitute a unique source of material for
studying neurodevelopmental features of psychiatric disorders in vitro.
Reports are now beginning to emerge in which this technology has been applied
to cells taken from psychiatric patients. For example, human keratinocytes from
healthy controls and patients with bipolar depression have been reprogrammed into
cortical neurons. When compared with control cells, neurons derived from patients
with bipolar depression showed an alteration in the expression of transcripts that
regulate Hedgehog signaling (Cheung et al. 2009), as well as modulations in key
components of the mTOR pathway (O’Shea and McInnis 2015), which have both
been shown to be among the mechanisms involved in the development of depres-
sive disorders (Rajendran et al. 2009; Ignacio et al. 2015). Using iPSC-derived
forebrain neurons, we showed that ketamine, known to have fast-acting antidepres-
sant efficacy in treatment-resistant patients, was able to rescue the detrimental
effects produced by treatment with IL-1β and to increase the number of presynaptic
and postsynaptic proteins.
Olfactory Neuroepithelium-Derived Stem Cells
Cells from the olfactory mucosa, which can be extracted through biopsy, can easily
propagate, forming neurospheres of neural stem cells and differentiating neural
progenitor cells. Although there are no studies using olfactory neuroepithelium-
derived cells from depressed patients, they have been used to study schizophrenia
(Matigian et al. 2010; Fan et al. 2012), suggesting the importance of using such
models to investigate genetic differences, which may allow for a predictive diag-
nosis of depression in certain individuals.
Conclusions and Limitations of the Cell Models
Stem cell-based approaches to study psychiatric disorders are advancing on two
main fronts. On one hand, clonal cell lines which accurately model the CNS are
being used in controlled experiments to assess the mechanisms of antidepressant
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action for psychiatric disorders, which might in the short term lead to advancements
in therapeutic strategies for these conditions. On the other hand, patient-derived
cells and cells from control patients allow the study of pathological processes
deriving from the multiple genetic susceptibility variants, which can now be
investigated with more accuracy. However, both cell models have some limitations
that need to be pointed out. Although human neural cell lines can be used to
investigate the molecular and cellular functions of individual susceptibility genes,
they do not capture the many genetic variables that contribute to the development of
psychiatric disorders (Bray et al. 2012). Patient-derived cell lines offer the advan-
tage of capturing each individual’s whole genome, but there is limited knowledge
as to which cell types are most relevant to study specific psychiatric conditions
(Sandoe and Eggan 2013). In addition, while iPSC technology can model the effects
of medications, these cells may lose the effects of environmental influences that
may contribute to the development of the psychiatric illnesses, such as stressors or
negative life events (Okano and Yamanaka 2014).
Although cell-based models are still unable to elucidate the molecular complex-
ity of psychiatric illnesses, the enormous progress in stem cell technologies has
revolutionized the field of “in vitro disease modeling,” providing not only a window
into the mechanisms underlying the depressive disorder but also a platform for
screening novel therapeutic strategies for the prevention and treatment of this
condition.
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Perspective on Stem Cells in Developmental
Biology, with Special Reference
to Neuroendocrine Systems
Karine Rizzoti, Carlotta Pires, and Robin Lovell-Badge
Abstract In the embryo, organs gradually take shape as tissue progenitors, proli-
ferate, differentiate and are organised, via cellular interactions, in tri-dimensional
functional structures. Most adult organs retain a cell population sharing important
similarities with embryonic progenitors, which includes the ability to both self-
renew and to differentiate into the full range of the specialised cell types corres-
ponding to the organ in which they reside. These two essential properties define
them as adult stem cells (AdSC). Their characterization in different contexts pro-
vides a better understanding of cell turnover modalities for organ function, which is
important for tumorigenesis, because adult tissue stem cells can give rise to cancer
stem cells. However, it is also relevant to regenerative medicine, because stem cells
can be transplanted or manipulated in vivo to restore missing cells. The successful
reprogramming of somatic cells into induced pluripotent stem cells (iPSC)
(Takahashi and Yamanaka, Cell 126:663–676, 2006), resembling pluripotent
embryonic stem cells (ESC), opened alternative strategies for cell replacement.
The required cell type can be differentiated in vitro from expandable progenitors
and transplanted where required. This approach is particularly promising, because
genetic defects can potentially be repaired in vitro prior to their engraftment;
moreover, a large number of cells can be produced (Fox et al., Science
345:1247391, 2014). However, the transplanted cells have to be able to functionally
integrate into the deficient organ. To potentially alleviate this problem,
tri-dimensional culture systems have been recently developed where mini-organs,
or organoids, can be obtained in vitro. These also represent unique models for
disease modelling and drug screening (Huch and Koo, Development
142:3113–3125, 2015). Within neuroendocrine systems, the hypothalamo-pituitary
axis has a crucial role for body homeostasis. It also regulates functions such as
growth, reproduction, stress and, more generally, metabolism. The hypothalamus
centralizes information from the periphery and other brain regions to regulate
pituitary hormone secretions and to control appetite, sleep and aging. Its functions
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are exerted through secretion of neurohormones and manipulation of these could be
of interest not only for the treatment of obesity and sleep disorders but also to
alleviate aging-related conditions. Pituitary hormone deficiencies can originate
from defects affecting the hypothalamus, pituitary, or both. Today these defi-
ciencies are treated by substitution or replacement therapies, which are costly and
have side effects. AdSC have recently been characterized in the hypothalamus and
pituitary (Castinetti et al., Endocr Rev 32:453–471, 2011; Bolborea and Dale,
Trends Neurosci 36:91–100, 2013). Moreover, hypothalamic neurons and pituitary
endocrine cells have been differentiated in vitro from ESC and iPSC and success-
fully transplanted. These promising routes for development of regenerative medi-
cine to restore or manipulate the function of the hypothalamo-pituitary axis will be
discussed here, and further challenges considered.
Introduction
It is now clear that multipotency, once thought to be largely restricted to embryonic
stages and to a few stem cell types in the adult, is preserved postnatally, as most
adult tissues comprise a population of undifferentiated cells. These are character-
ized by their ability to undergo asymmetric divisions, underlying self-renewal and
an ability to have differentiated cell progeny, the two essential properties of stem
cells. Pluripotency, the ability to produce all adult cell types, can be “recovered”
in vitro by reprogramming somatic cells into induced pluripotent stem cells (iPSC;
Takahashi and Yamanaka 2006). In addition, transdifferentiation to another cell
type or to multipotency can be forced onto differentiated cell types by activating
expression of specific factors or via cell fate conversion with chemicals and/or
growth factors (Vierbuchen and Wernig 2012). While these discoveries are by
themselves challenging our view of cellular plasticity and its limits, for medicine
they mean that therapies can progress from or incorporate both a pharmacological
approach and a cellular one, where abnormal, deficient or entirely missing cells can
be replaced (Fox et al. 2014). Cellular reprogramming implies, in particular, the
possibility of autologous transplantation, alleviating at least some aspects of
immune rejection that, in conjunction with genome editing tools (Hsu
et al. 2014), hold great promise for deriving, repairing, differentiating and
transplanting back functional, patient-specific cells. In addition, the derivation of
patient-specific cells by itself represents a great advance toward in vitro disease
modelling and drug screening (van de Wetering et al. 2015). In the clinic, some
promising results have already been obtained in pilot studies using retinal pigment
cells derived from human ESC (Schwartz et al. 2015), but other trials have also
highlighted the many challenges to be overcome (Steinbeck and Studer 2015). It is
likely that further development of three-dimensional (3D) organoids (Huch and
Koo 2015) and tissue engineering, combining several different cell types for
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formation of vascularized mini-organs, will greatly enhance transplantation effi-
ciency and functional repair (Shamir and Ewald 2014). Finally, another important
aspect to consider for use of these therapies is the financial one. Numerous quali-
tative criteria have to be satisfied to allow clinical use of stem cells. Currently, and
for good reasons, these criteria have to be stringent (French et al. 2015) and
therefore expensive. Although experience, scaling up, and automation might lead
to a relaxation of requirements and to reduced costs, we still need to question today
how feasible it will be to routinely offer such treatments in the future. It would be
unfair if treatments were only available to the very privileged few.
We will focus our attention here on stem cells of the hypothalamo-pituitary axis,
and why and how these could be used for regenerative medicine. The hypothalamo-
pituitary axis, while a crucial regulator of homeostasis, also ensures that the
organism responds appropriately to changing physiological situations such as
puberty, pregnancy, lactation, and stress. While many hypothalamic roles are exe-
cuted through the pituitary, with the seven different hormones secreted by the gland
affecting most physiological processes, some hypothalamic neurons also directly
interact with other regions of the brain to control appetite (Schneeberger
et al. 2014), sleep and wakefulness (Konadhode et al. 2014). Finally, it has recently
been proposed that systemic aging is initiated in the hypothalamus (Zhang
et al. 2013). Consequently, pathological situations leading to hypothalamic and/or
pituitary hormone imbalance have pleiotropic consequences, resulting in significant
morbidity and even mortality. These can be congenital or acquired and originate
from a defective pituitary, hypothalamus or both; moreover, in most cases they are
of unknown aetiology (Kelberman et al. 2009). The most frequent congenital defect
is isolated growth hormone deficiency, with a prevalence of 1 in 3500–10,000 births
(Kelberman et al. 2009). Later in life, acquired deficits develop mainly as a conse-
quence of pituitary tumors, mostly affecting lactotrophs, or from brain damage
(Hannon et al. 2013). Hormone substitution or replacement therapies are available
to treat pituitary deficiencies. However, these are not optimal, first because they do
not reproduce normal physiological secretion patterns, secondly because they are
associated with side effects (Alatzoglou et al. 2014), and thirdly, they are not
inexpensive; hGH treatment in the UK costs up to £12,000/year for children in
whom treatments can last for several years. Being able to provide secreting endo-
crine cells would, therefore, represent a significant advance, particularly for pedi-
atric patients where the pituitary is primarily affected but perhaps also for those
where an hypothalamic deficiency is thought to be responsible, such as Prader-Willi
syndrome, or more generally where a hypothalamic defect leads to formation of
an underdeveloped pituitary gland (Rizzoti et al. 2004). Pituitary hormones can,
in turn, also feed back on the formation of hypothalamic neuronal circuitry
(Sadagurski et al. 2015); therefore, they may be able to improve some hypothalamic
defects. Manipulating or restoring hypothalamic function would be beneficial in
cases of infertility and obesity, which has already been shown using cell or tissue
transplants (see below), but also for sleep disorders; importantly, it might lighten
some age-associated conditions.
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In this perspective we will first briefly describe the morphogenesis of the ventral
diencephalon, from which the hypothalamus derives, and of Rathke’s pouch (RP),
the pituitary anlagen. The transition between tissue progenitor and stem cell pheno-
type will then be discussed in the context of the developing pituitary. Recently,
populations of AdSCs have been described and partially characterized in both
compartments of the axis (Lee et al. 2012; Li et al. 2012; Andoniadou et al. 2013;
Haan et al. 2013; Rizzoti et al. 2013; Robins et al. 2013a, b; Castinetti et al. 2011)
and their characterization will be presented here, with reference to other chapters of
this book. Finally, exciting progress has been made toward the use of stem cells for
regenerative medicine in the axis: both hypothalamic neurons (Wataya et al. 2008;
Merkle et al. 2015; Wang et al. 2015) and pituitary endocrine cells (Suga
et al. 2011; Dincer et al. 2013) have been obtained in vitro from stem cells and
successfully transplanted in mice. We will discuss these reports and the future
challenges toward clinical use of stem cells in the hypothalamo-pituitary axis.
Morphogenesis of the Hypothalamo-Pituitary Axis (Fig. 1)
Hypothalamus
In the embryo, the hypothalamus develops from the ventral diencephalon. During
the specification of the neural plate, at 8 days post-coitum (dpc) in mice, the pros-
pective ventral diencephalon is situated at the midline, in the rostral-most position.
It is in contact with the future pituitary, which is present as the hypophyseal placode
at this stage, in the adjacent ectoderm at the anterior neural ridge (see below). As the
neural plate bends to close (McShane et al. 2015), increased proliferation of the
telencephalic progenitors versus those in the ventral diencephalon causes an appar-
ent posterior shift of the prospective hypothalamus, located ventrally and posterior
to the telencephalic vesicles in 9.5-dpc mouse embryos. A localized evagination of
the ventral diencephalon toward the underlying developing pituitary becomes
apparent at 9.5 dpc. From this particular region, called the infundibulum, the
median eminence (ME), pituitary stalk and pituitary posterior lobe will develop.
The ME, located at the floor of the third ventricle, is a circumventricular organ,
which means that the blood-brain barrier is interrupted at its level. Hypothalamic
neuro-hormones collect here into a bed of fenestred capillaries belonging to the
hypohyseal portal system, which then transport them to the pituitary. Within the
ME, special glial cells, the tanycytes, regulate neurohormone secretion at the axon
termini levels (Prevot et al. 2010). These also integrate peripheral information by,
for example, sensing glucose concentration and responding to thyroid hormone
(Bolborea and Dale 2013; Ebling 2015). Moreover, and importantly, at least a
proportion of tanycytes have been shown to comprise hypothalamic stem cells
(see below). These cells therefore perform crucial regulatory roles at this blood-
brain interface in the short term, by regulating neurohormone secretion, but also in
the long term, by modulating hypothalamic cell numbers. Some hypothalamic
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neurons, namely those secreting oxytocin and vasopressin, reach directly into the
posterior lobe of the pituitary; their axons, along with the portal system capillaries,
are located within the pituitary stalk. Pituicytes, glial cells present both in the stalk
and posterior pituitary, are proposed to regulate neurosecretion at these levels.
Tanycytes and pituicytes both originate from the infundibulum, and no neurons
are produced in this domain (Goto et al. 2015). The specification of the infundi-
bulum in the embryo is complex and relies on an antagonism between members of
the bone morphogenetic protein (BMP) family, present in the future infundibulum,
and the secreted molecule Sonic Hedgehog (SHH), which is excluded from it (Zhao
et al. 2012; Trowe et al. 2013). Members of the fibroblast growth factor (FGF)
family are in turn required for infundibular cell expansion (Pearson et al. 2011). The
transcription factor LHX2 is necessary for formation of the infundibulum in the
embryo and later on for expression of the RAX transcription factor, which is
essential for ventro-medial hypothalamic development (Lu et al. 2013) and the
emergence of tanycytes (Salvatierra et al. 2014). The NOTCH pathway is also
required for correct morphogenesis of this region (Goto et al. 2015), but it is unclear
at present how these different signalling pathways are integrated.
Fig. 1 Development and function of the murine pituitary-hypothalamic axis. Rostral to the
presumptive hypothalamus, pituitary development is initiated with the appearance of the hypo-
physeal placode at 8.5 dpc in the mouse. At 9.5 dpc, the placode invaginates to become the
Rathke’s pouch (RP). Within the diencephalon, the infundibulum evaginates towards RP by 10.5
dpc. It will give rise to the median eminence (ME), the pituitary stalk and the posterior lobe,
whereas the anterior and intermediate lobes originate from RP. Gradually, hypothalamic neurons
forming the different nuclei differentiate. Postnatally, the hypothalamus centralizes peripheral
information and controls, through release of hypophysiotropic hormones, pituitary endocrine
secretions. Hypothalamic peptide hormones can reach the gland directly, such as oxytocin and
vasopressin secreted directly in the posterior lobe, or via the hypophyseal portal system. Hypo-
thalamic neuropeptides (GnRH, gonadotrophin releasing hormone, GHRH GH releasing hormone,
TRH TSH releasing hormone, CRH corticotropin releasing hormone and the inhibitory SST,
somatostatin) are secreted at the ME and collected by capillaries. Anterior pituitary endocrine
cells comprise lactotrophs (producing prolactin, Prl), gonadotrophs (producing luteinizing hor-
mone, LH, and follicle stimulating hormone, FSH), thyrotrophs (producing thyroid stimulating
hormone, TSH), corticotrophs (producing adenocorticotropic hormone, ACTH, proteolytically
cleaved from proopiomelanocortin, POMC) and somatotrophs (producing growth hormone,
GH). Adapted from Rizzoti (2015)
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As neurogenesis takes place, hypothalamic neurons differentiate and migrate to
form groups of neurons, or nuclei. Nuclei located the furthest away from the third
ventricle are formed first, whereas the latest to differentiate are closest. The GnRH
neurons are the only exception, as these originate from the olfactory placode and
migrate through the developing brain to reach their destination around the ME,
where they control reproductive function (Stevenson et al. 2013) and aging (Zhang
et al. 2013). Each nucleus regulates different physiological functions, such as
circadian rhythms by the supra-chiasmatic nucleus or feeding behaviour by the
arcuate. Hypothalamic morphogenesis is complex because of its organization,
which lacks clear morphological landmarks; this explains why we know compar-
atively less about it compared to other regions of the brain where the anatomy is
somehow simpler. Mechanisms of hypothalamic neurogenesis are beyond the scope
of this perspective and have been recently comprehensively reviewed (Bedont
et al. 2015; Pearson and Placzek 2013).
Pituitary
The first sign of pituitary development is the appearance at 8 dpc of an ectodermal
thickening in the rostral-most position, in the anterior neural ridge just in front of
the future ventral diencephalon. This domain, the hypophyseal placode, forms
along with the olfactory, optic and otic placodes (Soukup et al. 2013; Schlosser
et al. 2014). As the presumptive diencephalon is apparently shifted posteriorly at
9.5 dpc, the hypophyseal placode is present just underneath and has become the
pituitary anlagen or RP. RP is an epithelial invagination that forms in continuity
with the oral ectoderm and extends dorsally toward the ventral diencephalon. RP is
also in contact with the anterior border of foregut endoderm (Khonsari et al. 2013),
and both dorsally and ventrally secreted signals are crucial for proper RP morpho-
genesis. SHH, independently of its role for formation of the infundibulum, is
required for RP development, but it is not expressed in the pouch (Wang
et al. 2010). The infundibulum is crucial for induction and maintenance of the
pouch at these early stages, predominantly through secretion of BMP and FGF
signals, respectively (Ericson et al. 1998; Treier et al. 1998). RP grows rapidly and
by 11.5 dpc it also separates from the oral ectoderm. The three pituitary lobes do not
have the same embryonic origin because anterior and intermediate lobes are RP
derivatives, whereas the posterior one has a neurectodermal origin.
As development progresses, the main wave of cell cycle exit in the developing
pituitary, correlating with endocrine cell commitment and differentiation, occurs
between 11.5 and 13.5 dpc (Japon et al. 1994; Davis et al. 2011). As cells exit the
cell cycle, they adopt more ventral and lateral locations and loose epithelial
characteristics, reminiscent of epithelial to mesenchymal transition (Himes and
Raetzman 2009). Endocrine cells then gradually organize in homotypic endocrine
networks, resulting in more efficient and coordinated hormonal secretion in the
adult (Mollard et al. 2012). Pituitary cell fate specification is also discussed in
Drouin (2016).
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In rodents, the gland will undergo a phase of important growth during the first
weeks of life. This is characterized by high levels of proliferation, both in pro-
genitors and in endocrine cells. Endocrine cells retain the capability to proliferate
throughout life, but they do so rarely (Levy 2002). After birth, the hypothalamus
will take control of pituitary endocrine maturation, secretions, and perhaps also
stem cell homeostasis, but it is not clear exactly when and how its influence starts to
be exerted.
Transition Between Tissue Progenitor and Stem Cell Phenotype
in the Developing Pituitary
Early RP progenitors express the transcription factor SOX2 (Fauquier et al. 2008),
and lineage-tracing experiments using a Sox2creERT2 allele have shown that SOX2-
positive progenitors give rise to all endocrine cell types in the pituitary
(Andoniadou et al. 2013; Rizzoti et al. 2013). In addition, embryonic progenitors
give rise to adult pituitary stem cells (Rizzoti et al. 2013). From 14.5 dpc and
towards the end of gestation in the mouse, SOX9 is upregulated in the pituitary,
exclusively in SOX2-positive cells. Both proteins will remain co-expressed post-
natally in pituitary stem cells (Fauquier et al. 2008; Rizzoti et al. 2013). While
SOX2 and SOX9 belong to the same group of transcriptional regulators, sequence
homology assigns them to different sub-families (SOXB1 and SOXE, respectively);
they therefore have different partners, target genes and hence, roles (Kamachi and
Kondoh 2013). SOX9 is required for maintenance of different ectodermal stem cell
populations, such as hair, retinal, neural crest, and neural stem cells (NSC) (Sarkar
and Hochedlinger 2013). In the developing neuroepithelium, SOX9 is both required
and sufficient for formation of multipotent NSC, seemingly given them the ability
to give rise to glial cell types and not just neurons (Scott et al. 2010). In the adult,
the protein is involved in the maintenance of NSC and their multipotentiality (Scott
et al. 2010).
In the developing pituitary, we observe that up-regulation of SOX9 correlates with
a decreased proliferative potential in pituitary progenitors, with the percentage of
SOX2-positive proliferating cells reduced by a factor of two between 12.5 and 16.5
dpc (Fig. 2). In addition, lineage-tracing experiments, using either a Sox9ires-creERT2
allele or the Sox2creERT2 allele, but where it is induced coincident with the upregulation
of SOX9 in pituitary progenitors, show that the SOX9;SOX2-positive progenitors also
tend to differentiate less often (Rizzoti et al. 2013). Therefore, the expression of SOX9
correlates both with reduced levels of proliferation and differentiation, two character-
istics of pituitary stem cells that distinguish them from embryonic progenitors. So far,
deletion of the gene during pituitary development has not revealed a significant role
for SOX9 in the gland before birth (unpublished data); therefore, its function in
pituitary progenitors does not parallel what is observed in the developing CNS.
Further investigations are now required to examine its function postnatally. Analysis
of its target genes may be informative to characterise the transition between tissue
progenitor and stem cell phenotypes.
Perspective on Stem Cells in Developmental Biology, with Special Reference. . . 141
Characterization of AdSC in the Hypothalamo-Pituitary Axis
(Fig. 3)
Hypothalamus
Initial investigations of cell proliferation patterns in the post-natal hypothalamus
revealed the presence of dividing cells, in particular around the third ventricle, just
above the ME. Cell proliferation could be stimulated by infusion of different
factors, such as BDNF (Pencea et al. 2001), EFG and FGF (Xu et al. 2005), IGF
(Perez-Martin et al. 2010) and CNTF (Kokoeva et al. 2005). In addition, label-
retaining experiments suggested active neurogenesis in the hypothalamus
(Kokoeva et al. 2005, 2007; Xu et al. 2005; Perez-Martin et al. 2010), defining a
Fig. 2 Rate of proliferation of pituitary embryonic progenitors before and after SOX9
up-regulation. (a) Assessment of proliferative rates by incorporation of EdU at 12.5 and
16.5dpc. Immunofluorescence for SOX2 (green) and EdU-labelling (red) after 1 h00 EdU pulse.
At 12.5dpc all cells express SOX2 and a high proportion is dividing. At 16.5dpc, progenitors/stem
cells are dorsally restricted to cells lining the cleft and proliferation is significantly reduced. (b)
Quantification of EdU incorporation. At 12.5 dpc, 40.5% (SD¼ 7.5 n¼ 6) of SOX2þve cells in RP
have incorporated EdU, whereas at 16.5 dpc, as SOX9 is up-regulated, only 19.2% (SD¼ 2.1,
n¼ 6) do so (asterisks in b?)
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Fig. 3 Regenerative medicine in the hypothalamo-pituitary axis: endogenous stem cells and
in vitro differentiated cell types. Endogenous stem cell (SC) populations (red) and differentiated
progeny (brown) obtained in vitro are represented. In the hypothalamus, tanycytes, specialized
glial cells located at the base of the third ventricle, form a diet-responsive stem cell population. In
the pituitary, stem cells are present in the epithelium lining the cleft and are also scattered in the
anterior lobe, sometimes as rosettes. Both hypothalamic neurons and pituitary endocrine cells have
been obtained in vitro from ESC and iPSC. In the hypothalamus, transplantation of neurons could
be used to modulate feeding behaviour to treat obesity for example, but the range of neurons
obtained in vitro could potentially be used to manipulate a range of hypothalamic functions. In the
pituitary, transplantation of endocrine cells would represent a significant improvement over
existing replacement or substitution therapies
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third neurogenic niche in the brain along with the sub-ventricular zone of the lateral
ventricles and the dentate gyrus of the hippocampus. Kokoeva et al. (2005) were the
first to suggest that hypothalamic neurogenesis was physiologically relevant, as
they demonstrated a role for newly generated neurons in feeding control. More
recently, lineage tracing experiments have firmly established the existence of active
hypothalamic neurogenesis and gliogenesis (Lee et al. 2012; Li et al. 2012; Haan
et al. 2013; Robins et al. 2013a, b; see also Blackshaw 2016) Precise dissections of
the third ventricle sub-ventricular zone revealed that α-tanycytes are hypothalamic
AdSC (Robins et al. 2013b); this area is also where cell proliferation is most
efficiently stimulated by IGF infusion (Perez-Martin et al. 2010). WNT signalling
appears to regulate tanycyte generation post-natally (Wang et al. 2012). In addition,
it has been suggested that some stem cells may reside in the parenchyma (Robins
et al. 2013a). Following the initial report by Kokoeva et al., investigations have
mostly focused on the role of hypothalamic neurogenesis in feeding control (Lee
et al. 2012; Li et al. 2012; McNay et al. 2012; Haan et al. 2013). Stem cells are
responsive to diet and a high fat diet reproducibly impairs neurogenesis in the
arcuate nucleus (Li et al. 2012; McNay et al. 2012; Lee et al. 2014). Further results
strengthen the association between pathological weight gain and neurogenesis
impairment. Leptin is a satiety hormone, secreted by adipose cells and transported
to the hypothalamus where it participates in appetite regulation. Obesity is associ-
ated with leptin insensitivity and, interestingly, leptin deficiency in mice results in
impaired neurogenesis (McNay et al. 2012). Moreover, it has been known for some
time that obesity is associated with hypothalamic inflammation. As this inflamma-
tion precedes obesity onset, it is increasingly suspected to be the cause, rather than
the consequence, of diet-induced metabolic disease (Valdearcos et al. 2015). The
association of high fat diet, leptin deficiency and hypothalamic inflammation with
impaired neurogenesis (Li et al. 2012; McNay et al. 2012) further highlights the
importance of neurogenesis in feeding control, all suggesting that manipulation of
this process may have therapeutic benefits for metabolic syndromes.
In addition to feeding control, studies in seasonal mammals support a role for
hypothalamic neurogenesis in the control of reproduction (Batailler et al. 2015;
Ebling 2015). Moreover, there is now evidence that systemic aging is initiated by
hypothalamic inflammation (Zhang et al. 2013). The relevant targets of this inflam-
mation, initiated by microglia, are the GnRH neurons, causing them to secrete less
GnRH. The authors show that this decrease in GnRH contributes to systemic aging
and that it is associated with decreased neurogenesis in both the hypothalamus and
hippocampus. Its contribution to these processes is so far unclear, but GnRH
administration rescues both GnRH levels and neurogenesis, demonstrating at
least a correlation (Zhang et al. 2013). It would now be of interest to investigate
the contribution of hypothalamic SC in other life-changing, physiological contexts,
such as puberty and pregnancy, where the organism needs to adapt to and trigger,
in the case of puberty, a new physiological status.
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Pituitary
In the adult gland, the persistence of an epithelial cell layer lining the pituitary cleft
(the remnant of the embryonic RP epithelium surrounding the lumen), and the
maintenance of SOX2 and SOX9 expression in this epithelial cell layer, was a good
argument for the persistence of a progenitor population (Fauquier et al. 2008).
The capacity of these cells to form spheres or colonies in vitro, an assay used to
characterize progenitors in different tissues further reinforced this hypothesis (Chen
et al. 2005; Lepore et al. 2005; Fauquier et al. 2008). Recently, lineage tracing
analysis using either Sox2 or Sox9CreERT2 targeted alleles definitively demonstrated
their presence in the adult (Andoniadou et al. 2013; Rizzoti et al. 2013; see also
Vankelecom 2016).
Under normal physiological conditions, adult pituitary stem cells proliferate and
differentiate very little, suggesting that most cell turnover is due to endocrine cell
division (Fauquier et al. 2008; Andoniadou et al. 2013; Rizzoti et al. 2013). Induc-
tion of apoptosis upon cell division, using specific genetic tools, confirmed this
hypothesis by demonstrating that corticotroph turnover relies on the proliferation of
differentiated cells (Langlais et al. 2013). A physiological role for pituitary stem
cells was initially suggested by studies investigating models of pituitary target
organ ablation (Nolan and Levy 2006). It has been known for some time that
ablation of the adrenals and/or gonads triggered a transient mitotic wave in the
gland, followed by generation of increased numbers of endocrine cells; moreover,
these were specifically the type that normally regulates the ablated organ. While
differentiated endocrine cells can divide, but do so rarely, Nolan and Levy were the
first to observe that, after adrenalectomy and/or gonadectomy, proliferation is
essentially restricted to non-endocrine cells of an immature appearance. Moreover,
double ablations do not have an additive proliferative effect, suggesting that a
single population of undifferentiated cells responds to both adrenalectomy and
gonadectomy (Nolan and Levy 2006). More recently, diphtheria toxin-mediated
endocrine cell ablation experiments confirmed these results by showing a mobili-
zation of SOX2-positive cells, with a transient induction of proliferation and,
presumably, differentiation. The extent of endocrine cell regeneration was limited
and initial endocrine cell numbers never fully recovered; however, this could
indicate that a partial recovery is physiologically sufficient (Fu et al. 2012; Fu
and Vankelecom 2012). Finally, lineage-tracing experiments performed after pitui-
tary target organ ablation firmly demonstrated that AdSCs both proliferate and
differentiate, exclusively to give rise to the required cell type, such as corticotrophs
(Rizzoti et al. 2013). This finding definitively established the regenerative potential
of pituitary stem cells but also showed that they seem to be mostly, and perhaps
only, mobilized under physiological challenge. Dissection of the mechanisms
underlying mobilization is now required to investigate whether it would be possible
to directly stimulate stem cells for therapeutic purposes. Further investigation into
different, more physiological “challenging” situations such as, for example,
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pregnancy and lactation will also be necessary to fully explore potential roles for
AdSCs.
While stem cells appear quiescent under normal physiological situations, their
proliferation or at least activation may also be involved in tumorigenesis. The WNT
signalling pathway is an important regulator of embryonic development but also of
many AdSC populations (see Andoniadou 2016). Moreover, deregulation of the
pathway is associated with cancer formation, a notable example being colorectal
tumors (Clevers and Nusse 2012). In mice, it had been shown that expression of a
degradation-resistant form of βcatenin, an important transducer of WNT signalling,
in RP induced the formation of tumors resembling the mostly pediatric pituitary
craniopharyngiomas (Gaston-Massuet et al. 2011). Postnatal induction of this
constitutively active form of βcatenin in SOX2-positive cells also resulted in
tumor formation, demonstrating the tumor-forming potential of the AdSC compart-
ment. Tumors were, however, not composed of mutant stem cells, which instead
induced neighboring cells to form them by a paracrine mechanism (Andoniadou
et al. 2013). In resected human pituitary adenomas, a side population could be
isolated. SOX2 expression was upregulated and spheres could be formed,
suggesting the presence of a SOX2-positive progenitor population in tumors
(Mertens et al. 2015). However, the role of SOX2-positive cells in adenoma
formation is at present unclear.
In vitro Recapitulation of Ontogenesis in the Hypothalamo-
Pituitary Axis (Fig. 3)
Two different methods have mostly been used to direct ESC differentiation towards
differentiated cell types: tri-dimensional floating aggregates with relatively mini-
mal exogenous treatments, where cell interactions underlie self-patterning into a
defined embryonic structure with spectacular results, such as formation of an
optic cup realized in the lab of the late Yoshiki Sasai (Eiraku et al. 2011); and
two-dimensional cultures where sequential exogenous treatments guide cells
through subsequent embryonic fates. Both methods have been successfully used
to reproduce the embryonic events described above and obtain both human and
murine neuroendocrine and endocrine cells.
Induction of Hypothalamic Identity from 3D ESC Aggregates
Mouse ESC aggregates were initially assayed for hypothalamic neuron generation
(Ohyama et al. 2005). Neural progenitor fate was first induced under serum-free
conditions (Okabe et al. 1996), followed by SHH and BMP7 treatment that resulted
in the generation of ventral hypothalamic neurons (Ohyama et al. 2005). In a later
146 K. Rizzoti et al.
study, culture under strictly defined chemical conditions to minimize exogenous
signals was shown to be key to obtain rostral-most hypothalamic character in mouse
ESC aggregates, which adopt an embryonic neuroepithelium-like morphology
because neural anterior fate is acquired by default in such conditions (Wataya
et al. 2008). Removal of insulin was crucial as it was shown to activate the Akt
pathway, which would otherwise inhibit hypothalamic induction. Further treatment
with SHH induces rostro-ventral hypothalamic identity, with a strong expression of
RAX. Selection and re-aggregation of RAX positive cells, without SHH addition,
resulted in the differentiation of morphologically mature, secreting vasopressin
neurons. Moreover, further treatment of the re-aggregated cells with SHH induces
efficient differentiation of other types of hypothalamic neurons (Wataya et al. 2008;
Merkle et al. 2015). Very recently, human ESC and iPSC were used to generate
hypothalamic neurons in aggregates (Merkle et al. 2015; Wang et al. 2015), fol-
lowing the previously dribed protocol (Wataya et al. 2008). Hypothalamic neurons
were successfully obtained, but important differences were noted. These included
the requirement for insulin for initial aggregate survival, along with an Akt inhibitor
(Merkle et al. 2015), whereas Wang et al. (2015) used SMAD inhibitors to
inactivate BMP and TGβ/Nodal/Activin pathways to promote neural differenti-
ation. The major types of hypothalamic neurons were obtained, and further cultur-
ing with supporting mouse glia showed that these adopted morphologies similar to
their in vivo counterpart, suggesting a mature phenotype. However there is a large
variability in induction efficiency between experiments (Merkle et al. 2015).
Generation of Hypothalamic Neurons from 2D ESC Cultures
Both Wang et al. (2015) and Merkle et al. (2015) subsequently developed 2D
differentiation protocols to reduce culture duration, providing an easier substrate
for expansion than individual aggregates and also reducing variability in differenti-
ation rate. Human ESC and iPSC were induced toward a hypothalamic progenitor
fate by sequentially performing dual SMAD inhibition while activating ventralizing
SHH signalling (Merkle et al. 2015; Wang et al. 2015). Subsequently, posterior-
izing WNT signals were blocked (Merkle et al. 2015) or the NOTCH pathway was
inhibited (Wang et al. 2015) to induce arcuate-ventral fate. Further culture on
cortical mouse glia supported neuronal differentiation and led to the generation of
the major types of hypothalamic neurons. These showed both the expected morpho-
logy and neuropeptide expression (Merkle et al. 2015), whereas addition of BDNF
induced differentiation of progenitors into functional neurons typical of the arcuate
nucleus. This process was further enhanced by co-culture with mouse astrocytes
(Wang et al. 2015). Neurons were then transplanted into newborn mouse brains.
The human MCH and orexin cells were maintained in the adult where they dis-
played features resembling synapses with mouse neurons, suggesting functional
integration (Merkle et al. 2015).
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Induction of RP from 3D Aggregates
Following their success with generation of hypothalamic-like tissue (Wataya
et al. 2008), Suga et al. (2011) reasoned that, by further inducing rostral character,
they should obtain a domain equivalent to the anterior neural ridge apposed to a
neurectoderm-like tissue, where RP formation may be induced (Ochiai et al. 2015;
see Suga 2016). Large ESC aggregates were made in growth factor-free medium in
the presence of SHH agonist, resulting in formation of a superficial ectodermal
layer surrounding a RAX-positive neurectodermal domain. Subsequently, ecto-
dermal patches thickened, RP marker expression was induced, and invagination
of RP-like structures was observed, more efficiently in the presence of both BMP
and FGF (Ochiai et al. 2015). The positive action of these two factors fits with
in vivo requirements, because these are secreted from the infundibulum and neces-
sary for RP induction and maintenance, respectively (Ericson et al. 1998; Treier
et al. 1998). Inhibition of NOTCH signalling resulted, as reported in vivo (Zhu
et al. 2006; Kita et al. 2007), in efficient differentiation of corticotrophs, one of the
earliest cell types to differentiate. Transplantation of differentiated aggregates
under the kidney capsule in hypophysectomised mice improved cortisol deficiency
symptoms, which demonstrated the functionality of the ESC-derived corticotrophs
(Suga et al. 2011). Obtaining other endocrine cell types was initially less efficient
(Suga et al. 2011); however, addition of BMP and FGF improves both corticotroph
and Pit-1 lineage endocrine cell differentiation (Ochiai et al. 2015).
Induction of placodal identity and differentiation of endocrine cells from 2D
cultures
Human ESC were used to devise a sequential protocol directing cells toward a
placodal fate (Dincer et al. 2013; see Studer 2016). Dual SMAD inhibition was
initially performed to impart neural fate, and subsequent de-repression in combi-
nation with FGF inhibition was sufficient for acquisition of placodal identity.
Modulation of FGF, BMP and SHH pathways further allowed specification of
lens, trigeminal and pituitary placode identity. As shown earlier (Suga
et al. 2011), treatment with an HH agonist induced pituitary placode fate and
subsequently an RP gene expression profile. Corticotroph differentiation followed,
whereas differentiation of somatotrophs and gonadotrophs relied on NOTCH path-
way inhibition. In vivo secretion was demonstrated after sub-cutaneous transplant-
ation in mice (Dincer et al. 2013).
Perspectives
Differentiation Strategies
It takes a minimum of 18 days to observe ACTH-positive cells from ESC aggre-
gates, and maturation of hypothalamic neurons can take much longer (Merkle
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et al. 2015). Moreover, the progression through different developmental stages
implies some degree of heterogeneity in the culture. Finally, and probably in conse-
quence, the percentage of desired cells obtained is often low. For disease modelling,
drug screening and clinical use of these variables should be improved. Culture
conditions can be modified and/or the starting cell type, as we will discuss here.
It has already been observed that co-culture with supporting cells, such as
cortical glia (Merkle et al. 2015) and specifically astrocytes (Wang et al. 2015),
improves differentiation rates of hypothalamic neurons. It has been proposed that
co-culture with neurons may also help (Merkle et al. 2015). Differentiation of
pituitary endocrine cells may similarly be improved by co-culture with folliculo-
stellate cells, a heterogeneous population comprising stem cells but also endocrine-
supporting cells (Allaerts and Vankelecom 2005) and/or endocrine cells. Different
endocrine cell lines exist and one could examine whether co-culture with these
might favor differentiation toward each particular cell type. In addition, generation
of 3D pituitary mixed cell type-aggregates has been described in which tissue-like
organization and endocrine secretions seem to mimic the in vivo situation; more-
over, these characteristics are efficiently maintained over several weeks (Denef
et al. 1989). Co-culture in these conditions may help progenitors to differentiate
more efficiently.
In aggregates, the absence of vascularization may compromise endocrine differ-
entiation and maturation, as observed in organoids, and affect cell survival more
generally in the expanding structures (Lancaster and Knoblich 2014). There are, of
course, many other structural and cellular components of the endogenous stem cell
niche that are missing in these aggregates. Therefore, reconstitution of the stem
cells’ microenvironment in vitro has been the focus of several investigations.
Biomaterials have been developed to support co-culture to supply vascularization,
for example, but also to allow applications of factors, either extracellular matrix or
signalling molecules. Recent and promising droplet-based microfluidic strategies
have been described that can be used in either 3D or 2D cultures (Allazetta and
Lutolf 2015). These in vitro micro-niches are of interest for drug screening because
they are scalable, but they may also offer a suitable substrate to obtain cells for
transplantation. Perhaps these would further allow organization into a pattern
typical of the anterior pituitary.
Starting from pluripotent stem cells, either ESC or iPSC implies a long develop-
mental “journey” to reach a mature terminally differentiated state. Since popu-
lations of progenitors have been characterized in both compartments of the
hypothalamo-pituitary axis, a “short cut” would be to start from somatic cells that
are then directly re-programmed into hypothalamic or pituitary specific stem cells.
Similar protocols were initially described for NSCs (Kim et al. 2011; Ring
et al. 2012; Thier et al. 2012) and many other cell types since. Self-renewal will
be comparable in ESC and iPSC, but the differentiation potential is now limited to
the cells of interest. This implies characterization of the factors necessary and
sufficient to impart the desired identity upon re-programming.
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Implantation in Homotypic Locations
Once the cell types of interest have been efficiently generated in vitro, they can be
transplanted back to restore function. Up to now, transplantations of either pituitary
or hypothalamic ES-derived cells have been realised in heterotopic locations; under
the kidney capsule (Suga et al. 2011), or subcutaneously (Dincer et al. 2013) for
endocrine cells, and in the lateral ventricle or brain parenchyma for hypothalamic
neurons (Merkle et al. 2015).
While Suga et al. (2011) successfully improved some hypophysectomy symp-
toms by implanting cells under the kidney capsule, the pituitary and hypothalamus
are physically and functionally connected: proper regulation of endocrine secre-
tions requires connection with the hypothalamus. In pilot experiments in the 1950s,
Harris and collaborators indeed demonstrated that anterior pituitary transplantation
away from its normal location, such as under the kidney capsule, resulted in chronic
PRL secretion and essentially loss of secretion of the other hormones. In contrast,
grafts implanted near the pituitary stalk, shortly after hypophysiectomy, resulted in
regeneration of the portal system and this was associated with functional integration
of the graft (Harris and Jacobsohn 1951). Therefore, transphenoidal endoscopic cell
transplantation in the human pituitary close to the pituitary stalk should promote
adequate integration and control (see Studer and Tabar 2016).
Hypothalamic neurons need to be able to make relevant connections, particularly
those controlling the pituitary via the ME. Transplantations of cells or grafts have
been realized in the hypothalamus with spectacular results. Placement of pre-optic
area (POA) grafts containing GnRH neurons close to the ME successfully restores
reproductive function in the gnrh1 mutant hypogonadal mice, independently of the
sex of the donor. As expected, success appears to rely on accession of GnRH axons
to the ME (Gibson et al. 1984; Charlton 2004). Anterior hypothalamic implants
comprising the suprachiasmatic nucleus restore periodicity in animals rendered
arrhythmic by hypothalamic lesions (Sollars et al. 1995). More recently, immature
hypothalamic neurons and progenitors were transplanted into the hypothalamic
parenchyma of early postnatal brains of leptin receptor-deficient mice. These
resulted in functional integration and partial restoration of leptin responsiveness
in the adult (Czupryn et al. 2011). However, transplantations close to the ME might
offer better results, because arcuate nucleus grafts transplanted into the third
ventricle, close to the ME, are associated with comparatively better anti-obesity
effects in obese rats (Ono et al. 1990; Fetissov et al. 2000). Integration near a site
where the blood-brain barrier is interrupted might allow access to peripheral
signals, such as leptin in this context and, therefore, better functionality. All these
studies show that hypothalamic implantation can restore function; therefore, they
offer hope that stem cell-derived hypothalamic neurons transplanted near the ME
would be successful. However, as demonstrated in mice, damage to the ME/stalk,
such as that observed after traumatic brain injuries, is probably causative of
pituitary deficiencies (Osterstock et al. 2014). Therefore, just as transplantation
close to this site has been proposed to improve the functionality of both pituitary
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and hypothalamic transplants, care should be taken not to damage this fragile
structure.
Conclusion
The generation of endocrine cells from ESC and their subsequent transplantation
in vivo represent exciting progress towards the use of regenerative medicine to treat
endocrine deficits or manipulate endocrine outputs. Improvement of differentiation
efficiencies and transplantation in homotypic locations should in the near future
demonstrate whether regenerative therapies are suitable for clinical use to treat
neuro-endocrinological disorders.
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